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Background
Chronic pancreatitis (CP) is characterized by an inflammatory process of the pancreas 
that leads to irreversible morphological changes. It represents a progressive fibro-
inflammatory disease that can be categorized in a large-duct (often with intraductal 
calculi) or small-duct form. CP is considered to be a difficult topic for research 
for the reason that it is a multifaceted disease with respect to cause and clinical 
presentation. It is associated with a large number of risk factors (ranging from 
environmental to genetic) and the clinical presentation varies from asymptomatic to 
a highly complicated disease course. Though this variation is not unique to CP, the 
relatively low prevalence of the disease and its association with alcohol as a major 
precipitating factor has left CP as a model for research in the limelight. However, the 
chief presentation requiring medical attention by CP patients is chronic pain. We took 
this symptom as the guiding theme of our studies and asked ourselves a number 
of questions. 
Questions relevant to this thesis: 
1. Why do some CP patients develop pain while others are left unscathed?
2. What is the clinical presentation of a subset of patients with CP, such as patients 
with hereditary or idiopathic forms of CP?
3. How do we need to treat these patients?
Disease model
In order to address these issues we chose to have patients with CP as a disease 
model. As we have a large outpatient clinic where we see these patients on a 
regular basis this came to us as a natural choice. We designed a clinical database 
that contained a large number of clinical variables of our CP patients and took that 
as an entry point. This enabled us to design a number of genetic case control 
studies that examined our first question.  Next, we established a number of case 
series that allowed us to delineate specific elements of CP as a disease entity. 
Lastly, we went back to the literature in order to examine the issue how we should 
treat our patients and checked whether we as clinicians adhere to the existing 
guidelines. These endeavors led to the following structure of this thesis.    
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Outline of this thesis
This thesis focuses on three different aspects of CP. In the first section, we focus 
on genetic aspects of CP. We questioned ourselves if we could detect genetic 
alterations that could explain the differences in the experience of pain in CP. In the 
second section, we studied clinical aspects of CP. We studied the phenotype and 
imaging findings in a specific group of CP in order to learn more about etiology and 
disease course. In the third section, we focus on diagnosis and management of 
CP. Since guidelines on CP are scarce, we wanted to know more about current 
practice in the diagnosis and management of CP in the Netherlands? Furthermore, 
we reviewed the management of pain in CP.
 
Question 1:  Why do some CP patients develop pain while others are left 
unscathed?
In the first section, we focus on genetic aspects of pain in CP. Since genetic 
factors may play a role in a patient’s pain experience, we investigated if the Cat-
echol-O-methyltransferase (COMT) gene and the transient receptor potential 
vanilloid receptor 1 (TRPV1) gene might be involved in pain in CP patients. The 
following research questions will be addressed: 
•	 What is the effect on COMT gene variants on the presence and severity of pain 
in CP? (Chapter 2)
•	 Could modifications in the TRPV1 gene modify the presence and the pheno - 
typical expression of CP? (Chapter 3)
Question 2:  What is the clinical presentation of a subset of patients with CP, 
such as patients with hereditary or idiopathic forms of CP?
In the second section, we focus on clinical aspects of CP.  In these chapters, we 
focus on different clinical aspects on specific types of pancreatitis: hereditary 
pancreatitis, idiopathic CP in the Western world and in India and pancreatitis in 
patients with familial adenomatous polyposis (FAP). In this specific subset of 
patients, we asked ourselves:
•	 Are there specific radiological findings in patients with hereditary pancreatitis 
and what is the evolution of pancreatic abnormalities during the disease 
course? (Chapter 4)
•	 Is the phenotype of CP and idiopathic CP in India different from CP and 
idiopathic CP in the Western world? (Chapter 5)
•	 Is there a relationship between FAP en CP and may SPINK1 mutations contribute 
to the risk of pancreatitis? (Chapter 6)
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Question 3: How do we need to treat these patients?
In the third section of this thesis, we focus on diagnosis and treatment of CP. 
There are many controversies in the diagnosis and treatment of CP and pain in CP 
due to lack of evidence. Our objectives with regards to this theme were:
•	 To evaluate current practice in the Netherlands by evaluating decisions 
regarding the diagnosis, management and screening in CP. (Chapter 7)
•	 To discuss the suggested mechanisms for pain in CP and review the therapeutic 
options. (Chapter 8)
In the appendix we focus on the difficulties we met in adopting a different study 
strategy, i.e. a randomized clinical trial. A randomized clinical trial is generally 
accepted as the most reliable evidence of whether a treatment is effective. 
Therefore, we designed a clinical trial on the effectiveness of nasogastric and 
nasojenunal feeding in CP patients with abdominal pain as a primary outcome 
measure. In the appendix we describe two patients who were included and focus 
on the results of the single patient who completed the entire protocol. The appendix 
highlights the reasons for difficult accrual of patients for this trial. 
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Chapter 1b.
Introduction in chronic pancreatitis as a clinical entity 
This chapter describes the clinical aspects of CP and serves as an introduction to 
the studies described in this thesis.  
Incidence of CP
The prevalence of CP is 26 per 100,000 in Europe and the USA.1 The reported 
incidence of CP in industrialized countries ranges from 3.5 to 10 per 100,000 
population.2 The overall incidence is stable over three decades (1977–2006).3 In the 
USA, there is an increase in the incidence of alcoholic CP.4 In Japan, there is a 
gradual increase of the annual incidence (to 11.9/100,000), especially in alcoholic 
CP.5 There is a male predominance in alcoholic CP and idiopathic CP (>71%) but 
not in hereditary CP (46%).6 The median age at onset differs between etiology; 36 
years in case of alcoholic CP, 10 years in case of hereditary CP. Idiopathic CP has 
an early onset or ‘juvenile’ form (median age at onset 23 years) and a late onset or 
‘senile’ form (at 62 years).6,7 The mean age of onset of CP in Japan is 59.4 years.5
Etiology
The predominant cause of CP in Western countries is excessive alcohol consumption, 
accounting for approximately 70% of all cases. However, since <10% of chronic 
alcoholics develop CP, other predisposing factors besides alcohol are involved.8 
Thus, alcohol requires additional cofactors to result in CP.3 About 20% of cases is 
considered to relate to idiopathic pancreatitis, while the remaining 10% is 
categorized as ‘other’. 
New classification systems have been established, for instance the M-ANNHEIM 
classification system.9 This classification is based on the assumption that CP 
results from the interaction of multiple (M) risk factors. The risk factors are 
categorized into the major subcategories of alcohol consumption (A), nicotine 
consumption (N), nutritional factors (N), hereditary factors (H), efferent pancreatic 
duct factors (E), immunological factors (I), and various rare miscellaneous and 
metabolic (M) factors. Another classification is the TIGAR-O risk factor classifica-
tions system.10,11 The risk factors are categorized according to causes that have a 
toxic-metabolic, idiopathic, genetic, autoimmune, recurrent severe acute pancrea-
titis-associated and obstructive background. There is a clear relationship between 
cigarette smoking and pancreatitis. Smoking is an important independent risk 
factor for CP and influences progression of acute pancreatitis to CP.3 
Genetic factors play an important role in the etiology of CP. There is a rare form of 
CP, hereditary pancreatitis, with an autosomal dominant inheritance caused by 
chapter 1
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cationic trypsinogen (PRSS1) gene mutations.12,13 Furthermore, genetic factors can 
explain a significant proportion of other CP cases. Genes like SPINK1, CTRC and 
CFTR are associated with CP and should be considered as predisposing or 
modifying rather than directly causative. SPINK1-mutations are associated with 
~20% of idiopathic CP cases but only ~5% of the alcoholic CP cases. Mutations in 
the Chymotrypsine C-gene are seen in only 2% of CP cases.14 
Clinical Features
The three major clinical features of CP are:
•	 Pain
•	 Pancreatic exocrine insufficiency
•	 Pancreatic endocrine insufficiency. 
Pain
Pain is the major presenting symptom of CP and the majority of patients will have 
pain at a given time during the course of their disease. It is the most frequent reason 
for CP patients to consult their physician. Pain in CP can occur as attacks that 
mimic acute pancreatitis or as constant and disabling pain. In a recent survey in 
Japan, 60.6% of the CP patients experienced abdominal pain.5 In alcoholic CP 
patients pain was present more frequently (alcoholic 65.0% vs. nonalcoholic 
53.0%).5 Often, the onset of CP is heralded by a severe painful attack, indistinguish-
able from an acute pancreatitis attack. After the first attack, patients become 
symptom free. However, with progression of the disease, the attack frequency 
increases and the symptom free periods progressively shorten. The inter- and intra-
individual variation of pain in CP is high, with pain duration varying from intermittent 
to persistent, and pain intensity ranging from mild to disabling. The pain is usually 
epigastric in location (although more diffuse pain in the upper abdomen can occur) 
and may radiate to the left infrascapular region. The pain can be accompanied by 
nausea and vomiting and can be partially eased by sitting up and leaning forward 
or by application of local heat or other counterirritants to the dorsal spine or 
epigastrium. Amman and Muellhaupt distinguished two typical pain patterns in 
alcoholic CP.15 The type A pain pattern, typically observed in acute relapsing 
pancreatitis, is short-lived and pain episodes usually last less than 10 days and are 
separated by long pain-free intervals of several months to a year. It is predominant 
in late-onset idiopathic CP and hereditary CP. B-type pain pattern, seen in more 
than 50% of patients, is characterized by prolonged periods of persistent pain or 
clusters of recurrent severe pain exacerbations, lasting two or more days per week 
for at least two months, and requiring frequent hospitalizations. Type B pain 
predominates in alcoholic CP and is associated with local complications, often 
requiring surgery.
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The pathogenesis of pancreatic pain is poorly understood and probably multi-
factorial. It can be a result from extrapancreatic (e.g. bile duct stenosis) or intra-
pancreatic complications (e.g. pseudocysts). Surgical or endoscopic complications 
can be involved. A few theories explaining the pathogenesis of pain in CP have 
been postulated: 1) the increased intrapancreatic pressure in the pancreatic duct or 
parenchyma; 2) inflammation of the pancreas; and 3) alterations in pancreatic 
nerves; pancreatic neuropathy.16 The neuropathic pain-hypothesis is supported by 
evidence from experimental human pain research that in many of these patients 
pain processing in the central nervous system is abnormal and mimics that seen in 
neuropathic pain disorders. Probably genetic factors also play a role in a patient’s 
pain experience, similar to the involvement of genes in neuropathic pain disorders. 
Pancreatic exocrine and endocrine insufficiency
The other clinical features of CP include exocrine and endocrine insufficiency. The 
main clinical manifestation of pancreatic exocrine insufficiency is malnutrition, resulting 
in low circulating levels of micronutrients, fat soluble vitamins and lipoproteins, 
which have been related to a high morbidity and mortality secondary to an increased 
risk of malnutrition-related complications and cardiovascular events.17 Steatorrhea 
does not occur until pancreatic lipase secretion is reduced to less than 10% of 
normal.
Diabetes mellitus may develop in the long-term course of the disease and is 
characterized by destruction of both insulin- and glucagon-producing cells. The 
diabetes is classified as type IIIc according to the American Diabetes Association.18 
The overall prevalence of diabetes in CP is 47%.19 The incidence of diabetes 
increase to more to more than 80% 25 years after onset.20
Diagnosis of CP
The diagnosis of CP is based on a combination of clinical symptoms, pancreatic 
function tests and imaging. In the diagnosis of CP different imaging modalities are 
used; transabdominal ultrasonography (TUS), CT-scanning, MRI, MRCP, secretin-
enhanced-MRCP and endoscopic ultrasound (EUS). TUS is able to identify thinning 
of pancreatic parenchyma, irregularity of the pancreatic margins, dilatation of the 
MPD and of side branches and ductal calcified stones. Therefore it can be used to 
confirm the diagnoses advanced CP.21 However, in diagnosis of CP TUS is not very 
useful. Early CP can best be diagnosed by gadolinium enhanced MR imaging 
combined with MRCP.21 MRCP and increasingly EUS have become the screening 
methods of choice.22
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Treatment 
The treatment of CP consists of different aspects:
•	 Treatment of pain
•	 Correction of metabolic disorders (diabetes, malnutrition)
•	 Treatment of pancreatic exocrine insufficiency
•	 Management of complications (e.g. pseudocysts)
•	 Behavior modification: cessation of alcohol consumption and cigarette smoking 
Treatment of pain
The treatment of pain in CP still is difficult, despite new strategies, new drugs and 
new interventional options. The treatment of pain in CP requires a multidisciplinary 
approach of gastroenterologists, surgeons, radiologists, anesthesiologists and 
psychiatrists. As advised in the AGA guidelines, treatable complications of chronic 
pancreatitis, such as pseudocysts, bile duct obstruction or duodenal obstruction 
should be excluded.23 The conservative management of CP included abstinence of 
alcohol and smoking. Alcohol abstinence improves the prognosis of CP and 
frequently results in a reduction of pain. The management of pain in CP include 
pharmacological, endoscopic and surgical treatment. In the treatment of pain, 
there are several pharmacological options, with different effectiveness.
Pharmacological treatment of pain in CP
In the most recent guidelines of diagnosis and treatment of CP, this pharmacologi-
cal options are mentioned:21,22
•	 Analgesics: acetaminophen, non-steroidal anti-inflammatory drugs are recommended 
as firs approach in pain in CP, followed by opioids such as tramadol.
•	 Antioxidant therapy (selenium, beta-carotene, ascorbic acid and tocopherol) 
may be useful to prevent painful recurrences of CP. 
•	 Tricyclic antidepressants, selective serotonin re-uptake inhibitors and combined 
serotonin and norepinephrine re-uptake inhibitors, will alleviate co-existent 
depression and may ameliorate pain and potentiate the effects of opiates.
•	 Opioid receptor agonists: the ‘classic’ opioids such as morphine, methadone, 
fentanyl. Ideally, ongoing regular opioid analgesia is reserved for those in whom 
endoscopic or surgical therapies are not appropriate and symptoms are intractable.
There are other pharmacological options in the management of pain in CP, such as 
octreotide, loxiglumide, secretine, oral protease inhibitors and leukotriene receptor 
antagonist, but the data of effectiveness are inconsistent and therefore cannot be 
routinely advised. A promising new drug in the treatment of pain is pregabalin, a 
gabapentoid effective in treating other causes of neuropathic pain, which has 
shown effective as adjuvant analgesic in pain control in patients with CP.24 
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Other therapeutic options and neuropathic pain treatments include nerve blocks, 
transcutaneous electronic nerve stimulation, acupuncture and intrathecal pumps 
for infusion of opioids and anesthetic agents, the latter to block afferent pain nerves 
accompanying sympathetic nerves to the central nervous system.25 
Endoscopic therapy for pain in CP
For treating painful uncomplicated CP, the ESGE recommends extracorporeal 
shockwave lithotripsy (ESWL)/endoscopic retrograde cholangiopancreatography 
(ERCP) as the first-line interventional option.26 This is only indicated in case of 
pancreatic duct dilation.21 In case of no response, surgical options should be 
considered. ESWL is recommended in case of radiopaque stones ≥5 mm 
obstructing the main pancreatic duct (MPD), followed by endoscopic extraction of 
stone fragments. In case of dominant MPD strictures, the ESGE recommends 
inserting a single 10-Fr plastic stent, with stent exchange planned within one year. 
If the ductal strictures persist after 12 months, other therapeutic options such as 
endoscopic placement of multiple simultaneous MPD stents or surgery should be 
discussed.26 Recently, two trials who compared endoscopic intervention to surgical 
intervention were reviewed.27 This review showed that in patients with obstructive 
CP and dilated MPD surgery is superior to endoscopy in terms of pain control. In a 
prospective randomized trial with a long-term follow-up was shown that symptomatic 
patients with advanced CP who underwent surgery as the initial treatment for 
pancreatic duct obstruction had more relief from pain, with fewer procedures, than 
patients who were treated endoscopically. Moreover, almost half of the patients 
who were treated with endoscopy eventually underwent surgery.28,29
Surgical therapy for pain in CP
If endoscopic therapy fails in the treatment of CP, or if there are complications of CP 
such as bile duct and duodenal obstructions, surgical therapy is indicated. Ideally, 
pancreatic surgery should be performed before narcotic addiction. In case of CP with 
MPD dilation (≥ 7 mm) a drainage procedure should be chosen (lateral pancreatico-
jejunostomy procedure proposed by Partington and Rochelle).30 When there is an 
inflammatory mass, a pancreatic resection is indicated. When there is a head 
mass-forming CP, mixed surgery (drainage and limited resection) can be performed.21 
Treatment of exocrine insufficiency
A fat restriction should not longer be routinely advised, but frequent meals of low 
volume are still recommended.17 Adequate pancreatic enzyme therapy is required 
to avoid malnutrition-related complications such as osteoporosis. Clinical indications 
for initiating enzyme supplementation are steatorrhea, weight loss or diarrhea. A 
minimum dose of pancreatic enzyme in the form of enteric-coated minimicro-
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spheres of 20 000- 40 000 U of lipase per meal and 10 000-20 000 U of lipase with 
snacks is required.17 Inhibition of gastric acid secretion by use of proton pump 
inhibitors can be added if steatorrhea is not controlled by pancreatic enzyme 
suppletion.21 In case of persistent signs of maldigestion, the dose of pancreatic 
enzymes should be increased. Therapy with pancreatic enzymes is not effective as 
treatment for pain in CP. A meta-analysis showed no significant benefit of pancreatic 
enzyme therapy on the relief op CP associated pain.31 
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Abstract
Background
Pain is the major symptom of chronic pancreatitis (CP). The role of genetics in 
pancreatic pain is unclear. Catechol-O-methyltransferase (COMT) regulates 
enkephalin levels and influences pain perception. The COMT gene contains 
functional polymorphisms that have been found to influence human pain perception. 
The aim of our study was to investigate COMT single-nucleotide polymorphisms 
(SNPs) and diplotypes in CP patients and healthy controls.
Methods
We genotyped four COMT gene SNPs: c.1-98A>G (rs6269), c.186C>T (p.=) (rs4633), 
c.408C>G (p.=) (rs4818) and c.472G>A (p.Val158Met) (rs4680) using a dual-colour 
discrimination assay in 240 CP patients and 445 controls. We generated five diplotypes 
with a frequency >0.5% and compared prevalence between patients and controls. 
Results
There was no significant association between the SNPs in the COMT gene and CP. 
The diplotype ATCA/ACCG was more prevalent in controls compared to patients 
(OR 0.48, 95% CI 0.24-0.93, p=0.03) where the most common diplotype GCGG/
ATCA served as reference. However, after correction for multiple testing, this is not 
a significant difference. The distribution of other diplotypes was not significantly 
different between patients and controls. 
Conclusion
COMT SNPs and diplotypes are not associated with CP. As a consequence, our 
results do not support a significant role for the COMT gene in CP.
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Introduction
Chronic abdominal pain is the major presenting symptom of chronic pancreatitis 
(CP) and the majority of patients will have pain at a given time during the course of 
their disease. A large majority of patients with CP presented with pain in a survey of 
the Asia-Pacific region, varying from 60% in Japan, to 90% in Australia, South Korea 
and South India and 100% in Singapore.1 The inter- and intra-individual variation of 
pain in CP is high, with pain duration varying from intermittent to persistent and pain 
intensity ranging from mild to disabling.2 The inter-individual differences in the 
response to pain suggest that genetic factors can be involved in its modulation.3,4 
Recently, several studies  have investigated the association between the Catechol-
O-methyltransferase (COMT) gene and pain sensitivity.5-12 In some studies, there 
was a positive association between COMT gene SNPs and pain.5,10-13 
This was not confirmed by other studies.6-8 Other studies have focused on the 
association between COMT and the efficacy of pain therapy, such as morphine.14,15 
The COMT enzyme metabolizes catecholamines, thereby acting as a key modulator 
of dopaminergic and adrenergic/noradrenergic neurotransmission.16,17 Low activity 
of COMT is associated with activation of dopaminergic neurons, a reduction in the 
neuronal content of enkephalin and an increase in the regional concentration of 
µ-opioid system receptors. The µ-opioid system system is activated in response to 
stressors, pain and other salient environmental stimuli, typically reducing pain and 
stress responses.9,18 COMT inhibition results in increased pain sensitivity via a β2/3-
adrenergic mechanism.19
The COMT gene is located on the long arm of chromosome 22, at the gene map 
locus of 22q11.2. The human COMT gene encodes two distinctive proteins: soluble 
COMT (S-COMT) and membrane-bound (MB-COMT) through the use of alternative 
translation initiations sites and promoters.20 There are different single-nucleotide 
polymorphisms (SNPs) in the COMT gene, which induce important functional 
alterations of the enzyme. The COMT gene contains a common functional 
polymorphism: c.472G>A (p.Val158Met) (rs4680). This substitution is associated 
with a reduction in thermostability and activity of the enzyme.21 Individuals with the 
Val158/Val158 genotype have the highest activity of COMT and have found to be less 
susceptible to pain compared with other genotypes. Individuals with the Met158/
Met158 genotype showed diminished regional µ-opioid system responses to pain 
compared with heterozygotes.9 The exact mechanism by which diminished COMT 
activity influences pain perception is not known. However, associations between 
the low-activity Met158 allele are often inconsistent.22 This suggests that additional 
SNPs in the COMT gene modulate COMT activity. There are three other SNPs in the 
COMT gene that exhibit a strong linkage disequilibrium with the Val158Met variation. 
One is located in the S-COMT promoter region: c.1-98A>G (rs6269). The two other 
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SNPs are located in the MB-COMT coding region: c.186C>T (p.=) (rs4633) and 
c.408C>G (p.=) (rs4818).23 Furthermore, haplotypes of the COMT gene that have 
functional consequences with respect to COMT enzyme activity have been 
revealed. Diatchenko identified three different haplotypes formed by the four 
different SNPs.23 The use of haplotype reconstruction is preferred because of 
combinations of SNPs might have a synergistic effect on COMT protein function. 
Since each person has two haplotypes for each gene, one can determine the 
variation on both haplotypes simultaneously; the diplotype. 
The aim of this study was (1) to compare four COMT SNPs and the diplotypes 
between patients with CP and controls and (2) examine the effect of COMT gene 
variants on presence and severity of pain in CP. 
Materials and methods
Subjects
We included patients diagnosed with CP who visited the outpatient clinic at the 
Department of Gastroenterology and Hepatology of the Radboud University 
Nijmegen Medical Centre between 1980 and 2009. We sampled patients and 
performed a cross-sectional study. Therefore we collected venous blood samples 
for DNA-analysis in these patients on our outpatient clinic. The clinical diagnosis of 
CP was based on one or more of the following criteria: presence of typical 
complaints (recurrent upper abdominal pain, radiating to the back, relieved by 
leaning forward or sitting upright and increased after eating), suggestive radiological 
findings, such as pancreatic calcifications or pseudocysts, and pathological 
findings (pancreatic ductal irregularities and dilatations) revealed by endoscopic 
retrograde pancreaticography or magnetic resonance imaging of the pancreas 
before and after stimulation with secretin. We collected data regarding the cause of 
pancreatitis. Patients who had an estimated intake of alcohol of more than 60 g 
(females) or 80 g (males) daily for more than two years were classified as CP of 
alcoholic origin. The diagnosis hereditary pancreatitis was established by fulfilling 
the international diagnostic criteria for hereditary pancreatitis: two first-degree 
relatives or three or more second-degree relatives, in two or more generations with 
recurrent acute pancreatitis, and/or CP for which there were no known precipitating 
factors.24 Idiopathic pancreatitis was diagnosed if precipitating factors such as 
alcohol abuse, bile stones, trauma, medication, infection, metabolic disorders, and 
a positive family history were absent. Patients with other causes of pancreatitis, 
such as anatomic or tropical, were classified as miscellaneous causes. The controls 
were unrelated, healthy individuals from the Netherlands who were not suffering 
from pancreatic disease. We matched cases and controls on gender while gender 
is a significant covariate in genetic studies of human pain. A positive family history 
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for pancreatic diseases was absent in all controls. In addition there was no chronic 
alcohol abuse (< 60 g for females and < 80 g for males) in our population. These 
data were collected through interviews.
Ethics 
The study was conducted in accordance with the principles of the Helsinki 
Declaration. The study protocol was approved by the local medical ethics review 
committee, the Institutional Review Board from the Radboud University Nijmegen 
Medical Center (CWOM-nr 0011-0242). All subjects gave their informed consent. 
The informed consent was obtained verbally in presence of a witness and documented 
in the patient’s medical file.
Genotyping
All patients donated a venous blood sample. Genomic DNA was extracted from 
300 µL whole blood using the Puregene® genomic DNA isolation kit (Gentra 
Systems, Minneapolis, USA). The 4 COMT SNPs (c.1-98A>G , c.186C>T (p.=), 
c.408C>G (p.=) and c.472G>A) were analysed by a dual-colour discrimination 
assay, using the iCycler iQ Multicolour Real-Time Detection System (Bio-Rad 
Laboratories; Hercules, USA). The PCR amplifications were carried out in a final 
volume of 25 µL, which contained 200 ng of genomic DNA, 10 mM Tris/HCl (pH 
9.0), 50 mM KCl, 0.1% Triton X-100, 3 mM MgCl2 0.25 mM dNTP’s, 200 nM of forward 
and reverse primer, 200 nM of both probes complementary to the two alleles of 
each SNP  labelled at the 5’ end with the fluorophore Fam or Hex and at the 3’ end 
with BHQ1 as quencher (primer sequences available on request) and 3.0 units of 
Taq-DNApolymerase. Genomic DNA was denatured at 95 °C for 5 minutes. 40 
Cycles were carried out, each composing denaturation for 30 seconds at 95 °C, 
annealing for 30 seconds at 63 °C, and extension for 30 seconds at 72 °C. Genotype 
assignment was conducted using the iCycler iQ Optical System Software version 
3.1. (Bio-Rad Laboratories; Hercules, USA) using the final fluorescent signals. 
Statistical methods
After testing for Hardy-Weinberg equilibrium (HWE) among controls, frequency 
tables were provided for the distribution of the four studied SNPs.25 Differences 
between continuous variables were tested using Student’s t-test and categorical 
variables by the chi-square test. Combination of haplotypes, diplotypes, were 
generated based on the four studied SNPs, missing SNPs were imputed. The relative 
risk associated with minor alleles was estimated as an odds ratio (OR) with a 95% 
confidence interval (CI) with the most common diplotype as a reference. Statistical 
significance was defined as p < 0.05. For diplotypes that were only present in 
either the patient population or healthy controls, no odds ratios could be calculated. 
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Statistical analysis was carried out with SPSS 16.0 for Windows. Pairwise linkage 
disequilibrium estimations between polymorphisms and haplotype reconstruction 
were performed with Haploview version 4.0.26
Results 
Characteristics of patients and controls
Samples of 685 subjects were included in our study cohort. The characteristics of 
the patients and controls are shown in Table 1. The cohort consisted of 240 CP 
patients (157 males, 83 females), with a mean age of 48 years (range 17-78 years). 
We included 445 controls (294 male, 150 female) with a mean age of 53 years 
(range 19-90 years). Patients and controls are Caucasians. Forty-four percent of 
the patients had alcohol related CP.  Healthy controls were significantly three years 
older than patients. 
The genotyping completion rate was 100%. The observed and expected frequencies 
of the different SNPs in controls were in Hardy-Weinberg equilibrium. The allele 
frequencies of the four SNPs in CP patients and healthy controls are shown in Table 2. 
There was no significant association between the SNPs and CP. 
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Table 1   Demographic and clinical characteristics of chronic pancreatitis patients 
and healthy controls
Patients Controls  p value
n 240 445
Age (mean, range, in years) 48 (17-78) 53 (19-90)   0.001*
Sex (male:female) 157;83 294;150; 1 N/A 0.833
Tobacco use
Smoking 158
Non-smoking 63
Unknown 19 445
Cause of chronic pancreatitis
Alcoholic 106
Hereditary 14
Idiopathic 103
Miscellaneous 17
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Diplotype analysis
Linkage analysis between the four SNPs showed that they were closely linked 
(figure 1). We then determined haplotypes and combinations of haplotypes 
(diplotypes). Based on the SNP distribution, five diplotypes with a frequency >0.5% 
were generated, three of them representing 84% of all diplotypes observed in this 
study. Diplotype GCGG/ATCA is most prevalent in both groups, but more frequent 
in patients compared to controls (47.5% vs. 38.4%). This haplotype served as 
reference in calculating the odds ratios for the remaining diplotypes (figure 2). 
ATCA/ACCG was more prevalent in controls compared to patients (9.2% vs. 5.4%, 
OR 0.48, 95% CI 0.24-0.93, p=0.03). After correction for multiple testing, this was 
no longer a significant difference. The distribution of other diplotypes was not 
significantly different between patients and controls. 
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Table 2   Allele frequencies of the four SNPs in chronic pancreatitis patients and 
healthy controls
Alleles Patients (n=240) Controls (n=445) p value
rs6269 0.25
A/A 84 (35%) 164 (37%)
A/G 123 (51%) 202 (45%)
G/G 33 (14%) 79 (18%)
rs4633 0.14
T/T 70 (29%) 122 (27%)
T/C 127 (53%) 214 (48%)
C/C 43 (18%) 109 (25%)
rs4818 0.26
C/C 82 (34%) 165 (37%)
C/G 126 (53%) 206 (46%)
G/G 32 (13%) 74 (17%)
rs4680 0.18
A/A 70 (29%) 120 (27%)
A/G 127 (53%) 218 (49%)
G/G 43 (18%) 107 (24%)
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Discussion 
This study investigated the association between four SNPs in the COMT gene in a 
large cohort of patients with CP and healthy controls. We considered the COMT 
gene is a candidate in CP because of several reasons. First, COMT has been 
associated with several chronic pain conditions, such as fibromyalgia syndrome, 
neuropathic pain and temporomandibular disorder. Second, pain is a major 
symptom in CP that ultimately will be present in nearly all patients and it causes 
substantial impairments in health-related quality of life in these patients. 
Gene association studies in CP have so far focussed on the presence vs. absence 
of the disease.27 For example, mutations in pancreatic serine protease inhibitor 
Kazal type 1 (SPINK 1) are enriched in patients with idiopathic CP as well in alcoholic 
pancreatitis in comparison to background population.28 Likewise, the G191R variant 
of anionic trypsinogen gene (PRSS2) affords protection against various forms of CP 
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Figure 1   Linkage disequilibrium plot
Linkage disequilibrium (LD) plot across the COMT. The box at the top indicates the COMT gene with the 
four investigated SNPs. The LD plot is based on the measure of D'. Each diamond indicates the pair wise 
magnitude of LD, with dark grey diamonds indicating strong LD (D' > 0.8).
LD: linkage disequilibrium is the non-random association of alleles at two or more loci, not necessarily on 
the same chromosome. Linkage disequilibrium describes a situation in which some combinations of alleles 
or genetic markers occur more or less frequently in a population than would be expected from a random 
formation of  haplotypes from alleles based on their frequencies.
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when compared to healthy controls.29 We tried to take this further and search for 
genetic variants that determine an important symptom in CP: pain. 
In our study, we investigated if COMT polymorphisms are associated with CP, but 
we were actually interested in the question whether “COMT polymorphisms are 
associated with pain in patients with CP?”. COMT itself has no role in the etiology 
of CP per se, but its genetic variants have a role in altered pain perception. Our CP 
group consisted of patients experiencing pain varying from intermittent to persistent 
and pain intensity ranging from disabling to no pain or mild pain. We did not directly 
quantify pain, which makes it difficult to study the exact correlation between COMT 
and pain due to CP in this population. It is very complex to investigate pain, due to 
different levels of pain that patients experience, the use of analgetic drugs and 
different pain scales. Furthermore, the difficulty in measuring pain is that there is no 
validated objective measurement of pain associated with CP. This is partially due to 
the unpredictable course of CP with relapses and remission. Pain in CP is highly 
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Figure 2   Diplotype distribution of chronic pancreatitis patients and healthy controls
Distribution of diplotypes in patients with CP and healthy controls. The diplotypes are compared to the most 
prevalent diplotype GCGG/ATCA (reference).
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variable and it varies greatly during the lifetime of the disease. But ultimately, the 
majority of the patients with CP will experience pain. 
Moreover, there are several confounding variables, such as dependence of 
analgetic drugs and the use of alcohol or other narcotic agents. However, since 
almost every patient with CP will experience pain during the course of their disease, 
we lumped patients and investigated COMT in CP patients from our cohort.
We did not limit ourselves to a single COMT SNP, but rather elected to perform 
haplotype (and diplotype) association studies. Haplotype and diplotype 
reconstruction, rather than individual SNPs, better predicts variability in pain 
sensitivity. Diplotype GCGG/ATCA is most prevalent in both groups and more 
frequent is patients than in controls. ATCA/ACCG was more prevalent in controls 
compared to patients (OR 0.48, 95% CI 0.24-0.93). However, after correction for 
multiple testing this is not a significant difference. 
Furthermore, we demonstrated no association between the SNPs c.1-98A>G 
(rs6269), c.186C>T (p.=) (rs4633), c.408C>G (p.=) (rs4818) and c.472G>A 
(p.Val158Met) (rs4680) and CP. As a consequence, our results do not support a 
significant role for the COMT gene in the CP.
A possible limitation of our study is that we do not have detailed insights in nicotine 
and alcohol use in our healthy controls. Numerous studies have explored the 
association of COMT with alcohol dependence. The Met158 allele has been 
associated with late onset alcoholism in men, but not in the development of 
early-onset alcoholism with severe antisocial behavior. 30,31 Second, the Met158 allele 
has also been associated with elevated weekly alcohol consumption in male social 
drinkers.32 However, these findings are not consistent, because others failed to find 
evidence to support an association between alcohol dependence and variation in 
COMT.33 In addition, we don’t know if the pain pattern is different between patients 
with idiopathic and alcoholic CP.
In conclusion, our study shows that the SNPs of the COMT gene are not associated 
with CP. Because our results do not answer the complete complex of pain, future 
studies are needed to characterize the joint effect of multiple genes affecting pain.
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Abstract
Background
The major clinical feature in chronic pancreatitis (CP) is pain, but the genetic basis 
of pancreatic pain in CP is poorly understood. The transient receptor potential 
vanilloid receptor 1 (TRPV1) gene has been associated with pain perception, and 
genetic variations in TRPV1 may modify the presence and phenotype of CP. The 
aim of our study was to investigate the genetic variation of TRPV1 in Dutch patients 
with CP and healthy controls. 
Methods
We genotyped four SNPs (rs222749, rs222747, rs224534 and rs8065080) in 228 
CP-patients and 207 healthy controls by PCR, followed by restriction-fragment-
length-polymorphism analysis and DNA sequencing. We generated 27 diplotypes 
and compared prevalence between patients and controls.
Results
There was no significant difference in allele frequency of the four TRPV1 gene SNPs 
in patients with CP and healthy controls. Distribution of diplotypes was not 
statistically significantly different between patients and controls. 
Conclusion
TRPV1 diplotypes are not associated with CP.
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Background 
Chronic pancreatitis (CP) is an inflammatory process that leads to a progressive 
and irreversible destruction of the pancreatic parenchyma. The major presenting 
clinical feature is abdominal pain.1 Some 60-100% of patients report abdominal 
pain at a given time during the course of their disease, with pain duration varying 
from intermittent to persistent and pain intensity ranging from mild to disabling.2 
Consequently, patients with CP experience substantial impairments in health-related 
quality of life.3 The mechanism of pancreatitis-induced pain is unknown.1  
The inter-individual differences in the response of pain suggest that genetic factors 
may be involved.2, 4, 5 A few studies suggest the transient receptor potential vanilloid 
receptor 1 (TRPV1) gene might be involved in pancreatitis.6-9 The TRPV1 receptor is 
a nonselective calcium permeant cation channel that belongs to the transient 
receptor potential family (TRP). It is expressed predominantly in nociceptors that 
participate in the detection of noxious chemical and thermal stimuli in the dorsal 
root ganglia and peripheral sensory nerve endings.6, 7 Capsaicin, red pepper, is its 
natural agonist. Activation of TRPV1 on neurons cause the release of pro-inflamma-
tory neuropeptide substance P and calcitonine G related peptide (CGRP) in the 
dorsal horn of the spinal cord which is critical for transmitting pain signals from the 
periphery to the central nervous system.7 Substance P then binds to the neurokinin-1 
receptor (NK1-R) on endothelial cells and promotes extravasation of plasma and 
proteins into the interstitial tissue and neutrophil infiltration, a process called 
neurogenic inflammation.10 There is evidence that activation of TRPV1 is implicated 
in CP. In a cerulein-induced pancreatitis model, activation of TRPV1 on sensory 
neurons promoted neurogenic pancreatic inflammation.10 This effect was blocked 
by administration of the selective TRPV1 antagonist capsazepine. In another 
experimental CP model, pancreatic TRPV1 receptor mediated inward currents have 
shown to be greatly enhanced. Moreover, systemic administration of the TRPV1 
antagonist SB-366791 markedly reduced both visceral pain behavior and referred 
somatic hyperalgesia in rats with CP, but not in control animals.6 
TRPV1 is localized on chromosome 17, and consists of 16 exons.11 HapMap analysis 
reveals that there are at least eight non-synonymous single nucleotide polymorphisms 
(SNPs) that have a heterozygosity rate that exceeds 10%. At least four SNPs affect 
structural domains of TRPV1: p.P91S (rs222749) affects the intracellular amino 
terminus of TRPV1; p.I315M (rs222747) is localized in the ankyrin repeat-containing 
domain which is predicted to play a role in mediating protein-protein interactions 
and homotetramerization of the channel; p.T469I (rs224534) is predicted to be 
located in the extracellular loop between membrane-spanning helices 1 and 2; and 
p.I585V (rs8065080) is predicted to reside within membrane-spanning helix 5 and 
affects the transmembrane domain which confers responsiveness to capsaicin 
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(Figure 1). Apart from structural changes, at least two SNPs (p.P91S, p.I315M) 
modify the functional properties of the channel and induce increased TRPV1 protein 
expression due to an increased copy number.6
Collectively, these data suggest a role for TRPV1 in CP, and we hypothesized that 
TRPV1 could act as a modifier for CP and that therefore genetic variations in TRPV1 
could modify the presence and/ or the phenotypical expression of CP. The aim of 
our study was to investigate the genetic variation of TRPV1 in Dutch CP patients and 
healthy controls. 
Methods
Subjects
We enrolled patients diagnosed with CP, who visited the outpatient clinic of the 
Department of Gastroenterology and Hepatology of the Radboud University 
Nijmegen Medical Centre in the Netherlands between 1999 and 2008. The clinical 
diagnosis of CP was based on one or more of the following criteria: presence of 
typical complaints (recurrent upper abdominal pain, radiating to the back, relieved 
by leaning forward or sitting upright and increased after eating), suggestive 
radiological findings, such as pancreatic calcifications or pseudo cysts, and 
pathological findings (pancreatic ductal irregularities and dilatations) revealed by 
endoscopic retrograde pancreaticography or magnetic resonance imaging of the 
pancreas before and after stimulation with secretin. We collected data with special 
emphasis on the cause of CP. We specified for the cause of pancreatitis. Patients 
who had an estimated intake of alcohol of more than 60 g (females) or 80 g (males) 
daily for more than two years were classified as CP of alcoholic origin. Hereditary 
pancreatitis was defined when CP was present in two or more family members.12 
Idiopathic pancreatitis was diagnosed when precipitating factors such as alcohol 
abuse, bile stones, trauma, medication, infection, metabolic disorders, and a 
positive family history were absent. Patients with other causes of pancreatitis, such 
as anatomic or tropical, were classified as miscellaneous causes. 
Ethics
The study was conducted in accordance with the principles of the Helsinki 
Declaration and was approved by the local medical ethics review committee. All 
subjects gave their informed consent. 
Genotyping
For genotyping, a venous blood sample from each subject was collected. Genomic 
DNA was extracted from peripheral blood leukocytes by standard techniques. We 
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selected four non-synonymous TRPV1 gene SNPs with a heterozygosity rate 
exceeding 10%. Primers flanking the SNPs were designed on the basis of publicly 
available nucleotide sequence of human TRPV1. Amplification was performed in a 
25 µl mixture containing 200 ng of genomic DNA 10 mM Tris-HCl (pH 9.0), 50 mM 
KCl, 0.1% Triton X-100, 0.25 mM dNTPs, 0.20 µM each primer, 2.5 U Taq polymerase, 
and 1.5 mM MgCl2, except the mixture of rs224534 which contained a concentration 
of 2.0 mM MgCl2. The protocol consists of an initial denaturation at 95 ºC for 
4 minutes, followed by 40 cycles of denaturation at 95 ºC for 30 seconds, 
annealing at a particular temperature for each exon for 30 seconds as shown in 
table 1, and extension at 72 ºC for 30 seconds, followed by a final extension at 
72 ºC for 7 minutes.
To detect SNP rs222749 (c.271C>T) PCR products were digested with Sau96I (New 
England Biolabs, Ipswich, USA) resulting in the following fragments: C/C, 322 + 99 
bp; C/T, 421 + 322 + 99 bp; T/T, 421 bp. SNP rs222747 (c.945C>G) was detected 
using BsaBI (New England Biolabs, Ipswich, USA) digestion of the PCR products 
resulting in the following fragments: C/C, 269 + 162 bp; C/G, 431 + 269 + 162 bp; 
G/G, 431 bp. To detect SNP rs224534 (c.1406C>T) PCR products were digested 
with BsrI (New England Biolabs, Ipswich, USA) resulting in the following fragments: 
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Figure 1   The TRPV1 gene
Genomic organization of the TRPV1 gene with genomic structures, positions of splice junction sites. 
p.P91S (rs222749), p.I315M rs(222747), p.T4691 (rs224534) and p.I585V (rs8065080)
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C/C, 191 + 115 + 21 bp; C/T, 191 + 136 + 115 + 21 bp; T/T, 191 + 136 bp.
All digested products were subjected to electrophoresis on a 3.5% pronarose MS-8 
gel (Hispanagar, Burgos, Spain) and detected by ethidium bromide. 
SNP rs8065080 (c.1753A>G) was detected by direct sequencing and analysed by 
the sequence facility of the Radboud University Nijmegen Medical Centre in the 
Netherlands.
Statistical analysis
Frequency tables were provided for the distribution of the four studied SNPs and 
compared between cases and controls by Pearson’s chi-squared test (two-sided 
Fisher’s exact test was used in case values in any of the cells within the table was 
below 10). We tested for Hardy-Weinberg equilibrium (HWE) among controls using 
a calculator available on the internet.13 
Diplotypes were generated based on the four studied SNPs, missing genes were 
imputed. The relative risk associated with rare alleles was estimated as an odds 
ratio (OR) with a 95% confidence interval (CI) with the most common diplotype as 
a reference. For diplotypes that were only present in either the patient population or 
healthy controls, no odds ratios were calculated.
We used Haploview 4.0 software to construct a figure of the linkage disequilibrium 
(LD) plot.14
Results
Characteristics of patients and controls
Samples from a total of 435 subjects were included in our study cohort. The clinical 
characteristics of the patients and controls are shown in Table 1. The cohort of 228 
patients with CP included 146 male and 82 female patients and the mean age was 
47 years (range 17-78 years). 42% of the patients had alcohol related CP. There 
were 207 healthy, unrelated controls (79 male and 128 female) with a mean age of 
39 (range 18-86 years). In the control group, participants were significantly more 
often of female gender than in the patient group and they were younger of age.
SNP 
The allele frequencies of the four TRPV1 gene SNPs in CP patients and healthy 
controls are shown in Table 2. There was no evidence that the genotype frequencies 
of the four SNPs among the CP patients and healthy controls deviated from those 
expected under Hardy-Weinberg equilibrium (p > 0.05), except for one SNP (rs8065080) 
in CP patients. There was no significant difference in allele frequency between CP 
patients and healthy controls. 
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Table 1   Demographic and clinical characteristics of chronic pancreatitis patients 
and healthy controls
Patients Controls p-value
n 228 207
Age (mean, range) 47 (17-78) 39 (18-86) p=0.002
Sex (M/F) 146/82 79/128 p<0.001
Cause of chronic 
pancreatitis
Alcoholic 96 (42.1%) 0
Hereditary 14 (6.1%) 0
Idiopathic 100 (43.9%) 0
Miscellaneous 18 (7.9%) 0
Table 2   Allele frequencies of the four TRPV1 gene SNPs in chronic pancreatitis 
patients and healthy controls
Alleles Patients Controls p value
rs222749 0.251
C/C wildtype 204 (89.5%) 189 (92.6%)
C/T heterozygote 24 (10.5%) 15 (7.4%)
T/T homozygote 0 0
rs222747 0.946
C/C wildtype 118 (52%) 106 (51.2%)
C/G heterozygote 86 (37.9%) 78 (37.7%)
G/G homozygote 23 (22.0%) 23 (11.1%)
rs224534 0.135
C/C wildtype 83 (39.1%) 65 (39.4%)
C/T heterozygote 91 (42.9%) 82 (49.7%)
T/T homozygote 38 (17.9%) 18 (10.9%)
rs8065080 0.512
A/A wildtype 85 (38.2%) 68 (35.0%)
A/G heterozygote 86 (38.7%) 86 (44.3%)
G/G homozygote 51 (23.0%) 40 (20.6%)
46
Diplotype analysis
Based on the SNP distribution, 27 diplotypes were generated which were present 
in chronic pancreatitis patients and in controls, of which 17 diplotypes were present 
in both groups. Diplotype CCCA/CCCA is most prevalent in both groups. This was 
therefore considered as the reference in calculating the odds ratios for the remaining 
diplotypes. Distribution of diplotypes was not statistically significantly different 
between patients and controls (Figure 2 and 3). 
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Figure 2   Diplotype distribution of chronic pancreatitis patients and healthy controls
Distribution of diplotypes in patients with CP and healthy controls. The diplotypes are compared to the most 
prevalent diplotype CCCA/CCCA (reference)
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Discussion and conclusion
We considered genetic variants of TRPV1 as a candidate gene for CP, as we 
hypothesized that TRPV1 could act as a modifier for CP and that therefore genetic 
variations in TRPV1 could modify the presence and the phenotypical expression of 
CP. In this study, we investigated the association between four SNPs in the TRPV1 
gene and CP in a large cohort of adult CP patients. We found that the genotypic 
distribution of none of these four SNPs was significantly different between the CP 
and control group. 
Furthermore, based on the SNP distribution 17 diplotypes were generated. There 
was no significant difference in distribution of diplotypes between patients and 
controls.
Our study seems to accord with data from TRPV1 knockout animals. There, mice
lacking TRPV1 were not protected against pancreatic inflammation induced by 
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Figure 3   LD plot D'/LOD
Linkage disequilibrium (LD) plot across the TRPV1. The box at the top indicates the TRPV1 gene with the 
four investigated SNP’s. The LD plot is based on the measure of D'. Each diamond indicates the pair wise 
magnitude of LD, with dark grey diamonds indicating strong LD (D' > 0.8) and light grey: uninformative.
LD: linkage disequilibrium is the non-random association of alleles at two or more loci, not necessarily on 
the same chromosome. Linkage disequilibrium describes a situation in which some combinations of alleles 
or genetic markers occur more or less frequently in a population than would be expected from a random 
formation of haplotypes from alleles based on their frequencies.
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cerulein. Because the knockout mice lack functional TRPV1, it seems likely that 
they developed an alternate inflammatory response pathway that compensates for 
the loss of TRPV1 signaling. However, compensation by other receptors in this 
model could not be excluded. The investigators addressed TNFα as a potential 
candidate for the compensatory response. This suggests that the role of TRPV1 in 
the generation of pancreatitis is smaller than anticipated on experimental data from 
other studies.15 We should remember that this is a study on an acute pancreatitis 
model that does not reflect CP. The pathogenesis in acute pancreatitis is probably 
to some extent dissimilar from CP. Therefore, one cannot extrapolate results from a 
secretagogue-induced acute pancreatitis to CP. 
So far, the majority of case-control studies has focused on the association between 
various TRPV1 gene SNPs, most often rs222747 and rs8065080, and pain. One 
study failed to identify a significant association between these SNPs and cold/heat 
pain sensitivity in European Americans.16 Few studies have investigated the role of 
TRPV1 gene and human CP. Further credibility to the role of TRPV1 is provided by 
histochemistry studies showing that TRPV1 is significant upregulated in human CP 
and in pancreatic cancer in comparison with patients with a normal pancreas. 
However, TRPV1 expression was related to the intensity of pain reported by cancer 
patients, but not to the intensity of pain reported by CP patients.17 
In our study, we investigated if TRPV1 polymorphisms are associated with CP, but 
we were actually interested in the question whether “TRPV1 polymorphisms are 
associated with pain in patients with CP?”. Our CP group consisted of patients 
experiencing pain varying from intermittent to persistent and pain intensity ranging 
from disabling to no pain or mild pain. We did not directly quantify pain, which 
makes it difficult to study the exact correlation between TRPV1 and pain due to CP 
in this population. It is very complex to investigate pain, due to different levels of 
pain that patients experience, the use of analgetic drugs and different pain scales. 
Moreover, there are several confounding variables, such as dependence of 
analgetic drugs and the use of alcohol or other narcotic agents. However, since 
almost every patient with CP will experience pain during the course of their disease, 
we lumped patients and investigated TRPV1 in CP patients from our cohort.
Xu and colleagues investigated functional effects of nonsynonymous SNPs in the 
human TRPV1 gene.18 They found that polymorphisms rs222747 and perhaps 
rs222749 resulted in markedly increased abundance of the variant TRPV1 protein at 
the level of whole-cell expression, and at the level of expression at the cell surface. 
The increment in rs222747 mRNA level was probably not sufficient to account for 
the marked change in protein expression.
Our study does have certain limitations. First, with our current sample size, we were 
able to detect a 10 percent difference with 80% power and a 0.05 two-sided 
significance level. As a consequence, we cannot rule out the existence of a smaller 
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than 10% difference between patients with pancreatitis and controls. The clinical 
relevance of a difference below 10% is rather low. Moreover, we combined four 
SNPs into diplotypes, making the study even more robust excluding chance results. 
Second, we have no insights in alcohol use in our healthy controls. Recently other 
investigators  found that the TRPV1 receptor is activated by ethanol and has a role 
in specific behavioral effects of ethanol.19 Since a large proportion of CP patients 
developed CP as a result of liberal alcohol use, these variables may likewise be 
important. 
In conclusion, our results suggest that these four SNPs in do not seem to modify 
the presence and phenotypical expression of CP.  
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Abstract
Background 
Hereditary pancreatitis (HP) is a rare disease which is diagnosed based on clinical 
findings, family history, genetic studies and imaging. Radiological imaging is used 
in diagnosing HP and complications during disease course. There is not much 
known about specific imaging findings in HP. The aim of this study was to describe 
specific imaging findings in HP and to assess the evolution of pancreatic abnormalities 
on different imaging modalities during the clinical course of HP from childhood to 
adulthood.
Methods
We included children and adults with HP if any data of disease course at childhood 
and in which serial imaging (≥ 2) were available. We reviewed all radiological imaging 
studies.
Results
We included 15 HP patients, with a mean age of 32.5 years (range 9-61) and mean 
disease duration of 24.1 years (range 6-42). In total 152 imaging studies (mean 10.1, 
range 3-21) were performed from 1979 until 2012, mostly transabdominal ultraso-
nography or MR. Some 73% of patients had a dilated main pancreatic duct (MPD) 
(width 3.5-18 mm). There was a large variation in size of MPD during the disease 
course, with only a temporary reduction in diameter after a drainage procedure. A 
very wide MPD often coincided with presence of intraductal stones (33%; size 1-12 
mm). In 73% a variable degree of atrophy was visible. This did not correlate with the 
presence of exocrine or endocrine insufficiency. 
Conclusion
There was a large variation on pancreatic imaging in HP patients, with as most 
remarkable finding an increased diameter of the MPD, often accompanied by large 
intraductal stones, with a large variation in MPD size inter- and intraindividually 
during the disease course of HP. 
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Introduction
Hereditary pancreatitis (HP) is a rare disease with an autosomal dominant 
inheritance and an incomplete penetrance of 80-93%.1,2,3 It is most frequently 
caused by cationic trypsinogen (PRSS1) gene mutations.3 Furthermore, mutations 
in the serine protease inhibitor, Kazal type I (SPINK1) are associated with HP.4 The 
diagnosis of HP is made through a combination of clinical findings, family history, 
genetic studies and imaging. Radiological imaging of the pancreas in search for 
findings such as pancreas atrophy, calcifications or pancreatic duct dilatation is the 
cornerstone in diagnosis and staging of chronic pancreatitis (CP). There is a 
number of  imaging modalities available for pancreatitis such as transabdominal 
ultrasonography (TUS), computed tomography (CT), magnetic resonance (MR) 
and magnetic resonance cholangiopancreatography (MRCP) and (previously) 
endoscopic retrograde cholangiopancreatography (ERCP).5 It is unclear which role 
the various imaging modalities play in the diagnostic workup of HP. Furthermore, 
not much is known about the correlation between abnormalities on pancreatic 
imaging, the disease course of pancreatitis and the presence of complications. 
Along the same lines, there is no evidence of the correlation between pancreatic 
atrophy and the presence of endocrine and exocrine insufficiency. Lastly, there is 
no systematic grading system of the degree of atrophy on imaging.
The aim of this study was to describe specific findings on pancreatic imaging in HP 
and to assess the evolution of radiological abnormalities of the pancreas on 
different imaging modalities evolving with the clinical course of HP from childhood 
to adulthood. 
Materials and methods
We screened all HP patients known in the Department of Pediatrics and Gastro-
enterology & Hepatology of the Radboud University Nijmegen Medical Centre in 
the period 1995-2011 for the inclusion criteria (figure 1). The HP diagnosis was 
defined by genetic criteria (the presence of a detected cationic trypsinogen gene 
mutation) or if they met the EUROPAC criteria for HP: two first-degree relatives, or 
at least three second-degree relatives, in two or more generations, with CP for 
which there is no other etiology.2,6 General characteristics including date of birth, 
sex, type of mutation, age at onset and operations and interventions were recorded. 
Furthermore, we recorded the presence of endocrine insufficiency, use of pancreatic 
enzyme suppletion and the presence of diabetes. We reviewed all radiological 
imaging studies of patients during the disease course which were available in our 
hospital. We included all radiological imaging modalities; TUS, CT, MR, MRCP, 
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 secretin-enhanced MRCP and ERCP. We only included patients if two or more 
serial imaging studies were available to assess the evolution of radiological 
abnormalities during the disease course. Each study was reviewed by an 
experienced radiologist (JH). We reassessed the following aspects systematically: 
the size of the main pancreatic duct (MPD), the presence of intraductal stones and 
calcifications and the presence of atrophy. A normal diameter of the MPD was less 
than 2 mm on US and 3 mm on MRCP.7,8 The degree of atrophy is classified as: 1) 
‘none’; no signs of atrophy, 2) ‘moderate’; some signs of atrophy with decreased 
transverse diameter of the pancreas, and 3) ‘severe atrophy’; almost no visible 
pancreatic tissue. If there was more than one study performed in one year, the 
average size of pancreatic duct and other aspects were used as a value.
Statistical analysis
The mean age, age of onset, duration of disease with median and range were 
calculated with SPSS for Windows (version 18.0; SPSS Inc., Chicago, IL). Figure 2 
was generated using GraphPad Prism 4 for Windows.
Results
Sample characteristics 
A total of 42 patients with HP were identified. For 17 HP patients, radiological 
imaging studies were available (figure 1). We excluded two patients, where only a 
single imaging study was available. A large proportion of the patients was only 
seen in our department for second opinion and genetic analysis and therefore no 
serial imaging was available. As a consequence, we included 15 HP patients in this 
study (table 1); two children and 13 adults. There were nine males (60%). The mean 
age of patients was 32.5 years (range 9-61). Thirteen patients (87%) had a mutation 
in the PRSS1-gene (seven R122H mutations and six N29I mutations). Two patients 
(13%) had a homozygous mutation in the SPINK-gene (N34S). In these two patients, 
the HP diagnosis was also based on a positive family history. The mean age of 
onset of disease was 8.6 years, but with a wide range (1-22). In one patient HP was 
diagnosed at adult age (22 years). In approximately half of patients, HP was 
diagnosed < 12 years-of-age. The mean duration of disease was 24.1 years (range 
6-42). Eight (53%) patients underwent an intervention: surgical drainage in two 
patients (longitudinal pancreaticojejunostomy), combined drainage and resection-
procedure in two patients, cystogastrostomy in one patient and an ERCP with 
ESWL in one patient. In two patients, a bilateral thoracoscopic splanchnicectomy 
was performed because of severe pain. Two patients had diabetes mellitus and 
in one patient there was concomitant exocrine insufficiency However, exocrine 
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insufficiency was not assessed systematically in all patients (by use of fecal elastase). 
Pancreatic enzyme suppletion was initiated in five patients, mostly based on presence 
of fatty stools.
Imaging modalities
In total 152 imaging studies were performed from 1979 until 2012 (table 2). There 
was a wide range in the number of imaging studies performed in each patient 
(range 3-21) with an average of 10.1 studies (median 10) per patient. The reason for 
imaging was variable: routine workup, imaging at exacerbation and imaging in case 
of pain. Particularly, TUS was used frequently; 71% (108) of all imaging studies were 
TUS. In a third of patients more than 10 TUS were performed. Furthermore, MR was 
performed frequently. In 80% (12/15) of patients a MR-study was performed: eight 
MRs, 10 MRCPs and seven secretin-enhanced MRCPs. In six patients a total of 10 
ERCPs were performed. ERCPs were performed from 1978-2001. Since 2001 no 
ERCPs were performed in this cohort of HP patients. One patient was subjected to 
therapeutic ERCPs with ESWL with stone-extraction.
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Figure 1   Flowchart of study population
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Findings at imaging
In three patients (age 9, 13 and 17 years) a normal pancreas was visible during a 
mean follow-up of disease of 6.3 years (range 4-8 years) (table 3). In one child at 
the age of 13 years already signs of CP were present with a dilated MPD, calculi and 
pancreatic atrophy.
Pancreatic duct
In 11 patients (73%) the MPD was dilated (table 3, figure 2). In 6/11 patients, there 
was a moderate dilatation of the MPD with a maximum diameter of 8.5 mm (mean 
5.3 mm, range 3.5-8.5) during an average disease duration of 30.3 years (range 
24-42 years). In 5/11 patients, there was a large dilatation of the MPD with a 
maximum diameter of 18 mm (mean 13.2 mm, range 10-18) during an average 
disease follow-up of 26.8 years (range 11-34 years). An extremely dilated MPD (>10 
mm) often coincided with presence of pancreatic stones. In 33% of patients (5/15) 
stones in the MPD were present. The size of stones varied from 1-2 mm to 12 mm. 
The number of stones in the MPD could not be evaluated, but mostly more than one 
stone was present. Frequently there was a uniform dilatation of the MPD, both 
proximal and distal from intraductal stones. In 80% (4/5) of the patients with 
intraductal stones the diameter of the MPD was greater than 10 mm (mean 12.3 
mm, range 10-18 mm). In 6/11 patients a dilated MPD was seen without intraductal 
stones. However, in this subset of patients, the MPD was less dilated than in patients 
with intraductal stones (mean 7.5 mm, range 5.5-17 mm). Six patients underwent an 
intervention either a surgical drainage procedure or therapeutic ERCP with ESWL 
(indicated by arrow in figure 1). After intervention, a decrease in MPD-size was seen 
in all patients, persistent during a few years after the procedure. However, in two 
patients although the MPD was not dilated, a surgical drainage procedure was 
performed. Eventually in 3/6 of patients there was a renewed increase of MPD size 
varying from 5 to 16 mm (patient 2), 2 to 5 mm (patient 8) and 5 to 10 mm (patient 
9) during 10-22 years following an intervention. Overall, there was a progression of 
MPD dilatation during course of disease.   
Atrophy
Signs of atrophy were visible in 73% of patients (11/15) (table 3). In nine patients 
atrophy was classified as moderate and in two patients there were signs of severe 
atrophy. There was no clear association between pancreatic atrophy and presence 
of exocrine or endocrine insufficiency. In two patients with severe atrophy one 
patient had no signs of exocrine or endocrine insufficiency. On the other hand, one 
patient with no signs of atrophy on imaging had clear signs of exocrine insufficiency 
(fecal elastase < 15 mg/g). In the group of patients with moderate atrophy (n=9), 
there were six patients who did not use supplementary pancreatic enzymes. Some 
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patients did use pancreatic enzymes without confirmation of exocrine insufficiency, 
but based on presumed presence of fatty stools. There was no clear relationship 
between the duration of disease and the presence of exocrine insufficiency. There 
was only one patient with diabetes; this patient underwent a resection procedure 
and had signs of severe atrophy on imaging.
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Figure 2   Diameter of MPD (mm) during course of disease (years) per patient
This figure represents the variation of the size of the main pancreatic duct (MPD) during the disease 
course. After an intervention a decrease in MPD size  is seen, but eventually in 3/6 of patients there was  
a renewed increase of MPD size.
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Other aspects of imaging
In four patients there were pseudocysts. Small calcifications in small ductuli were 
seen (often seen on CT in the parenchyma) in two patients. In two patients a pancreas 
divisum was likely to be present as judged by MRCP and CT.
Discussion
In this study, we reviewed 152 radiological imaging studies in 15 HP patients during 
a disease course of 23.8 years. In some patients, imaging was repeated frequently, 
with a maximum of 21 imaging studies in one patient during a disease course of 34 
years. The most often used imaging modality was TUS, followed by MR-scanning. 
At imaging a total of 73% of patients developed a dilated MPD. The size of MPD 
varied between 3.5 mm and 18 mm. This accords with the literature.9 The inter- but 
also intraindividual variation is remarkable, as shown in figure 1. Eighty percent of 
patients with a very wide MPD (>10 mm) also had intraductal stones. The size of 
MPD decreased in all patients who underwent a drainage procedure, but recurrence 
was frequent and occurred in about 50% of patients. This finding has clinical 
consequences as the indication for some drainage procedures depends on the 
dilation of the MPD (for example a Puestow procedure). 
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Figure 3
Two imaging modalities in one patient (patient 10): MRCP March 2010 and CT-scan in April 2010. 
They show a dilated MPD (size 12.8 mm) with multiple intraductal stones. The stones are not calcified, as 
seen on the CT
66
CHAPTER 4
Figure 4
In the same patient (patient 4) three imaging modalities: a CT-scan (2002), a transabdominal ultrasonography 
(2009) and a secretin-enhanced MRCP (June 2012). They show a dilated MPD and atrophy of the pancreas
67
In our cohort we observed intraductal stones in a third of patients; frequently 
multiple and large stones, with a size of 1 mm to 12 mm. These findings accord with 
data from the literature that reports intraductal stones in up to 52% of HP patients.10,11 
Graziani et al.  described stones as large with a typical pattern at CT examination 
with hyperdense peripheral margins and a hypodense center due to the lack of 
calcium deposits in the central core, an aspect often described as a “bull’s-eye”.9 
Pancreatic atrophy was classified as moderate in 60% of our patients, while 13% of 
patients had signs of severe atrophy. When signs of atrophy were detected on 
imaging, suppletion of pancreatic enzymes was started in only 5/11 patients with 
presumed exocrine insufficiency. 
When we evaluate the different imaging modalities used in our study, there are 
some important issues. TUS is used frequently in our study population, not only in 
advanced stages of disease, but also for the diagnosis of disease. TUS allows 
identification of thinning of pancreatic parenchyma, dilatation of the MPD and of 
side branches and intraductal (calcified) stones. Therefore it can be used to confirm 
4
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Table 4  The presence of atrophy
Patient Atrophy Diabetes Exocriene insufficiency Suppletion of 
pancreatic enzymes
1 moderate - - -
2 moderate - NR +
3 none - + +
4 severe - - -
5 moderate - - -
6 moderate - - -
7 moderate - - -
8 moderate - - -
9 severe + NR +
10 moderate - NR +
11 moderate - - -
12 moderate - NR +
13 none - - -
14 none - - -
15 none - - -
NR: not reported
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the diagnosis of advanced CP, but is probably not very accurate in diagnosing early 
CP.12 Dynamic MRCP during secretin administration is able to identify initial 
morphological changes of the pancreatic duct system and could therefore be used 
in the early diagnosis of CP.12,13 As a (variable) dilatation of the MPD and pancreas 
atrophy are the most remarkable imaging findings in our HP patients, we advise to 
perform a dynamic MRCP during secretin administration in the early diagnosis of 
HP, and during follow up in case of exacerbation and for analysis of exocrine 
function.14  Due to the young age of the patients and long term follow up, CT imaging 
should be minimized. Another advantage of MRCP, besides the lack of radiation, is 
the reproducible depiction of the entire gland and its ductal system, as opposed to 
the operator and patient dependent TUS.
Limitations
Our first limitation is the sample size. This is a small group with HP patients in which 
frequent/serial imaging is available. On the other hand, to the best of our knowledge, 
this is one of the first studies to report multiple imaging findings in HP patients with 
a long disease follow-up.
Our second limitation is the revision of imaging studies. We had to revise imaging 
studies from 1979 onwards. Our reassessment depended on the static images of 
TUS that were recorded. Furthermore, the quality of imaging from 1979 until now 
has greatly improved. However, this was inherent to a retrospective analysis with a 
long duration of follow up. 
In conclusion, this is the first retrospective radiologic analysis of a cohort of 15 HP 
patients with a long term follow-up with mostly TUS and MR. Key findings in imaging 
were the dilatation of the MPD with a large intra- and interindividual variation during 
the course of the disease, often accompanied by large intraductal stones.
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Abstract
Background & Aims
Chronic pancreatitis (CP) has a heterogeneous aetiology. In the Western world, the 
predominant cause is alcoholism, while in India idiopathic chronic pancreatitis 
(ICP) including tropical chronic pancreatitis (TCP) is thought to be common. TCP 
has been defined as a form chronic pancreatitis, with unique epidemiological and 
clinical features. However, the clinical profile of CP and ICP in India is changing. 
The aim of our study was to investigate the phenotype of ICP in India compared to 
the phenotype of ICP in the Western World.
Methods
We included CP patients from three registries from India, Germany and the 
Netherlands. We compared data regarding age, age of onset, cause of CP and the 
presence of CP complications between the three cohorts. 
Results
We included 1777 CP patients; (India n=1033; Germany n=386; Netherlands n=358). 
The majority (68%) of patients were male. Relative to the Western cohorts Indian CP 
patients were younger, had a younger age of onset and smoked less frequently. 
The majority of Indian subjects were diagnosed with ICP (65%) (Netherlands 
40%, Germany 22%). Endocrine insufficiency and pancreatic calcifications were 
more frequently seen in Indian ICP patients. Pain was present in the large majority 
(> 85%) of all CP patients. 
Conclusions
The phenotype of Indian CP patients is changing, as our analysis demonstrates 
that most of Indian patients now have a form of CP that bear phenotypic resemblance 
to ICP. Indian patients have younger onset of CP with more endocrine insufficiency 
and pancreatic calcifications, and there is a shift towards the phenotype of ICP in 
the Western world.
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Introduction
Chronic pancreatitis (CP) is a disease with a heterogeneous etiology characterized 
by progressive destructive changes of the pancreas. In the Western world, the 
predominant cause of CP is alcohol abuse, while in tropical countries like India, 
tropical chronic pancreatitis (TCP) has been reported as relatively common.1 TCP 
was first described in 1959 in a group of young malnourished diabetics from 
Indonesia.2 TCP has been loosely defined as a form of “idiopathic chronic 
pancreatitis (ICP)”, with unique epidemiological and clinical features3. Initially,  it 
was defined as “pain in childhood, diabetes in puberty and death at the prime of 
life”.4 Several reports of pancreatitis patients stemming from tropical regions 
followed which fed the idea that there is a specific form of CP unique to the tropics.4-8 
Later studies described it as a form of CP characterized by recurrent abdominal 
pain, pancreatic calculi and diabetes mellitus, occurring mostly among poor 
children and young adults of developing nations. Other forms of CP such as caused 
by alcohol have been reported although earlier series from India are dominated by 
TCP.9,10 TCP is an enigmatic type of pancreatitis and the etiology is elusive. The 
classical phenotype of TCP as described in early publications is seen less 
frequently, while idiopathic CP (ICP) is described more commonly. Our hypothesis 
is that the phenotype of ICP in India now resembles the phenotype of ICP in the 
Western world. This is important as if our hypothesis is true, the results from Indian 
studies can be generalized to other populations and vice versa. The aim of our 
study was to investigate the phenotype of CP and ICP in India compared to the two 
large cohorts of CP patients from the Netherlands and Germany.
Methods
Databases
This is a comparative analysis of the phenotype of CP cases recorded in three 
separate registries. The Dutch registry was initiated in 2000 by the Department of 
Gastroenterology & Hepatology of the Radboud University Nijmegen Medical Centre, 
The Netherlands. It was designed to be compatible with international registries and to 
satisfy the need for accurate phenotypical data of CP patients. The registry collects 
detailed demographic data, data on past medical history, in addition to clinical and 
procedural information. Furthermore, this registry records pharmaceutical therapy. 
The patients included in the database are regularly (> once a year) seen in the 
Department of Gastroenterology & Hepatology. The  registry is updated continuously 
and for the purpose of this study in 2012 all records were scrutinized and compared 
against paper records and electronically recorded patient information.11
5
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The Indian registry stems from the “Indian Pancreatitis Study group (IPANS)”. This 
registry was initiated by members of the study group. This registry collects data on 
Indian CP patients using an online data entry website as interface (www.ipans.org). 
Investigators of a national network of thirty-two centers participated in the study by 
entering clinical information on CP patients using the online interface.12 Investigators 
needed to enter data prospectively, consecutively and completely. The nationwide 
character of the registry was assured as major centres were targeted to enrol 
patients.12 A full list of participating sites appears at the end of the article.
The German database originates from Germany and selected CP patients according 
to the M-ANNHEIM-criteria.13 Clinical data from patients with CP presenting to the 
Department of Medicine II, University Hospital of Mannheim, Germany, during the 
period 1997 until 2007 were retrospectively recorded from patient charts and, if 
possible, prospectively collected during daily clinical practice.
All the three registries maintained the same definition for the diagnosis of CP. CP is 
based on the presence of typical complaints (recurrent upper abdominal pain, 
radiating to the back, relieved by leaning forward or sitting upright and increased 
after eating) and suggestive radiological findings, such as pancreatic ductal lesions 
and pancreatic calcifications revealed by  ultrasonography, CT scan, MRI, magnetic 
resonance cholangiopancreatography (MRCP), endoscopic cholangiopancreato-
graphy (ERCP) or endoscopic ultrasound (EUS).13-15
Data collection
Data were extracted from these three registries in order to create a merged 
database. We collected data regarding the cause of CP. Patients who had an 
estimated intake of alcohol of more than 60 g (females) or 80 g (males) daily for 
more than two years were classified as CP of alcoholic origin. 
The diagnosis of hereditary pancreatitis is defined by the presence of a detected 
cationic trypsinogen gene mutation (with or without clinical or radiological 
manifestations of CP) (genetic criterion) or by the presence of a CP with a familial 
history (genealogical and clinical criteria). A familial history is defined by recurrent 
acute pancreatitis or CP occurring in two first degree relatives or three or more 
second degree relatives, in two or more generations in the absence of precipitating 
factors after negative work-up for known CP aetiology.16 ICP was diagnosed if 
precipitating factors such as alcohol abuse, bile stones, trauma, medication, 
infection, metabolic disorders. In the Indian database, a distinction between 
alcoholic CP and ICP has been made. Patients with TCP have been included in the 
idiopathic group. TCP was defined based on three most distinctive features of the 
disease: 1) onset at less than 30 years of age; 2) a BMI less than 18 kg/m2; 3) 
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subjects with CP who also did not consume alcohol and who did not have any other 
specific cause for the pancreatitis.12
In the Indian database, pain was dichotomously recorded as present or not present. 
In the Dutch database, pain was assessed as type A and type B pain. The type A 
pain pattern, typically observed in acute relapsing pancreatitis, is short-lived and 
pain episodes usually last less than 10 days and are separated by long pain-free 
intervals of several months to a year. B-type pain pattern is characterised by 
prolonged periods of persistent pain or clusters of recurrent severe pain 
exacerbations, lasting two or more days per week for at least two months, and 
requiring frequent hospitalisations.17 In the German database, a classification of 
pancreatic pain according to the severity index was done by combining the 
observed pain patterns together with their treatment interventions.13 For the purpose 
of the current analysis we categorized “pain only during acute pancreatitis’ and 
‘intermittent episodes of pain’ as type A pain, and “constant pain” as type B pain. 
Statistical analysis
Statistical analysis was performed using SPSS for Windows (version 18.0; SPSS 
Inc., Chicago, IL). Differences between continuous variables were tested using the 
ANOVA test and categorical variables by the chi-square test. The analysis of our 
data was performed in two stages. First, we lumped cases of all causes from India, 
Germany and the Netherlands together and we compared the clinical characteris-
tics and demographic variables between the three different cohorts. Next we 
separated the ICP patients from other causes and analyzed this cohort separately. 
Results
All CP patients
Demography
We included a total of 1777 CP patients; 1033 patients from India, 386 patients from 
Germany and 358 patients from the Netherlands (table 1, figure 1). The mean age 
is 51.4 years (95% CI 50.7-52.2). CP patients from India are significantly younger 
than CP patients from Germany and the Netherlands; 45.9 years (95% CI 45.0-46.8) 
compared to 60.5 years (95% CI 59.0-62.1) and 57.2 years (95% CI 55.8-58.6) 
(p<0.05). There were 1213 male patients (68%). The gender balance was not different 
between the three cohorts. The age of onset of disease in Indian CP patients (36.4, 
95% CI 35.6-37.3) was significantly lower than in German (47.4, 95% CI45.7-49.1) or 
Dutch CP patients (39.6 years, 95% CI 38.1-41.1) (p<0.05). There are more smokers 
in the Western European cohorts (Netherlands 65%, Germany 62%) compared to 
India (28%) (p<0.05).
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Etiology
Regarding etiology, overall 894 (51%) patients had ICP and 719 (41%) patients had 
ACP. ICP was more common in India (65%) compared to Germany (22%) and the 
Netherlands (40%). In the Indian ICP cohort, 39 (3.8%) patients fulfi lled the criteria 
for TCP (data from a previous publication of the same cohort).12 For purpose of the 
analysis they were included in the ICP group.
Hereditary CP was not very common: 22 (6%) German CP patients and 33 (9%) Dutch 
patients had hereditary CP.  In Germany there was a substantial group ‘miscellaneous 
cause’ (17%): autoimmune pancreatitis, hypertriglyceridemia, anatomical variations. 
Phenotype
Pain was present in the large majority of patients. In India, 94% of the CP patients 
experienced pain. In Germany and the Netherlands, the type of pain differed; in 
Germany, a large majority (80%) experienced type A-pain, while in the Netherlands 
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Figure 1   The cohort of our study
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the majority (53%) has type B-pain. The presence of calcifications varied greatly 
between the cohorts. In India, 69% of the CP patients had calcifications, compared 
to 52% in the Netherlands and 39% in Germany (p<0.001). Endocrine insufficiency 
was more common in Indian CP patients (in 41%) than in German CP patients (in 
34%) and Dutch CP patients (33%) (p<0.001). 
CP patients in the Netherlands were frequently subjected to surgery compared to 
Indian or German patients: 56% compared to 13% and 8%. 
In the Indian database the presence of exocrine insufficiency was only documented in 
a small subset of patients (95, 9.2%).  In ten Indian CP patients exocrine insufficiency 
was present. In Germany and the Netherlands exocrine insufficiency was present in 
54% and 40% of CP patients. Pancreatic adenocarcinoma was reported in 42 (4%) 
Indian CP patients, compared to seven (2%) German CP patients and six (2%) Dutch 
CP patients.
ICP
Demography 
Upon analysis of ICP patients the differences between the 3 cohorts are amplified 
(table 2). 
A total of  719 cases have been classified as ICP: 666 patients from India, 84 patients 
from Germany and 144 patients from the Netherlands. ICP patients overall were 
younger then patients with CP of all causes: 47.3 years (95% CI 46.2-48.5) compared 
to 51.4 years (95% CI 50.7-52.2). There was a large difference in age of onset of 
disease; in Indian ICP patients 32.8 years (95% CI 31.7-33.9), compared to 42.4 
years (39.9-45.0) in Dutch ICP patients and 51.0 years (95% CI 47.0-55.0) in German 
ICP patients. 
The majority of ICP patients was male (56%), and this was equal in all cohorts. A small 
minority of the Indian ICP patients smoked (11%), compared to 51% of the Dutch 
ICP patients and 35% of German ICP patients.
Phenotype
As in CP of all causes, most ICP patients experienced pain: in 94% of the Indian ICP 
patients, in 78% of the German ICP patients and in 93% of the Dutch ICP patients. 
In the Netherlands, type B pain was more common than in Germany. Indian ICP 
patients had more endocrine insufficiency (39%) compared to German ICP patients 
(32%) and Dutch ICP patients (28%). There was a large difference in the presence 
of calcifications: 72% in the cohort from India, in contrast to 31% in Germany and 
44% in the Netherlands
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Discussion
This large comprehensive issue aimed to compare the phenotype of CP in India to 
CP in Western countries. We found that Indian CP patients were younger and had a 
younger age of onset of disease than CP patients in Germany and the Netherlands. 
The majority of Indian patients were diagnosed with ICP and a minority with ACP. In 
Germany and the Netherlands this ratio is exactly reversed. 
There are regional differences in CP etiology. In Western counties, alcohol is the 
most frequent cause of CP. In India, TCP is known as a distinct type of disease. TCP 
is generally characterized by an advanced form of CP with large pancreatic calculi 
that affects very young malnourished individuals who often develop diabetes and 
have an aggressive course of the disease.4 Nowadays, the classical form of TCP 
appears to be less frequent. In a study of 411 CP patients, only 5.8% of the patients 
fulfilled the classical criteria for TCP.18 This is similar to the proportion of patients 
seen in our Indian cohort (3.8%).12 The majority of Indian patients in our cohort were 
diagnosed with ICP and a minority with ACP. When we compare ICP in India to ICP 
in the Western world, there are still important differences. The age of onset of ICP 
in Indian patients in our cohort was 32.8 years, more than a decade younger than 
in the Western cohort. In the last decades though, the age of onset of CP in India 
has shifted upwards. In a study in 1987, the mean age of onset of CP was 20.7 
years.19 In a cohort in 2004, the age of onset was 30.6 years.3 In another cohort, the 
age of onset of ICP in India was 27.5 years.18 So ICP in India still occurs at a younger 
age, but there has already been a shift towards an older age of onset, as in ICP in 
the Western cohort. 
The prevalence of endocrine insufficiency in Indian CP patients has dropped with 
time. In 1987 diabetes was prevalent in 77% of cases, compared to 59.7 % in 
2004.19,20 In 2010, diabetes was prevalent in 35.5% in ICP.18 In our study, diabetes 
was prevalent in about 40% in Indian CP and ICP patients, compared to 
approximately 30% in the Western cohort. So the prevalence of diabetes seems to 
decline in CP in India, equal to the Western world. 
Another remarkable aspect of TCP which has been reported repeatedly, is the high 
association between TCP and pancreatic carcinoma.21,22 In our study, the frequency 
of pancreatic carcinoma in Indian CP patients was 4%, comparable with the 
incidence of pancreatic carcinoma in CP patients overall.23 In the Indian ICP group 
the frequency of pancreatic carcinoma was also 4%. This is much lower than the 
elevated risk reported in TCP. The frequency in the Dutch group is relatively low 
(2%), but probably due to small numbers.  
All together, the phenotype of CP and ICP in India is rapidly being replaced by a 
more ‘Western’ type of disease (older onset of disease, less endocrine insufficiency, 
less frequent calcifications). This  could be due to changes in environmental factors, 
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dietary and lifestyle patterns, such as industrialization, and environmental factors 
such as alcohol and smoking.24 Furthermore, several genetic alterations have been 
discovered to be associated with ICP in Western counties, which has changed the 
understanding of the pathogenesis of CP. The change of phenotype of ICP in India 
towards the ICP phenotype in the Western world, suggests that genetic defects 
might play a role in ICP in India. Variants in at least two genes, SPINK1 and CTRC, 
are strongly associated with TCP.25 A loss-of-function alteration in chymotrypsino-
gen C (CTRC) gene has been shown to be associated with TCP.26 Furthermore, TCP 
was found to be strongly associated with the N34S mutation in the SPINK1 gene.27 
In that study, approximately 50% of the TCP patients were carriers for N34S, 
whereas 14% were homozygous for this mutation. Mutations in cationic and anionic 
trypsinogen gene were not found to play an important role in causing CP in Asia 
Pacific region.26 Thus, the genetic predisposition to TCP and ICP in India is partially 
similar to ICP in the Western world since TCP shares similar susceptibility loci with 
ICP in the West.25 This suggests that TCP and ICP in the West could be related 
disease entities. 
This study has several strengths and weaknesses. Obvious strengths include the 
large sample size. The first limitation is the use of three different cohorts, with 
occasionally different inclusion of data in the different countries and missing data. 
For instance, exocrine insufficiency is only reported in a minority of the Indian 
patients (95 of 1033), because in this aspect there was no uniformity of method 
across all centers. The second limitation may be a selection bias, whereas the CP 
population partially originates from tertiary referral centers. This is reflected by the 
large number of surgical procedures in the Dutch cohort. This can be explained by 
the large number of thoracoscopic splanchninectomy performed in Dutch patients 
(78), due to expertise in the local hospital.
In conclusion, the phenotypes of Indian ICP patients used to include a significant 
proportion of patients with TCP, but now most of Indian patients have a form of CP 
that bear phenotypic resemblance to ICP. Indian ICP patients still have younger 
onset of CP with more endocrine insufficiency and pancreatic calcifications, but 
there is a shift towards the phenotype of ICP in the Western world, associated with 
various environmental factors and genetic alterations.28 
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Abstract
Familial adenomatous polyposis (FAP) is characterized by the development of 
multiple adenomatous polyps predominantly in the colon but also in the duodenum. 
Scattered case reports indicate that there is a risk for pancreatitis in FAP. The most 
likely cause of pancreatitis in FAP is obstructing ampullary adenomas. We describe 
seven FAP patients who experienced one or more episodes of pancreatitis. Two 
patients experienced pancreatitis after endoscopic treatment of ampullary adenoma. 
The cause of the pancreatitis in five of seven patients could not be determined, as 
none of the patients had obstruction of the ampulla. Furthermore, other risk factors 
for pancreatitis such as pancreatic serine protease inhibitor Kazal type I (SPINK1) 
gene mutations were ruled out. A review of literature identified 20 FAP patients who 
developed the first episode of pancreatitis at a mean age of 45 years (range 23 to 
72 years). Some 55% had recurrent episodes of pancreatitis. Eight patients had 
(peri) ampullary adenomas or carcinomas. In most cases, the course of pancreatitis 
was mild with an uneventful outcome, but one patient died after an episode of 
acute pancreatitis. 
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Introduction
Familial adenomatous polyposis (FAP) is an autosomal dominant inherited disorder, 
caused by germline mutations in the adenomatous polyposis coli (APC) tumor 
suppressor gene. Phenotypically, it is characterized predominantly by the 
development of multiple colonic adenomatous polyps. Apart from colonic 
adenomas, 58-90% of FAP patients develop duodenal adenomas, most notably in 
the proximity of the ampulla. The presence of duodenal adenomas is associated 
with an approximately 300 times higher risk for duodenal cancer compared to the 
general population and the lifetime risk is estimated to be 5%.1-5 
Apart from the presence of colonic and duodenal adenomas, few case reports 
point to an association of FAP with recurrent acute pancreatitis.6-13 One reasonable 
hypothesis is that ampullary adenomas may cause pancreatitis by obstructing the 
common bile duct.6-13 On the other hand, not every FAP patient with duodenal 
adenomatosis will develop pancreatitis, and FAP patients without duodenal 
adenomas also appear to be at risk for pancreatitis. This suggests that other, as of 
yet unidentified, factors play a role. Pancreatic serine protease inhibitor, Kazal type 
I (SPINK1), is a potent inhibitor inhibitor of trypsin activity, and a recent study found 
that a SPINK1 allele was enriched in a population of patients with acute recurrent 
pancreatitis.14 The N34S mutation was present in a frequency of 7.8% in patients, 
but only in 2.6% of healthy controls, which suggests that SPINK1 may play a role in 
the susceptibility for acute pancreatitis.
The purpose of this study is to report the clinical characteristics of seven FAP 
patients who presented with acute pancreatitis and to illustrate this condition with 
an overview of the current literature. In addition, we explored whether SPINK1 
mutations contribute to the risk of pancreatitis in these patients. 
Materials and methods
Patients
The setting of the study was a tertiary referral centre for FAP in the Netherlands. We 
identified patients by a search of the morbidity database of the department of Gas-
troenterology and Hepatology, which includes the ICD-9 diagnoses of 114 FAP 
patients. FAP was diagnosed based upon the presence of more than 100 
adenomatous colorectal polyps and a positive family history and/or by genetic 
testing of an APC mutation. We selected cases with a diagnosis of at least one 
documented episode of pancreatitis. We reviewed medical records of all cases 
including results of radiological, endoscopic or pathologic studies. Pancreatitis 
was diagnosed by clinical abdominal symptoms and elevated serum amylase and 
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defined as idiopathic in case precipitating factors such as alcohol abuse, trauma, 
medication, infection, metabolic disorders and/or a family history were all absent. 
Duodenal adenomas were detected by a side viewing duodenoscope (TJF-160 
Olympus) and classified according to the modified Spigelman classification.15 This 
classification is based on the number and size of polyps, their histology, and the 
degree of dysplasia. Stage I and II signify mild duodenal polyposis while stage III 
and IV indicate severe disease.15
Literature
We performed a MEDLINE literature search using the Pubmed interface (http://
www.ncbi.nlm.nih.gov/entrez) for articles focused on patients who had FAP and 
presented with acute pancreatitis in order to obtain a comprehensive overview of 
the condition. Our search strategy was performed with the following terms: familial 
adenomatous polyposis; FAP; acute pancreatitis; duodenal polyposis, for the 
period 1970–2005.
Articles written in English, French, Italian, Dutch, or German were considered for 
inclusion in the analysis. The references of the traced articles were scrutinized for 
additional articles. Data were collected with special attention to the following items: 
demographic features, age at onset of FAP and pancreatitis, presence and 
localization of duodenal polyps, comorbidity, and follow-up.
DNA studies
We extracted genomic DNA from whole blood according to established protocols 
using the Puregene DNA isolation kit (GENTRA systems, Minneapolis, Mn, USA). 
We searched for two prevalent SPINK1 gene mutations: N34S and P55S. We sought 
for these mutations using an allele specific PCR as described elsewhere. Briefly, a 
50µl reaction was prepared that contained 200 ng genomic DNA, 10 mM Tris-HCl 
(pH 9.0), 50 mM KCl, 0.1% TRITON, 2 mM MgCl2, 0.25 mM dNTP’s, 3.0 U Taq-DNA-
polymerase and 100 ng of sense, anti sense and mutation primers 16. Cycling 
conditions called for an initial step at 94C for 5 minutes then 35 cycles at 94C for 30 
seconds, 59C for 30 seconds, 72C for 30 seconds, and a final elongation step at 
72C for 5 minutes. The PCR product was subjected to gel electrophoresis and 
analysed by visual inspection. 
Results
We identified seven FAP patients (five female, three male) with a mean age of 44 
years (range 21–64 years) who had at least one single episode of acute pancreatitis 
(table 1). 
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Case 1
A 34-yr-old woman (table 1) with FAP underwent a subtotal colectomy at 17 years 
of age. She was admitted to the hospital with acute abdominal pain and vomiting. 
She did not use any medication. Past history included occasional alcohol intake. 
Laboratory investigations demonstrated an elevated serum amylase (3955 IU/l; 
normal values < 100 IU/l). Other laboratory values including liver enzymes, 
peripheral blood count, serum calcium and triglyceride levels were within normal 
range. Ultrasound examination of the abdomen demonstrated signs of acute 
pancreatitis with fluid surrounding the pancreas, but no abnormalities to the liver or 
bile duct. A computed tomography (CT) revealed slight swelling of the pancreas 
and some infiltration in surrounding areas. Acute pancreatitis was diagnosed and 
treated conservatively. Because of an elevation of temperature and infection 
parameters antibiotics were added, although the CT did not show any signs of 
necrosis or infection. She recovered well and after seven days she was discharged 
from the hospital. She had two recurrences of pancreatitis, which were treated 
conservatively and the subsequent course was uneventful so far. The etiology of 
the recurrent episodes of pancreatitis could not be determined. Alcohol abuse was 
ruled out, and we failed to elicit a positive family history for the disease. 
Duodenoscopy showed approximately five small duodenal polyps, none in the 
proximity of the ampulla, classified as Spigelman stage II. Histological analysis 
showed only low-grade dysplasia. Magnetic resonance imaging (MRI-MRCP) 
revealed no abnormalities of the pancreatic ducts and no signs of gallstones.
Molecular analysis demonstrated that she possessed two wild type copies of the 
SPINK1 gene, excluding the N34S and P55S mutations.
Case series
Table 1 summarizes the pertinent clinical data of all FAP patients who had at least 
one single episode of acute pancreatitis. Two patients experienced pancreatitis 
after endoscopic treatment of an ampullary adenoma. In one patient endoscopic 
snare papillectomy was performed because of an ampullary adenoma with high 
grade dysplasia. Immediately after the procedure he developed pancreatitis, which 
was treated conservatively and resolved without sequelae. Another patient 
experienced pancreatitis after endoscopic plasma coagulation treatment of an 
ampullary adenoma. This was treated conservatively and the subsequent course 
was uneventful. She underwent a surgical papillectomy one year later uneventful.
We could exclude obvious causes for acute pancreatitis in all other cases. All 
patients have duodenal polyps, but there were no signs of obstruction of the 
ampulla. Gallstones either in the gallbladder or in the common bile duct were 
absent. Furthermore, there was no history of excessive alcohol consumption. At the 
time of pancreatitis, the patients did not use drugs associated with pancreatitis. 
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One patient had concomitant hyperparathyroidism, with marginally elevated serum 
calcium concentrations (Calcium 2.73 mmol/l, albumin 32 g/L). Although hyperpar-
athyroidism may be associated with acute pancreatitis, it is debatable whether it 
contributed to the development of this episode of pancreatitis. In most instances it 
occurs when hypercalcaemia is moderate to severe or if concomitant risk factors 
such as treatment with steroids and azathioprin are present. One patient had 
recurrent episodes of acute pancreatitis resulting in chronic pancreatitis, while 
pancreatitis resolved without sequelae in the remaining four patients. Genetic 
analysis of the SPINK1 gene showed no mutation in all cases. The patients with 
single bouts of pancreatitis after endoscopic treatment of ampullary adenoma were 
not genetically tested.
Literature search
We identified eight articles describing patients with FAP and pancreatitis.6-13 (Table 2) 
Most articles were case reports on one to three cases.6,8-12 Two articles described a 
series of patients.7,13 In a series of 141 patients with FAP, 5 patients with pancreatitis 
were reported.7 The total population of patients with pancreatitis from all articles 
combined consisted of 21 patients (13 female, four male, four unknown). All patients 
were diagnosed with FAP and underwent colectomy. The mean age of onset of 
pancreatitis was 45 years (range 23 to 72 years). The oldest patient (72 years) was 
diagnosed with pancreatitis after biopsies of a papillary polyp. A total of 12 of 20 
patients experienced recurrent episodes of pancreatitis. The majority of patients 
were subjected to endoscopic retrograde cholangiopancreaticography (ERCP). 
Three patients had a peri-ampullary adenocarcinoma and five patients had an 
ampullary adenoma. Six patients had duodenal adenomas. Snare resection of the 
ampullary adenoma and subsequent sphincterotomy was performed in four 
patients. Sixteen patients underwent pancreatic surgery. The performed procedures 
ranged from drainage of a pancreatic abscess to Whipple’s resection and Roux-Y 
choledochojejunostomy. Eight patients eventually underwent a pancreatectomy or 
pancreaticoduodenectomy was performed. In most cases, the outcome was 
uneventful. Follow-up was not reported in all cases. One patient died after an 
episode of acute pancreatitis. 
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Table 2  Patients with FAP and pancreatitis
Case report No. of patients  
with FAP  
and pancreatitis
Sex Age of 
colectomy 
(years)
Age of onset 
pancreatitis 
(years)
Recurrent 
episodes of 
pancreatitis
Endoscopy Comorbidity Surgery
Clark et al.6 1978 1 M ? 42 Yes (2) peri-ampullary carcinoma
Sener et al.7 1984 5 of 141 FAP patients 4 F Range 23-50 Range 23-62 No 1: adenoma of the pancreas 1: postoperative pancreatitis 1:  laparotomy for drainage of 
pancreatic ascites.
1 NR* 1: ampullary adenocarcinoma 1:  history of alcohol abuse, but 
not at the time of pancreatitis.
1:  pancreatectomy for ampullary 
carcinoma
1: no duodenal polyps 1:  laparotomy for lysis of 
intestinal lesions
2:  endoscopic examination not 
done
Berk et al.8 1985 1 F 29 41 Yes (4) obstructing ampullary adenoma 
with carcinoma in situ
Whipple’s resection of the 
periampullary duodenum and a 
repeat laparotomy with Roux-Y 
choledochojejunostomy.
Stevenson et al.9 1986 3 NR NR NR Yes 1: ampullary adenoma 1: partial pancreatectomy
1: refused endoscopy
1:  dilated duct but normal  
papilla on ERCP
Burt et al.10 1987 1 M 34 51 No ampullary adenoma and 10 
duodenal adenomas 
occasional alcohol intake and 
chlorthalidone use 
laparotomy for drainage of a 
pancreatic abscess and later on 
a duodenostomy 
Nugent et al.11 1993 1 F 32 72 No >20 duodenal adenomas and  
an ampullary adenoma
iatrogenic pancreatitis after 
biopsies of ampullary adenoma
explorative laparotomy
Futami  et al.12 1997 1 F 31 33 Yes ERCP: obstructing adenoma of 
the inferior bile duct
laparotomy: resection of the 
polyp
Wright et al.13 1999 8 6 F NR NR Yes (6/8) 5:  obstructive adenomatous 
disease: 4 diffuse 
adenomatous changes,  
1 focal adenoma compressing 
the ampulla, 7 sphincterotomy, 
1 stent placed
2: pancreatitis attributed to other 
causes (divisum, stones)
5: pancreaticoduodenectomy 
2 M 3:  transduodenal 
sphincteroplasty
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Discussion
This report describes seven patients from one centre who developed acute 
pancreatitis in the context of FAP. Pancreatitis is a severe and potentially lethal 
complication in FAP patients and may contribute to the extracolonic causes of 
morbidity and mortality in FAP. Acute pancreatitis in itself is a rare event and it has 
been estimated that the incidence of acute pancreatitis (of all causes) lies around 
5-10 per 100.000 (0.005-0.01%) in Western Europe.17 Our data along with data from 
the literature suggests that the risk for pancreatitis in FAP higher than that, and one 
series reported a frequency of pancreatitis in FAP of 3.5% (5/141).7 This suggests 
that pancreatitis is part of the extracolonic phenotype of FAP. Few aspects can be 
gleaned from literature review. First, the first episode of pancreatitis occurs at 
middle age, mean 45 years; range 23 to 72 years. Second, it appears that the 
majority of patients will have a recurrence of their pancreatitis. Further, eight of 21 
patients had (peri) ampullary adenomas that might or might not have contributed to 
the pancreatitis. Lastly, although outcome was uneventful in most cases, one 
patient died after an episode of acute pancreatitis
There appear to be a few major causes for pancreatitis in FAP patients. First, 
pancreatitis that arises from obstruction of the pancreatic duct / common bile duct 
because of ampullary adenomas. Duodenal adenomas are a common manifestation 
of FAP and it is estimated that 54% of FAP patients will develop duodenal adenomas 
twenty years after colectomy while at 75-years-of-age the prevalence may reach 
98%.3,4,18 Advanced periampullary adenomas are seen in 20% of patients by 60-
years-of-age.18 Duodenal adenomas are not usually associated with symptoms, but 
there is an increased risk for development of duodenal and especially ampullary 
cancer. The incidence of duodenal cancer in FAP may reach 4%, which is 100 to 
300 times higher than the background population.2 The high risk for malignant 
degeneration underscores the necessity for screening, most preferably using 
side-viewing endoscopes. Lastly, we identified a sample of five of seven patients in 
whom no clear risk factor was apparent. We carefully searched for underlying risk 
factors but none of the patients had obstructing ampullary adenomas. Furthermore, 
other common risk factors for pancreatitis were absent. This contrasts the common 
dogma that FAP related pancreatitis is caused by obstruction by ampullary 
adenomas. We therefore sought for other host factors that might explain why these 
patients are at high risk for the development of acute pancreatitis. As a recent study 
demonstrated that recurrent idiopathic pancreatitis might be associated with a 
SPINK1 gene mutation, we searched for two of the most common SPINK1 gene 
mutations (N34S / P55S), but failed to detect them in our sample. Although this 
does not rule out that SPINK1 plays a role in FAP associated pancreatitis, it makes 
it less likely. 
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In conclusion, we report seven FAP patients who presented with acute (recurrent) 
idiopathic pancreatitis without the presence of obstructing ampullary adenomas. 
This suggests that pancreatitis may be a manifestation of FAP although the actual 
mechanism is unclear.
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Abstract
Background
Optimal diagnostic and treatment modalities in chronic pancreatitis (CP) are 
controversial due to lack of evidence. To evaluate current clinical practice, we 
conducted a survey with the primary objective to evaluate decisions regarding the 
diagnosis, management and screening in CP. 
Methods
We developed a vignette survey.  We surveyed Dutch gastroenterologists, internists, 
gastrointestinal surgeons and an international expert panel. 
Results 
A total of 110 questionnaires (31% gastroenterologists, 39% internists and 20% gas-
trointestinal surgeons) were returned out of the 1,324 sent (response 8.3%). There 
was a wide variation in strategies regarding diagnosis, treatment and screening in CP. 
As a diagnostic test, serum amylase is used frequently by internists, while gastro-
enterologists and experts often use fecal elastase. Most respondents preferred 
CT-scanning for diagnosis, while experts preferred transabdominal ultrasonography 
as an initial test. Respondents frequently use pancreatic enzymes for treatment of 
pain in CP. The majority advised to perform an intervention (endoscopic or surgical) 
in case of morphological changes of the pancreatic duct.
Conclusions 
The results of our survey identify important differences between physicians in 
diagnosis and management of CP. This is often due to lack of evidence and 
consensus in literature. Certain wide-spread practices are in contrast with available 
vidence, and should be addressed by improved education and adherence to 
guidelines.
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Introduction
There are a number of challenges when it comes to the diagnosis and treatment of 
chronic pancreatitis (CP). The diagnosis of CP depends on interpretation of a 
variety of diagnostic tests, all of them aimed to detect structural and functional 
changes of the pancreas. Early in the disease course diagnosis is difficult, 
particularly when abdominal pain is the only symptom and the results of imaging 
tests are unequivocal.1 In order to guide the clinician, several groups have attempted 
to design classifications and scorings systems for CP.1-4 For example, the 
M-ANNHEIM classification formulates criteria for definitive, probably and borderline 
CP.5 This classification also has components that allow patients to be categorized 
according to etiology, clinical stage, and severity of CP. 
Even when the diagnosis is established, a clear treatment protocol for CP is lacking. 
Common opinion is that the treatment of CP should be guided by the clinical 
presentation and specific complaints of the patient. A major issue is the lack of 
evidence for treatment paradigms. Nevertheless, several recommendations on 
therapy in CP have been published.6-10 In addition two recent guidelines have been 
published.11,12 In 2010 the Italian Association for the Study of the Pancreas published 
an Italian consensus regarding diagnosis and treatment in CP.  This consensus 
appraised the best available evidence combined with input from experts.11 After a 
consensus meeting several statements on the diagnosis and treatment on CP were 
made. The South African guidelines are based on best practice principles determined 
by the available evidence and the opinions of an expert group.12 
All in all, despite guidelines, important controversies concerning the diagnosis and 
treatment of CP remain. Moreover, adherence to these guidelines is unclear. In an 
effort to revisit the most important issues, we developed a survey to evaluate 
current clinical practice in the Netherlands. The primary objective of this study was 
to evaluate decisions regarding the diagnosis, management and screening in CP.
Methods
Vignette Survey Design
We developed a vignette survey to evaluate decisions regarding essential aspects 
of the diagnosis and management of CP aided by representative scenarios in CP. 
The questionnaire included three clinical CP cases (vignettes), followed by multi-
ple-choice and open questions. The three vignettes were designed to evaluate 
controversies in the diagnosis, treatment and screening of CP. The first clinical 
vignette assessed the use of diagnostic tests and the criteria to diagnose CP. The 
second vignette assessed therapeutic decision making in CP, regarding both 
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medical and interventional therapies. The third vignette assessed aspects regarding 
screening and follow-up of hereditary  pancreatitis. We developed the vignettes in 
cooperation with CP experts of the Dutch Pancreatitis Study Group and the 
Scientific Institute for Quality of Healthcare of our institution.13,14 Each vignette 
included the patient’s history, physical examination and results of relevant additional 
investigations (e.g., laboratory investigation, imaging or other diagnostic tests). This 
was followed by a number of questions pertaining to diagnostic testing, treatment 
and follow-up decisions. The full vignettes are presented in the supplementary file. 
Furthermore, the questionnaire included several questions regarding the clinical 
experience and the setting in which the physician provides care: type of hospital 
(academic vs. community), the number of CP patients in their practice, and type of 
interventions performed, if any.  
Sampling Frame
Three provider groups mainly involved in care for CP patients in the Netherlands 
were surveyed: 1) gastroenterologists; 2) specialists internal medicine (internists); 
and 3) gastrointestinal surgeons. Additionally, we established an expert panel 
comprised of seven health professionals and leading researchers in the field of CP 
as a fourth group (i.e., experts). Members of this panel were non-Dutch physicians 
selected on the basis of demonstration of knowledge and competence documented 
by an extensive publication record on CP. We surveyed all gastroenterologists 
registered as members of the Dutch Association of Specialists for Gastroenterolo-
gy-Hepatology (n=344). We also surveyed  all internists  registered as members of 
the Netherlands Association  of  Internal  Medicine,  working  in  a  non-academic 
hospitals  (n=833).  Furthermore, we surveyed gastrointestinal surgeons, registered 
as member of the Netherlands Society for Gastrointestinal Surgery (n=422).
Survey Distribution and Follow-up Procedures 
A  request  to  participate  in  the  survey  was  sent  to  the  gastroenterologists  and 
internists  directly  by  e-mail, accompanying by a link to an online questionnaire 
platform. Non-responders received two reminder e-mails. In the provider  group  of 
gastrointestinal  surgeons,  a request was forwarded by the secretary of Netherlands 
Society for Gastrointestinal Surgery.
Statistics
Results of all questions were analyzed separately and presented according to 
topic. Data are presented for the group of gastroenterologists, internists and gas-
trointestinal surgeons together and for the provider groups separately. We discuss  
differences of Dutch physicians and compare them to the strategies of non-Dutch 
experts. Statistical analysis was carried out by using the SPSS 18.0 for Windows. 
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Frequencies of proposed diagnostic or treatment strategies for each vignette  were 
calculated  and  compared  among  the  three  groups (gastroenterologists,  internists, 
gastrointestinal surgeons) using the chi-square test (asymptotic P values). When 
the expected values in any of the cells of a contingency table were below five, 
the Fisher’s exact test was used (exact p-values). We only performed a statistical 
analysis on diagnostic and therapeutical strategies of the gastroenterologists, 
internists and gastrointestinal surgeons. Statistical significance was defined as 
two-tailed P values less than 0.05. We discussed these outcomes in relation with 
the strategies of the experts.
Results 
Sample Characteristics
Table 1 displays the characteristics of the survey respondents. Requests for 
participation were sent to 1,599 physicians. 236 surveys sent to internists and gastro-
enterologists were returned because of incorrect addresses. Some 39 surveys 
were returned because the addressee did not treat CP patients. One hundred ten 
physicians of the remaining 1,324 requests for participation sent returned their 
surveys (response percentage 8.3%). From the respondents, 34 of the responders 
were gastroenterologists (30.9%), 43 internists (39.1%), 22 gastrointestinal surgeons 
(20.0%) and 11 (10.0%) respondents ‘other’ (e.g., five intensivists, one nephrologist 
and five not reported) (Table 1). The mean age of respondents was 47 years (range: 
33-66 years). The majority of physicians provided care in a non-academic hospital 
(63/105, 60.0%) and had a clinical experience of 10-20 years (gastroenterologists 
20/33, 60.6%; gastrointestinal surgeons: 13/22, 59.1%) or more than 20 years 
(internists 28/43, 65.1%).
Seventy-three (71.6%) out of 102 respondents provided care for CP patients. Most 
indicated that they treat CP patients themselves, and only a minority (n=29, 28.4%) 
referred patients to specialized centers on a regular basis.  A total of 12 (35.3%) 
responding gastroenterologists also indicated to perform endoscopic ultrasonog-
raphy (EUS)-guided drainage of pancreatic fluid collections and 16 (47.1%) of  the 
gastroenterologists performed endoscopic intervention in CP patients. Fourteen 
(63.6%) of all responding surgeons indicated that they did operate on CP patients.
Diagnosis
We presented a typical case of CP with continuous abdominal pain and frequent 
exacerbations and asked which laboratory test is an important part of the 
diagnostics. The most common test used was fecal elastase (54/110, 49.1%). Fecal 
elastase was most often chosen by gastroenterologists (25/34, 73.5%) and by 
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experts in 71.4% (5/7). On the other hand, amylase was considered as a diagnostic 
tool in CP by 42.9% (3/7) of experts, compared to 38.2% (13/34) of the gastroenter-
ologists, 27.3% (6/22) of the gastrointestinal surgeons and 72.1% (31/43) of the 
internists (Figure 1). When subsequently asked which imaging modality was used 
first at suspicion of CP, only a minority (22/91, 24.2%) of all respondents considered 
transabdominal ultrasonography as useful in diagnosing CP, compared to 71.4% 
(5/7) experts (Figure 2). The majority of the respondents (63/91, 69.2%) indicated 
they used CT instead as the confirmatory test, whereas only two out of seven 
(28.6%) experts would perform a CT in this case.
Regarding the criteria for establishing CP, we noted large differences between the 
different categories of respondents (Table 2). Some 73.8% (62/84) of the respondents 
and all seven experts diagnosed CP in case of chronic abdominal pain and 
calcifications on a plain abdominal X-ray. In case of relapsing pseudocysts 78.8% 
(67/85) of all respondents regarded this as indicative for CP compared to 71.4% 
CHAPTER 7
Table 1  Characteristics of the respondents
Gastro- 
enterologists
Internists Gastrointestinal 
surgeons
Other*
(n = 34) (n=43) (n = 22)
Practice
Academic hospital 3 0 7 0
Non-academic teaching hospital 23 24 11 5
Non-academic non-teaching hospital 8 19 4 0
Number of valid responses 34 43 22 5
Years in practice
0-10 years 4 5 1 1
10-20 years 20 10 13 2
>20 years 9 28 8 3
Number of valid responses 33 43 22 6
Number of CP patients seen (yearly)
0-10 17 37 15 5
10-30 14 4 4 0
>30 2 1 3 0
Number of valid responses 33 42 22 5
*Other: 5 intensivists,  1 nephrologist, and 5 not reported 
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Figure 1   
In a clinical vignette diagnostic strategies are questioned. In this case, we ask the physicians which 
laboratory test plays an important part of their diagnostics
Figure 2   Role of imaging in the diagnosis of CP
In a clinical vignette, the respondents were asked which radiological modality they prefer first diagnostic tool 
in considering CP in a patient.
TUS: transabdominal ultrasonography
EUS: endoscopic ultrasonography 
CT: computed tomography
MRI: magnetic resonance imaging
EUS: endoscopic ultrasonography
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(5/7) experts. Five out of 12 (41.7%) of the gastrointestinal surgeons and 32.4% 
(12/37) of the internists diagnosed CP in case of chronic abdominal pain and 
elevated amylase, compared to only 6.3% (2/30) of the gastroenterologists (p<0.010). 
Regarding etiology, 46.1% (41/89) of the respondents considered alcohol as a cause 
of CP at consumption of four or more standard drinks/day for men and three or 
more standard drinks/day for women during more than six months (by considering 
12 g ethanol in each drink).
Medical Treatment of Pain
In general, all of the 34 gastroenterologists indicated that they prescribe pancreatic 
enzymes for CP, compared to 86.0% (37/43) of the internists and 40.9% (9/22) of 
the gastrointestinal surgeons (p<0.001). When a patient with uncomplicated CP 
presents with daily abdominal pain using only acetaminophen and non-steroidal 
anti-inflammatory agents (NSAIDs), pancreatic enzymes were prescribed as 
subsequent treatment for pain by half of the respondents: 58.8% (20/34) of the 
gastroenterologists, 55.8% (24/43) of the internists and 27.3% (6/22) of the gastro-
intestinal surgeons (p=0.046). This contrasts with the experts where only one out of 
seven experts (14.3%) would do so.
A large majority of the respondents prescribed analgesics. When asked about type 
of analgesics commonly prescribed for CP patients, 42.7% (47/110) indicated to use 
acetaminophen and 26.4% (29/110) used NSAIDs. Different morphine derivates were 
prescribed in a frequency ranging between 6.4 and 50.9% of the 110 respondents: 
buprenorphine in 6.4% (n=7), morphine sulfate in 11.8% (n=13), fentanyl in 28.2% 
(n=31), oxycodon in 35.5% (n=39) and tramadol in 50.9% (n=56). Only few indicated 
the use of pregabalin (5/110, 4.5%) for CP. Analgesics usually were advised on 
continuous basis (73/110, 66.4% of the respondents) rather than on demand.
Treatment of Pancreatic Exocrine and Endocrine Insufficiency
Fifty percent of the respondents (42/84) indicated that in case of exocrine 
insufficiency their preferred initial dose of pancreatic enzymes would be 25,000 
units of lipase per meal and 10,000 units of lipase with snacks. A higher initial dose 
(50,000 units of lipase per meal and 25.000 units of lipase with snacks) was more 
frequently (although not significantly, p=0.701) prescribed by experts (3/7, 42.9%) 
compared to the respondents (30/84, 35.7%). Diabetes secondary to CP was 
treated only by internists (38/43, 88.4%).
Interventional Treatment
In case of persistent pain in a CP patient, respondents but also experts had a low 
threshold for interventional treatment (Table 3). All 79 respondents and seven 
experts advised to perform an intervention in case of morphological changes of the 
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pancreatic duct (e.g., dilation of pancreatic duct, intraductal stones). Endoscopic 
treatment (lithotripsy and stenting of the pancreatic duct in case of stenosis) 
was preferred by internists (31/36, 86.1%) and 4 out of 7 experts (57.1%). Surgical 
treatment (pancreaticojejunostomy) was preferred by gastroenterologists (15/29, 
51.7%), gastrointestinal surgeons (8/12, 66.7%) and 2 out of 7 experts (28.6%). On 
the other hand, internists rarely referred for surgery in this case (5/36, 13.9%; 
p<0.001 among gastroenterologists, gastrointestinal surgeons and internists). 
In case of a CP patient with ongoing pain despite narcotics, but without dilated 
pancreatic duct or duct stones, still 22.2% (18/81) of the respondents and one out 
of seven experts (14.3%) considered endoscopic treatment. A majority of the 
experts (4/7, 57.1%) considered surgery, as would 9.9% (8/81) of the respondents. 
Few respondents (13/81, 16.0%) considered a thoracoscopic splanchnicectomy 
(p=0.097 among gastroenterologists, gastrointestinal surgeons and internists). 
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Table 3  Clinical vignette: Interventional treatment in chronic pancreatitis
We present a patient with idiopathic chronic pancreatitis with persistent abdominal pain  
despite analgesic use, including opiods. We ask the respondents which additional treatment  
they consider in two different scenarios: with and without pancreatic duct dilation).  
Which additional treatment do you consider at this moment?
In case of no dilated pancreatic duct p=0.097b Overall 
(n=110)a
Gastro-
enterologists 
(n=34)
Internists 
(n=43)
Gastrointestinal 
surgeons 
(n=22)
Experts (n=7)
Continue narcotics in a higher dose 37 (46%) 14 (48%) 15 (41%) 6 (46%) 2 (29%)
Thoracoscopic splanchninectomy 13 (16%) 6 (20%) 5 (14%) 2 (15%) 0
Enteral feeding (jejunal tube) 5 (6%) 2 (7%) 2 (5%) 1 (8%) 0
Endoscopic therapy 18 (22%) 3 (10%) 14 (38%) 1 (8%) 1 (14%)
Surgical treatment 8 (10%) 4 (14%) 1 (3%) 3 (23%) 4 (57%)
In case of a dilated pancreatic duct with intraductal stones (p<0.001b) Overall Gastro-
enterologists
Internists Gastrointestinal 
surgeons
Experts
Endoscopic treatment; lithotripsy and stenting of the pancreatic duct in case of stenosis 50 (63%) 13 (45%) 31 (86%) 3 (33%) 4 (57%)
Thoracoscopic splanchninectomy 1 (1%) 1 (3%) 0 0 0
Surgical treatment: pancreaticojejunostomy (Partington-Rochelle) 28 (35%) 15 (52%) 5 (14%) 8 (67%) 3 (43%)
I do not consider additional treatment at the moment 0 0 0 0 0
a The 11 respondents other than gastroenterologists, internists and gastrointestinal surgeons are also included
b Gastroenterologists, internists and gastrointestinal surgeons were compared 
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Furthermore, respondents differed in their timing of additional treatment (endoscopic 
or surgical treatment). Even in case of a CP patient with a dilated pancreatic duct 
and stones, 29.6% (24/81) of the respondents only considered additional treatment 
if the patient still experiences pain (despite a maximum dose of narcotics). On the 
other hand, 70.4% (57/81) also considered additional treatment in this case if there 
is adequate pain relief (with a maximum dose of narcotics).
Screening for Pancreatic Cancer
Some 62.3% (37 out of the 59 respondents) recommended that patients with hereditary 
pancreatitis should enter a screening program for pancreatic adenocarcinoma. The 
majority of the respondents (n=19, 32.2%) would use EUS as screening modality, 
as would 2/7 experts (28.6%). Twenty-five percent of the respondents (n=15) would 
use CT-scanning in screening, unlike any of the seven experts. Screening was 
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performed annually or biannually, according to the respondents. Only 5.1% (n=3) of 
the respondents used MRCP for screening purposes. Screening of young relatives 
of hereditary pancreatitis patients did not yield wide support. In such cases, 84.7% 
(61/72) of the respondents (25/30, 83.3% of the gastroenterologists; 26/29, 89.7% 
of the internists; 9/11, 81.8% of the gastrointestinal surgeons; and one out of the 
two other respondents) would first refer relatives of hereditary pancreatitis patients 
to a department of clinical genetics for consultation. In order to decrease the risk 
of pancreatic carcinoma, a large majority of the respondents strongly advised 
cessation of alcohol consumption and cigarette smoking.
Discussion
The results of our survey display the discordance between physicians when it 
comes to diagnosis, treatment and follow-up of CP. The discordance is present 
between different specialties that treat and care for CP patients, but also among 
experts. This is not an unexpected result as diagnosis and treatment of these patients 
is difficult. Moreover, there is a paucity of evidence in this field and the large variation 
in answers by physicians involved in CP care reflects this. We focused on three 
major components of CP; diagnostics, management and screening.
When it comes to laboratory test for diagnosing CP, amylase was used frequently 
by internists, while gastroenterologists and experts often use fecal elastase as a 
diagnostic tool. Fecal elastase-1 test has a high predictive value for pancreatic 
insufficiency, but test lacks sensitivity for mild to moderate pancreatic exocrine 
insufficiency.12,15 A  majority  of  the  chronic  pancreatitis  experts  considered  trans- 
abdominal  US  as  useful  diagnostic  imaging technique to confirm the clinical 
suspicion of CP. In the recently published South African guidelines, transabdominal US 
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Table 4  Main controversies from this survey
· Overall variation in the diagnostic and therapeutic decision-making process in clinical 
practice
· Different strategies in the diagnoses of CP between internists and gastroenterologists, 
and experts on the other hand
· Treatment with pancreatic enzymes frequently used in management of pain in CP despite 
of lack of evidence
· A wide variation in timing of interventional procedures in uncomplicated CP
· Different opinions on screening for pancreatic cancer in hereditary pancreatitis
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is considered to carry limited value because of lack of sensitivity and specificity.12 The 
Italian guidelines promote transabdominal US in confirming the diagnosis of 
advanced CP, since it identifies gross  abnormalities  of  the  pancreas,  e.g.,  dilatation 
of the pancreatic duct.11 However, the main value of transabdominal US is the ability 
to differentiate CP from other causes of abdominal pain. 
CT, MRCP and increasingly EUS emerge from our survey as tools to confirm the 
diagnosis, in concordance with the guidelines. The choice of diagnostic modality 
depends on the reported sensitivity and specificity, but also on the local availability 
and available skills. In addition, the diagnostic accuracy depends on the stage of 
disease. MRI can be used for the assessment of CP to evaluate both parenchymal 
and ductal changes.16 MRCP-secretin is able to detect side-branch ecstasies and 
can yield functional information of the pancreas.17 CT has a high sensitivity and 
specificity and is frequently used as the screening test of choice. CT can show 
multiple aspects of CP such as gland atrophy, dilation of the main pancreatic duct 
and pancreatic stones. However, these signs are typically restricted to advanced 
CP. EUS on the other hand is increasingly being used to diagnose CP and has 
proven ability to assess changes of the pancreatic parenchyma. On the other hand, 
the inter-observer variability is great, in particular in cases with so called “early” CP. 
In the treatment of pain in uncomplicated CP, respondents of this survey frequently 
use pancreatic enzymes. This is surprisingly since evidence for this strategy is 
absent. There have been several small randomized placebo-controlled trials 
assessing the ability of pancreatic enzymes to reduce pain. Two small studies 
using non-enteric-coated enzymes demonstrated a reduction in pain, while three 
other studies using enteric-coated preparations showed no improvement in pain. A 
meta-analysis and a Cochrane review corroborated that enzymes are ineffective for 
pain.18,19 However, the South African guidelines advise a six-week trial of high-dose 
pancreatic enzymes (in uncoated tablet form) in patients who fail to acetaminophen 
or NSAIDs which contrasts with the Italian guidelines.12 All respondents of this 
survey use non-narcotic episodic analgesia and narcotic analgesia for pain relief. 
Few use pregabalin, as well as two of the seven experts. The use of pregabalin is 
supported by the positive outcome of a recent randomized clinical trial, where it 
relieved CP pain after three weeks of treatment.20 
In the area of interventional treatment, there are more controversies. In case of a CP 
patient with pain despite narcotics but no morphological changes of the pancreas, 
22% of the respondents and one expert still considered endoscopic treatment. 
Surprisingly, a majority of the experts (4/7; 57%) considered surgery, compared to 
10% of the respondents. Both guidelines stipulate that interventional procedures 
should be reserved for symptomatic patients. There are no robust data that favor 
use of interventional therapy in asymptomatic patient with pancreatic duct dilatation. 
However, the Italian guidelines suggest that surgical decompression of the main 
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pancreatic duct may be considered in patients with asymptomatic CP and ductal 
dilation (greater than seven mm) to prevent the progression of exocrine and endocrine 
insufficiency, but evidence is lacking.11 Nonetheless, interventional procedures are 
either directed at addressing the morphological changes of the pancreatic duct 
system (strictures and stones), and inflammatory changes of the parenchyma, or by 
neurolysis of its nerve supply. This is clearly an area of uncertainty as studies in 
experimental obstructive pancreatitis, show that early drainage leads to 
improvement of and recovery of histological changes.21 If there is an indication for 
an interventional treatment, responders of this survey have a different strategy 
regarding endoscopic or surgical treatment.  In case of main pancreatic duct 
dilation, guidelines advice endoscopic treatment as a reasonable first option, 
because of the less invasive nature of this treatment.12 A recent study showed that 
after five-year follow-up, symptomatic patients with advanced CP who underwent 
surgery as the initial treatment for pancreatic duct obstruction had more pain relief 
with fewer procedures, than patients who were treated endoscopically.22 Moreover, 
almost half of the patients who were treated with endoscopy eventually underwent 
surgery. This suggests that the advice of endoscopic treatment in case of pancreatic 
duct dilation in patients with advanced disease is at odds with the available 
evidence. In case of early disease, there might be a role for endoscopic therapy but 
this requires further investigation. 
Furthermore, there are important controversies on the timing of interventional 
treatment; early in disease course or only in complicated disease. Previously, 
interventional treatment was only considered in case of pain despite narcotics. 
Nowadays, more frequently interventional treatment is advised in case of a failure 
of non-narcotic analgesia to avoid narcotic addiction. Moreover, this may lead to a 
better recovery of histological changes and pancreatic exocrine function.21 
Currently, there is ongoing research about timing of surgery in painful CP. 
A total of some 62% of the respondents of our survey recommend screening for 
pancreatic carcinoma in hereditary pancreatitis patients with EUS or CT, annually or 
biannually. CP is known risk factor for pancreatic adenocarcinoma.23 The risk is 
most prominent in hereditary pancreatitis. Patients with hereditary pancreatitis run 
cumulative risks of pancreatic cancer up to 53.5% at 75 years of age.24 However, 
routine screening of all forms of CP for adenocarcinoma is not currently 
recommended12 Some advice screening for pancreatic adenocarcinoma.24 Yet, 
there is no generally accepted protocol for screening CP patients for early pancreatic 
cancer.25 In   recommendations for surveillance on pancreatic cancer in   general 
usually no recommendations for patients on hereditary pancreatitis are proposed. 
A recent narrative review recommends yearly screening preferably in a referral 
center starting at the age of 40.23 MRI and CT are preferred as method of screening, 
despite lack of data. In case of absence of multiple calcifications, an EUS can be 
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performed. When there is advanced hereditary pancreatitis, the diagnostic value of 
EUS is limited because fibrosis the early detection of lesion. The recommendations 
posed in the South African guidelines correspond with this review.12,24
Limitations
This study has limitations. There is a limited response rate. We do not know the 
specific reasons why non-responders declined participation. This may be partly 
due to the limited number of physicians involved in the care for CP patients. In the 
Netherlands there are about 100 hospitals in which only a few specialists in every 
hospital treats CP patients. Together they treat approximately 1,000 new CP patients 
every year.14 Thus, a large majority of gastroenterologists, internists and gastroin-
testinal surgeons sees few or even no CP patients. Therefore, the 110 included 
physicians represent a significant part of the total group of specialist managing CP 
in the Netherlands.  Interestingly,  a  relatively  large  proportion  of  the responding 
physicians  indicate  that  they  perform  interventional  procedures  in  chronic 
pancreatitis  (EUS-guided drainage of pancreatic fluid collections and surgery in 
CP). This may reflect an increased interest in CP by responders of the survey and 
suggest that respondents are knowledgeable of the published literature.
In conclusion, our study documents the presence of heterogeneity in diagnostic 
and therapeutic strategies probably reflecting the lack of evidence in this field 
(Table 4). This  paper  also  illustrates  the  need  for  continuing  education  regarding 
the  diagnosis  and  treatment  of  CP, since wide adopted practices are not in line 
with current evidence. Considering the high number of physicians in non-academic 
centers and small hospitals, centralization of the care for CP might increase 
uniformity and also improve the level of care for this complex disease.
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Appendix
Supplementary file
Survey of the treatment of CP.
Clinical vignette 1
A 54 year old male presents to your office complaining of abdominal pain for the 
last 8 months. The pain is continues, but frequently exacerbates. He has a weight 
loss of 5 kg (121 lbs). He is not taking any medication. He reports alcohol use of 
4-5 glasses of beer and smokes 25 cigarettes a day since the age of 17. An upper 
endoscopy and transabdominal ultrasound show no abnormalities. You consider 
the diagnosis of CP. 
Question 1:
Which laboratory test is an important part of your diagnostics?
You can select multiple answers.
   Amylase
   IgG4
   Fecal elastase 
   Fecal fat collection
   None of these items
   Other,…
Question 2: 
Which test is the first you do at suspicion of CP? 
You can select only one answer.
   Transabdominal ultrasound
   CT 
   ERCP
   MRI/MRCP
   Endoscopic ultrasound
Question 3:
When do you diagnose ‘CP?’
For each option, choose if you consider this as sufficient for diagnosing CP?
Chronic ‘typical” abdominal pain without alternative diagnosis 		Yes 		No
Chronic abdominal pain and elevated amylase 		Yes 		No
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Chronic abdominal pain and calcifications on an abdominal X-ray 		Yes 		No
Chronic abdominal pain and complaints of steatorrhea 		Yes 		No
Steatorrhea, improving with pancreatic enzyme supplementation 		Yes 		No
Decreased fecal elastase 		Yes 		No
Relapsing pseudocysts 		Yes 		No
Dilation of the main pancreatic duct (>4 mm) 		Yes 		No
Other,…
Question 4: 
What are your criteria for the diagnosis of alcoholic pancreatitis?
a standard glass of alcohol: 12 g ethanol in each drink (15 cl wine, 33 cl beer and  
4 cl spirits)
You can select only one answer.
			Consumption of ≥ 2 standard drinks in a day for men and ≥ 1 in a day for 
women during > 6 months
			Consumption of ≥ 3 standard drinks in a day for men and ≥ 2 in a day for 
women during > 6 months
			Consumption of ≥ 4 standard drinks in a day for men and ≥ 3 in a day for 
women during > 6 months
			Consumption of ≥ 5 standard drinks in a day for men and ≥ 4 in a day for 
women during > 6 months
Clinical Vignette 2 
A 42-year old woman is recently diagnosed with idiopathic CP. She experiences 
daily abdominal pain for the last 8 months. She has a weight loss of 3 kg. She uses 
acetaminophen and diclofenac, but keeps invalidating pain. She reports no 
alcohol use. She does not smoke. She has a family history of cardiovascular 
diseases. 
Question 1:
With which medical treatment you start to relieve the pain? 
You can select multiple answers.
   Pancreatic enzyme supplementation
   Analgesics
   Protonpump inhibitors
   None of these items
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Question 2:
Which analgesics do you prescribe?
You can select multiple answers.
   Acetaminophen 
   NSAIDs
   Tramadol 
   Buprenorphine 
   Oxycodone 
   Pregabaline 
   Morphine 
   Other; …
Question 3: 
When you prescribe analgesics, how do you prescribe them?
You can select only one answer.
   On demand
   On a regularly scheduled basis
Patient now has steatorrhea (16 g fat/24 h)
Question 4: 
When you prescribe pancreatic enzyme supplementation,  
what is your initial dose?
You can select only one answer.
   10.000 FIP-E lipase with the main meal and 5.000 FIP-E lipase with snacks
   25.000 FIP-E lipase with the main meal and 10.000 FIP-E lipase with snacks
   50.000 FIP-E lipase with the main meal and 25.000 FIP-E lipase with snacks
   I never prescribe pancreatic enzyme suppletion. 
A CT of the abdomen is performed, which shows calcifications in the pancreas. 
The main pancreatic duct is not dilated (2 mm). The patient still experiences a lot 
of pain despite the use of narcotics. 
Question 5: 
Which treatment do you consider?
You can select only one answer.
   Continue narcotics in a higher dose
   Thoracoscopic splanchnicectomy
   Enteral feeding (jejunal tube)
   Endoscopic therapy
   Surgical treatment
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A year later a second CT is performed. This shows a dilation of the pancreatic duct 
of 6 mm with intraductal stones. 
Question 6: 
When do consider additional treatment?
You can select only one answer.
   When she is in pain despite maximum dose of narcotics
   No pain with maximum dose of narcotics.
Question 7:
Which additional treatment do you consider at this moment?
You can select only one answer.
   Endoscopic treatment; lithotripsy and stenting of the pancreatic duct in 
case of stenosis
   Thoracoscopic splanchnicectomy
   Surgical treatment: pancreaticojejunostomy (Partington-Rochelle)
   I do not consider additional treatment at this moment
Clinical vignette 3
A 35-year-old male is known with hereditary pancreatitis causes by a mutation in 
the PRSS1 gene. His sister and father also have hereditary pancreatitis.
Question 1: 
Do you perform screening for pancreatic cancer in patients with hereditary 
pancreatitis?
You can select only one answer.
   No, these is no evidence for the efficacy and significance of screening  
   Yes; endoscopic ultrasonography
   Yes; CT
   Yes; MRCP
   Yes; PET-scan
   Other;…
Question 2: 
How frequent do you perform screening?
You can select only one answer.
   Once a year
   Once every two years 
   Once every five years
   Other:…
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He’s become father recently. He and his wife ask you to perform genetic testing on 
their 6-month-old son. 
Question 3: 
Do you consider genetic testing on this 6-month-old boy?
You can select only one answer.
   Yes, it is important to detect a genetic mutation to recognize possible 
complications of CP.
   Yes, only to report the parents
   No, it is not possible to give genetic counseling to this 6-month-old boy, so 
screening is not appropriate.
   Possibly, first I refer the parents to the department of clinical genetics.
Question 4: 
What advice regarding lifestyle would you give to a patient with hereditary 
pancreatitis?
   Cessation of alcohol intake 
   Cessation of smoking 
   A restriction in fat intake
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Abstract
Pain is the major presenting symptom of chronic pancreatitis (CP). Patients with CP 
experience substantial impairment in health-related quality in most part due to 
persisting pain. The pathogenesis of pancreatic pain is poorly understood and 
probably multifactorial. This article discusses the various hypotheses that have 
been suggested to underlie pain. Special attention is paid to the concept of 
autonomous central sensitization and hyperalgesia. Strict abstinence from alcohol 
is the first step of chronic pancreatic pain management. As a second step, it is 
important to exclude treatable complications of CP, such as pseudocysts. 
Symptomatic treatment with analgesics is often unavoidable in patients with CP. 
Acetaminophen, non-steroidal anti-inflammatory drugs and eventually opioids are 
suitable. Several trials have been performed with pancreatic enzymes, but a 
meta-analysis demonstrated no significant benefit in terms of pain relief. The 
treatment of chronic pancreatic pain requires a multidisciplinary approach that 
tailors the various therapeutic options to meet the need of the individual patient. 
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Introduction
Pain is the major presenting symptom of chronic pancreatitis (CP) and the majority 
of patients will have pain at a given time during the course of their disease. There is 
a male predominance, with males about three to four times more likely to be 
affected by CP than females. The age of onset of CP is approximately 40 years, 
although patients with hereditary pancreatitis are younger at first presentation.1 
Often, the onset of CP is heralded by a severe painful attack, indistinguishable from 
an acute pancreatitis attack. After the first attack, patients become symptom free. 
However, with progression of the disease, the attack frequency increases and the 
symptom free periods progressively shorten. Ultimately continuous pain ensues. In 
a survey of the Asia-Pacific region, CP presented with pain in 60-100% of patients, 
ranging from 60% in Japan to 80-100% in other Asian countries.2 Pancreatic pain is 
steady and agonizing, felt in the epigastrium, and sometimes radiates to the back 
or left shoulder. Typically, the pain is postprandial, but frequently the pain manifests 
itself without any relation to the meal. Pancreatic pain is difficult to quantify, mostly 
persistent, and difficult to manage. The inter- and intra-individual variation of pain in 
CP is high, with pain duration varying from intermittent to persistent, and pain 
intensity ranging from mild to disabling. Pain has immediate consequences for the 
quality of life of patients as it leads to inability to work and frequent hospitalization. 
Amman et al. distinguishes two typical pain patterns in alcoholic CP.3 The type A 
pain pattern, typically observed in acute relapsing pancreatitis, is short-lived, and 
pain episodes usually last less than 10 days and are separated by long pain-free 
intervals of several months to a year. Nearly all patients with an A-type pain pattern 
need to be hospitalized because of severe clinical acute pancreatitis. This pain 
pattern is estimated present in nearly 50% of unoperated patients. B-type pain 
pattern, seen in more than 50% of patients, is characterized by prolonged periods 
of persistent pain or clusters of recurrent severe pain exacerbations, lasting two or 
more days per week for at least two months, and requiring frequent hospitaliza-
tions. B-type pain is typically associated with local complications, such as 
pseudocysts, cholestasis and presumptive ductal hypertension. These patients 
underwent surgery for pain relief.3,4
Aetiology
Excessive alcohol consumption is the most frequent cause of CP in industrialized 
countries.5  It is estimated that in 60-70% of patients with CP alcohol use preceded 
onset of the disease. However, it is thought that genetic or environmental factors 
must be present before alcoholic pancreatitis develops. To categorize the risk 
factors, the TIGAR-O risk factor classification system has been developed.5,6 The 
risk factors are categorized according to causes that have a toxic-metabolic, 
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idiopathic, genetic, autoimmune, recurrent severe acute pancreatitis-associated 
and obstructive background. Toxic-metabolic factors include alcohol, hyper-
calcaemia and hyperlipidaemia.7 Genetic factors play an important role in the 
susceptibility to pancreatic injury, severity and evolution of inflammatory process, 
leading in some cases to chronic inflammation and/or fibrosis. Mutations in the 
cationic trypsinogen gene (PRSS1) have been identified in patients with hereditary 
pancreatitis. Mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) were also found to be associated with pancreatitis as were serine protease 
inhibitor (SPINK1) mutations.8,9,10 Another risk factor for the development of CP is 
smoking.11 Smoking also is associated with earlier diagnosis of chronic alcoholic 
pancreatitis and with the appearance of calcifications and diabetes, independent 
of alcohol consumption.12 The category of idiopathic CP includes patients in whom 
a clear associated factor is not present.5  
The anatomical changes in CP include irregular sclerosis of the pancreatic gland 
with destruction and loss of exocrine parenchyma, dilation of the ductal system 
associated with strictures or stones, or inflammatory cell infiltration. The islets 
appear to be spared somewhat when compared with acini. The pathogenesis of 
pancreatic fibrosis has received increasing attention over the past few years, largely 
due to the identification and characterization of stellate cells in the pancreas. 
Repeated episodes of acute pancreatitis and thus exposure to increased cytokine 
secretion may contribute to persistent chronic activation of pancreatic stellate cells, 
resulting in pancreatic fibrosis and CP.13-16
The pathogenesis of pancreatic pain is poorly understood and several theories 
have been proposed to explain pain in CP.  
Elevated pressure
One of the most controversial theories focuses on ductal hypertension. This theory 
builds on the observation that intraoperative and endoscopic measurements reveal 
high intraductal pressure in CP. Morphological changes of the pancreas, such as 
ductal strictures or obstruction by stones, are thought to contribute to intraductal 
hypertension. 
Stenosis of the common bile duct has been considered a possible cause of chronic 
pancreatic pain. However, this has been refuted by a recent investigation finding 
neither influence of common bile duct obstruction on pain intensity, nor effects of 
successful endoscopic drainage of biliary obstruction on pain pattern in CP 
patients.17 Along the same line, it has been hypothesized that sphincter of Oddi 
dysfunction may affect intrapancreatic ductal pressure, but this has not been 
supported by experimental data.18 An investigation in 263 patients with abdominal 
pain, acute recurrent pancreatitis, or CP suggested that sphincter of Oddi 
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dysfunction increases intrapancreatic ductal pressure in CP. However, similar 
changes were also seen in acute pancreatitis and in patients with recurrent 
abdominal pain. There was no correlation between intrapancreatic ductal pressure 
and CP severity.18 Despite the fact that experimental data are lacking, presence of 
pancreatic duct stricture or obstruction due to fibrosis or stones causing pancreatic 
duct hypertension and dilatation remains one of the most widely accepted theories 
for causing pain in CP.19
Elevated pressure in the pancreatic parenchyma (a form of ‘compartment 
syndrome’) might be another factor in the pathogenesis of pancreatic pain. High 
interstitial pressure increases vascular resistance and reduces pancreatic blood 
flow. A number of studies have focused on evaluating the association between 
pancreatic fluid tissue pressure and pain in patients undergoing surgical drainage 
procedures for CP. Increased tissue pressures have been recorded in these 
patients, with a significant correlation between pressure and pain.19 
Oxidative stress
There is growing recognition that an imbalance between reactive oxygen species 
(ROS) producing and ROS scavenging processes leads to the damage of 
pancreatic acinar cells, initiating auto-digestion of the entire pancreas. According 
to this theory, pancreatic pain is caused by release of excessive amounts of 
oxygen-derived free radicals by alcohol, smoking and toxic chemicals, resulting in 
an inflammatory response and tissue damage.20 Polymorphonuclear neutrophils of 
patients with alcohol-related CP produced in vitro increased amounts of ROS. This 
strongly suggest that the neutrophils of patients with pancreatitis are activated and 
also can produce ROS in vivo, which, in turn, can contribute to cell and tissue 
injury.21 
There is evidence that micronutrient deficiency increases oxidative stress. In a 
study of Bhardwaj et al. patients with CP had significantly decreased micronutrient 
intake (vitamin E, riboflavin, choline, magnesium, copper, manganese and sulfur) 
owing to diet modifications because of pain.22 Multiple antioxidant deficiencies 
have been observed in CP but not in acute pancreatitis.23 
Peripheral nerve damage
CP pain may be the result of damage to nerves supplying the pancreas. In the 
pancreatic tissue of CP patients, predominant eosinophil infiltration is present 
which is thought to be responsible for the release of pain mediating substances.19 
Another pathological study has shown increased mean diameter of nerves in the 
CP damaged pancreas.24 Invasion of neural tissue by inflammatory cells was seen, 
together with lymphocytic infiltration leading to a local pancreatitis-associated 
neuritis. Other reports have revealed correlations between growth associated 
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protein 43 (GAP-43) expression, immune cell infiltration and pain.25 Furthermore, in 
CP concentrations of nerve growth factor and tyrosine kinase A (TrKA) receptor 
correlate with nerve growth and pain intensity.26 The expression level of brain-derived 
neurotrophic factor (BDNF) has also been demonstrated to positively correlate with 
pain intensity and pain frequency.27
Central sensitization and hyperalgesia
Nerve damage in CP as described above – particularly if combined with ongoing 
inflammation – can be expected to produce ongoing, intense visceral nociceptive 
input to the central nervous system. Such powerful nociceptive input is accepted to 
result in marked increases in the sensitivity of central nervous system pain 
processing (central sensitization).28,29 Visceral nociception is not only particularly 
effective in producing central sensitization per se, it has also been demonstrated to 
further activate descending facilitatory controls from the brain stem to the spinal 
cord posterior horn.30 An ongoing barrage of visceral nociceptive input, amplified 
by transmission via damaged nerves, and impinging on an already sensitized 
central nervous system is likely to elicit permanent changes in pain processing if it 
persists.31 If prolonged, this may ultimately result in an autonomous state where the 
central nervous system reports pain even in the absence of peripheral noxious 
input.32 Recent research suggests the presence of aggressive central sensitization 
and facilitation in long-term patients with CP, with these showing marked generalized 
hyperalgesia compared to healthy controls despite taking large doses of opioids.33 
The fact that such patients frequently do not respond to denervation procedures 
such as thoracoscopic splanchnic denervation further suggests that in at least 
some patients with CP central hyperalgesia has become autonomous – i.e. 
independent of peripheral input – making these patients in need of therapeutic 
intervention to correct a dysfunctional central nervous system.34,35
Quality of life in CP
The majority of patients with CP experience substantial impairment in health-related 
quality of life. Clinical symptoms of CP, like abdominal pain, chronic diarrhoea, low 
body weight and also unemployment were independent and significant predictors 
of a deterioration in health-related quality of life.36 Pain may be considered the most 
important factor affecting the quality of life.37 The aetiology and duration of the 
disease or changes in pancreatic morphology had no impact on quality of life. 
Furthermore, the impairment in quality of life in younger patients is higher than in 
older ones and carries obvious economic consequences for society.37 Consequently, 
early and effective treatment of pain and malabsorption is likely to improve quality 
of life.36 
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Management of pancreatic pain
The treatment of pain in CP is challenging. Despite novel imaging tools and better 
possibilities of accessing the pancreas, the treatment of pain in CP has been 
strategically haphazard, ill-directed, and all too often unsuccessful. Given the 
complexity of pain in CP and the fact that its mechanisms remain ill understood, it 
is not surprising that treatment of pain in CP is so difficult. The basis of chronic 
pancreatic pain management is that it takes a multi-disciplinary approach. It is our 
view that gastroenterologists, surgeons, radiologists, anesthesiologists and 
psychiatrists alike should be part of the team that treats the pain in patients with CP. 
Treatment of pancreatic pain can be complicated by previous or current drug and 
alcohol dependency and underlying psychological problems. 
According to the AGA guidelines, it is important to judge whether there are any 
treatable complications of CP, such as pseudocysts, bile duct obstruction or duodenal 
obstruction.38 However, this is not widely accepted as mentioned earlier.17,18 Other 
causes of abdominal pain, including peptic ulcer disease, gallbladder disease, gas-
trointestinal motility disorders should be excluded. Abstinence from alcohol improves 
the prognosis of patients with CP. Continuing alcohol consumption clearly accelerates 
progression to pancreatic exocrine and endocrine insufficiency.3 Pancreatic functional 
changes caused by alcoholic pancreatitis progress even after cessation of alcohol 
use; however, the progression is slower and less severe when alcohol intake is 
stopped.39 Alcohol abuse has no influence on the pain profile once the patient has 
reached advanced alcoholic CP stage. However, the mortality rate is three times 
higher in patients with continued alcohol abuse than in patients who stop or reduce 
alcohol intake.3 Furthermore, the rate of physical impairment is three times higher in 
patients with continued alcohol abuse. As a corollary, absolute abstinence from 
alcohol should be the first step in the management of chronic pancreatic pain.
Diet
Specific dietary advice should be given to patients with CP. Conventional wisdom 
suggests a diet avoiding excessive stimulation of the pancreas that is low in fat and 
small in quantity (fat limitation to 60 g/day) and is thought to avoid excessive 
stimulation of the pancreas. However, this has never been thoroughly evaluated. 
Endocrine and exocrine insufficiency requires specific dietary measures, as does 
micronutrient deficiency.22,40
Pharmacological treatment 
Table 1-3 list a number of randomised trials that have been performed in patients with 
pain due to CP. Table 1 mentions the specific drug and the rationale that supports 
its testing in chronic pancreatic pain. 
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Analgesics
Analgesics are often unavoidable in patients with CP. As a first step, non-narcotic 
analgesics such as acetaminophen or non-steroidal anti-inflammatory drugs 
should be considered. However, non-opioid analgesics usually do not yield 
sufficient pain relief, so eventually most patients will go on to the next step and 
receive opioids. Different strengths of opioids are applicable. A less potent narcotic 
drug such as tramadol can be used as a first measure. Tramadol and morphine are 
potent analgesics in severe CP when individually titrated to effect. Tramadol exhibits 
fewer gastrointestinal adverse effects, particularly regarding motility.41 
An inevitable consequence of the use of opioids is a whole range of side effects, of 
which narcotic dependence and/or abuse are arguably the most important. In order 
to minimize problems of dependence and abuse, it is now accepted that chronic 
pain patients – such as those with CP – should preferentially be prescribed opioids 
with long durations of action (e.g. slow-release preparations or similar) and slow 
access to the central nervous system (to avoid euphoriant effects). Thus parenteral 
application of rapidly acting opioids such as pethidine (meperidine) has to be 
avoided.
Opioid receptor agonists
Mu opioid receptor agonists are the “classic” opioids and represent the present 
gold standard for strong analgesia for chronic pancreatitic pain. Different long- 
acting formulations are available for morphine, and methadone – which also 
exhibits some N-methyl-D-aspartate (NMDA) receptor antagonistic activity – is 
inherently long-acting. Another possible alternative is transdermal fentanyl. Fentanyl 
has a high and selective affinity for the mu opioid receptor, has higher analgesic 
potency than morphine, better uptake into the brain and possibly fewer side effects 
such as constipation. The presently available plaster only needs to be changed 
every three days, and achieves defined stable plasma concentrations within 12 
hours of first application. In an open, crossover trial transdermal fentanyl was 
compared with sustained release morphine tablets, but no difference was observed 
regarding patients’ preference, analgesic effect or quality of life. Some of the 
patients experienced mild skin side effects during treatment with transdermal 
fentanyl. The use of rescue medication, in this case immediate release morphine, 
was significantly higher during the transdermal fentanyl period than during the 
sustained release morphine period. The results of this study suggest that 
transdermal fentanyl might be a useful alternative to slow-release morphine or 
methadone in individual patients, but it is not recommended as a first-choice 
analgesic.42 8
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Visceral pain may be particularly well inhibited by kappa opioid receptor agonists. 
This has been postulated to be the consequence of selective inhibition of visceral 
primary afferent inputs to the spinal cord by kappa opioid receptor -linked 
mechanisms.43 (Table 1)  In small trial with six CP patients a peripherally restricted 
selective kappa opioid receptor agonist established a statistically significant 
reduction in pain scores.44 Interestingly, no serious side effects were reported, 
apart from a mild headache in a single patient; however, the treatment period was 
short. This in contrast to mu opioid receptor agonist therapy, which is often 
accompanied by serious side effects like constipation and central effects such as 
sedation, severe nausea or respiratory depression. At present the only clinically 
available kappa opioid receptor agonist is oxycodone which has weak kappa 
opioid receptor agonist action in addition to its predominantly mu opioid receptor 
agonist effects.45 To date, however, no formal study data are available regarding its 
clinical use in patients with CP.
Treatment of central sensitization
As indicated above, CP patients may be suffering from hyperalgesia due to central 
sensitization.33 In general, opioids are not very effective in treating established 
central sensitization – and may even cause hyperalgesia themselves.46,47 The NMDA 
receptor is known to play a central role in the production of central sensitization.28,29,31 
Blockade of the NMDA receptor would thus appear to be a logical therapeutic 
approach to central sensitization. The anaesthetic agent ketamine is at present the 
only clinically available potent NMDA blocker, and it has been proven to be effective 
in treating central sensitization and hyperalgesia – and reducing pain – in a number 
of clinical situations.48-50 In this context it has been used in conscious, mobile 
patients at low, subanaesthetic doses as an intravenous infusion at 1-2 µg/kg/min. 
At this dose hallucinations and psychotomimetic phenomena are relatively rare and 
easy to manage by dose reduction or the addition of small doses of benzodiaz-
epines or neuroleptics. There are also anecdotal reports of the oral use of the 
intravenous ketamine formulation (e.g. on a sugar cube) in the literature for difficult 
chronic pain patients.48,51 At present there are no formal studies available on the use 
of ketamine – as an intravenous infusion or otherwise – for the pain of CP.
Pancreatic enzymes
The presumed mechanism of pain relief by pancreatic enzymes in patients with CP 
is based on the concept of negative feedback inhibition of the pancreas. (Table 1) 
Normally, a cholecystokinin-releasing peptide in the duodenum is denatured by 
pancreatic trypsin. Intraduodenal serine proteases modulate pancreatic exocrine 
secretion by regulating CCK release.52 In CP, there is decreased intraduodenal 
protease activity because of damage to acinar cells, followed by decreased denaturation 
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of the CCK-releasing peptide. The result is an increased release of CCK, which is 
itself hyperalgesic, and leads to an enhanced stimulation of exocrine tissue that is 
thought to also contribute to pancreatic pain.53,54 The inhibition of pancreatic 
enzyme secretion by the presence of pancreatic proteases in the duodenum via 
negative feedback has been demonstrated in various animals, such as rats, 
chickens and pigs.52 The application of this model to the human situation is 
controversial, and has not been proven to date, although elevated plasma CCK 
levels have been reported in CP.55 
Several trials have been executed with pancreatic enzymes in CP. (Table 2 & 3) 
One of the earliest trials was a double-blind randomised trial in 19 patients with CP, 
treated for one week with a granulated pancreatic enzyme preparation (Pankreon®; 
five times daily 7.5 ml) or placebo and vice versa. Pain was evaluated using an 
analog scale and by questioning. A 30% pain reduction was seen after treatment 
with pancreatic extract compared to placebo. 15 of 19 patients had less pain during 
the week of treatment with pancreatic extracts.56 These results could not be 
confirmed by Halgreen, who conducted a 4-week double-blind crossover study 
with pancreatic enzymes (Pancrease®) in 20 CP patients. There was no significant 
pain reduction.57 In a trial conducted by Mössner et al with pancreatic extracts in 47 
patients, there was no significant difference between placebo and pancreatic 
extracts either.58 Furthermore, pancreatic enzyme therapy also failed to show any 
amelioration of pain scores in patients who had surgery for CP.59 In a meta-analysis 
six randomised, double blind, placebo-controlled trials of the treatment of CP with 
pancreatic enzymes were evaluated. The pooled estimate of the percentage of 
patients per study who preferred enzymes relative to placebo was 52% (95% 
confidence interval 45-60%). This was not statistically different from 50%. Thus this 
analysis demonstrates no significant benefit of pancreatic enzyme therapy to 
relieve CP associated pain.60 It should be pointed out that the studies using 
pancreatic enzymes are heterogeneous with respect to population, study length, 
and inclusion-criteria, which makes head to head comparison of the studies 
difficult. (Table 3)
Loxiglumide
A new approach in the treatment of CP involves lowering plasma-CCK-levels via a 
CCK-receptor antagonist such as loxiglumide. (Table 1) As already outlined, plasma 
CCK-levels are higher in CP causing hyperalgesia. This concept has been tested in 
acute pancreatitis patients. (Table 2) Shiratori investigated the effect of loxiglumide 
in a dose of 300, 600 and 1200 mg/d in 207 patients with an acute exacerbation of 
CP. Administration of loxiglumide 600 mg resulted in a significantly higher rate of 
improvement of pain than with placebo. Loxiglumide at 600 mg seemed to be the 
8
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optimal dose as it led to significant decreases of serum pancreatic amylase and 
trypsine levels. This study indicates that loxiglumide in a dosage of 600 mg may 
become a useful drug for the treatment of painful attacks of CP.61 
Secretin 
Another therapeutic approach is based on the concept of resting the pancreas, as 
in acute pancreatitis, by washing out the sticky, protease-rich secretion of the 
pancreas in patients with advanced chronic recurrent CP with a depot of secretin. 
(Table 1)  In a 7-day randomised double-blind trial a depot of secretin (800 CU b.i.d. 
s.c.) significantly improved secretion viscosity as well as trypsin and lactoferrin 
serum concentrations, and – importantly – reduced pain. (Table 2) This was 
achieved without side effects. This therapy is only appropriate in patients with CP 
without pancreatic duct obstruction or pancreatic pseudocysts.62
Allopurinol/Antioxidants
As outlined, Bhardwaj et al reported a decreased micronutrient intake (vitamin E, 
riboflavin, choline, magnesium, copper, manganese and sulfur) in patients with CP 
owing to diet modifications due to pain, in addition to a lower caloric intake.22 The 
key concept here is that micronutrient deficiency might contribute to increased 
oxidative stress. (Table 1) In a comparison between patients with CP and acute 
8
PHARMACOLOGICAL MANAGEMENT OF PAIN IN CHRONIC PANCREATITIS
Table 3   The characteristics of four randomised trials that used pancreatic 
enzymes as pharmacological option in the treatment of chronic  
pancreatic pain.
Study Isaksson  
and Ihse56
Mössner  
et al.58
Halgreen  
et al.57
Van Hoozen  
et al.59
Design Cross-over Cross-over Cross-over Cross-over
Number of patients 19 47 20 11
Dropouts - - - 11
Drug Pankreon® Panzytrat® Pancrease® Creon®
Dosage 5 x 7.5 ml 5 x 2 capsules 2 capsules at 
meals, 1 capsule 
at snacks
4-12 capsules/
day
Length (weeks) 1 2 2 4
Painscale Linear 3-point scale Linear 5-point scale
Result Positive:  
30% pain-reduction
Negative Negative Negative
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pancreatitis, the anti-oxidant profiles appeared to be different. Patients with CP had 
significantly lower plasma concentrations of selenium, vitamin A and E, 
beta-carotene, xanthine, beta-cryptoxanthine and lycopen in comparison with 
patients with recurrent acute pancreatitis.23 Furthermore, the antioxidant capacity 
as measured by the FRAP assay (ferric reducing ability of plasma) was significantly 
lower in patients with CP as compared with healthy controls; whereas oxidative 
damage, measured by oxidative protein and lipid damage, was increased.63 There 
also appears to be an association between oxidative stress and pancreatic cancer. 
The evidence on whether antioxidant supplements are effective in preventing gas-
trointestinal cancers is contradictory. Cullen et al. reported a decrease in antioxidant 
enzyme expression in pancreatic cells from normal pancreas to CP to pancreatic 
cancer.64 Another observation concerning antioxidants is the altering of antioxidant 
status in CP patients, which is worsened in patients with diabetes mellitus.65 
Based on the observations that activation of oxygen free radicals can cause 
metabolic changes leading to pancreatic ischaemia, antioxidant treatment with 
allopurinol seems a valid option. A trial with 13 patients with CP investigated the 
effect of allopurinol on pain in a crossover double-blind, randomised treatment 
trial66. Allopurinol 300 mg/d during four weeks with two weeks wash-out did not 
yield a reduction in pain scores during treatment nor a significant increase in 
activities of daily living compared to placebo. (Table 2)  In contrast, others showed 
that addition of allopurinol or dimethyl sulfoxide to intramuscular pethidine 
hydrochloride significantly enhanced the efficacy of the analgesic regime.67 This 
report suggests that removing oxygen free radicals in CP may result in a beneficial 
therapeutic effect. A one-year clinical trial with 10 patients studied the effect of food 
supplementation using a complex containing L-methionine, beta-carotene, vitamin 
C and E and organic selenium.68 This resulted in a significant decrease in the 
intensity of pain as well as in days of hospital admission. Based on a placebo-
controlled trial, followed by a retrospective cross-sectional study in 94 patients, 
some authors recommend anti-oxidant therapy consisting of supplements of 
methionine, vitamin C and selenium.69 In summary, there are conflicting data about 
the effectiveness of anti-oxidant therapy. A few trials show potential benefit, but 
further research is needed before it can become standard of therapy.
Oral protease inhibitors
An oral protease inhibitor, camostat, has been used clinically for the treatment of 
CP in Japan. However, the pharmacological mechanism is not fully understood and 
so far there scientific evidence supporting its effectiveness is lacking. Experimental 
animal studies demonstrated that oral administration of camostat inhibits inflammation, 
cytokines expression and fibrosis in the pancreas. In addition camostat attenuated 
pancreatic fibrosis in dibutyltin dichloride-induced rat by inhibition of monocytes 
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and pancreatic stellate cell activity.70 Another study found that camostat suppressed 
gene expression of pancreatitis-associated protein, p8, and cytokines.71 Nevertheless, 
clinical trials to support the use of oral protease inhibitors in CP are lacking. 
Leukotriene receptor antagonist
Leukotrienes are inflammatory mediators, which may play a role in acute and CP. 
(Table 1) Cysteinyl leukotrienes are present in elevated concentrations in experimental 
acute pancreatitis in pigs. Leukotriene-receptor antagonists are at present mainly 
used in the treatment of asthma. A double-blind, placebo-controlled cross-over 
trial with 15 patients with CP studied the effect of montelukast, a cysteinyl leukotriene 
receptor antagonist, on pain measured by visual analogue pain scores.72 (Table 2) 
There was no significant effect on primary or secondary outcomes. Interestingly, 
leukotriene receptor antagonism by zafirlukast did improve the pancreatic histo-
pathological score and fatty necrosis in rats with acute pancreatitis.73 This suggests 
that it might be worthwhile to evaluate the effect of leukotriene receptor antagonists 
in other studies.
Octreotide
One of the suggested mechanisms for pain in CP is hypertension of the pancreatic 
duct due to outflow obstruction. Inhibition of pancreatic secretion using somatostatin 
might therefore be effective in reducing pain in CP. Octreotide is a synthetic 
somatostatin analogue with an increased half-life, higher potency and the possibility 
of subcutaneous application. Experimental data suggest that octreotide increases 
the contractibility of the Sphincter of Oddi, while somatostatin decreases it. (Table 1) 
This has, however, not consistently been demonstrated in man.74
There are conflicting data about the efficacy of octreotide in the treatment of pain in 
CP. Expert opinion suggests that octreotide might relieve pain in severe CP 
refractory to any other medical treatment.75 These results have not been confirmed 
in a formal controlled clinical trial. In a double-blind cross-over study ten patients 
with CP were treated with octreotide (100 µg SC three times daily) or placebo for 
three days, with two days wash-out. (Table 2) This short-term inhibition of pancreas 
secretion did not result in pain relief. Apart from the lack of effect, the numerous 
side-effects of somatostatin-analogues and their cost preclude widespread use of 
somatostatin-analogues in the treatment of CP.76  
On the other hand, the place of octreotide in the prevention of complications of 
pancreatic surgery and in the therapy of fistulas and pseudocysts is well established.77 
Octreotide effectively decreases the output from percutaneously drained pseudocysts.74 8
PHARMACOLOGICAL MANAGEMENT OF PAIN IN CHRONIC PANCREATITIS
140
Conclusion
The management of pain in CP is often very difficult and remains controversial. The 
main reasons for this are the heterogeneity of the patient population, poor under -
standing of the underlying pathophysiology and the difficulties regarding objective 
assessment of the patients´ pain and underlying mechanisms. There are few 
randomised controlled trials, and these have been performed in widely divergent 
study populations. According to Mössner, the ideal trial of a treatment for pain in CP 
should meet the following conditions: the pain must be chronic, there must be 
different study groups of alcoholic versus idiopathic CP, amylase should be normal, 
the ERCP must show only minimal duct changes, and steatorrhoea, duct stones, or 
pseudocysts should be absent.58 Pain should be measured in a standardized 
manner, and objective measures of neuroplasticity may be useful to make 
underlying mechanisms visible.  Despite these potential limitations several well 
designed clinical trials have been performed that enable us to draw some clinical 
relevant conclusions. Though there is evidence from a controlled trial that κ-opioid 
receptor agonists might be beneficial, the number of patients was limited and the 
observation period was very short. Contrary to the many guidelines and reviews on 
the management of pain in CP, treatment with pancreatic enzymes cannot be 
advised for treatment of pain on basis of the data provided by the clinical trials. 
There are inconsistent data on the effectiveness of anti-oxidant therapy, and 
anti-oxidant therapy should not be regarded to be uniformly effective at present. 
There are no large clinical trials regarding oral protease inhibitors in CP. Leukotriene 
receptor antagonists have not shown any benefit yet, nor has octreotide. Loxiglumide 
(600 mg daily) holds some promise but confirmatory trials are lacking so far. In view 
of the rather limited pharmacological options as indicated above, clinicians rely on 
analgesics. In this respect a classical ladder approach to pain should be used: 
starting with acetominophen and non-steroidal anti-inflammatory drugs, proceeding 
to tramadol and morphine, and possibly ending with more invasive measures such 
as administration of intrathecal analgesics. Opioids should not be given on demand, 
with an emphasis on achieving steady-state conditions via regular, fixed scheme 
use of long-acting or slow release formulated opioids. Such schemes will help 
reduce undesirable opioid toxicity and the likelihood of opioid abuse and 
dependence. The attending physician should be aware of the side effects of opioids 
and take appropriate precautions, e.g. routine laxative prophylaxis. 
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Summary
This thesis discussed different aspects of the etiology, clinical presentation and 
management of chronic pancreatitis (CP). CP is a disease of the pancreas characterized 
by progressive inflammation, ultimately resulting in irreversible damage to the 
pancreas with exocrine and endocrine dysfunction. Most CP patients have recurrent 
attacks of incapacitating abdominal pain such that it requires the use of narcotics. 
Because of its devastating chronic course, patients need a lot of medical care. In 
this thesis we focused on genetic aspects of pain in CP, clinical aspects of CP 
and diagnosis and management of CP. 
In Chapter 2 and 3 we focused on genetic aspects of pain in CP. Pain is the most 
frequent complaint of CP patients and has a major impact on their quality of life. 
However, there is a large difference in pain presentation between CP patients. This 
suggests that genetic factors play a role in patient’s pain experience. Furthermore, 
there is growing evidence that supports a shift in emphasis toward neurogenic 
mechanisms rather than the traditional focus on morphologic changes in the 
pancreas. In this section, we searched for genes that alter pain perception in CP 
patients. First, we studied the COMT gene in Chapter 2. There is some evidence that 
polymorphisms of the COMT gene, some of which substantially affect COMT activity, 
may affect pain perception and a patient’s ability to cope with pain. Catechol-O-
methyltransferase (COMT) regulates enkephalin levels and influences pain 
perception. We studied the four COMT gene SNPs (rs6269, rs4633, rs4818 and 
rs4680) in 240 CP patients and 445 controls. We generated diplotypes. A diplotype is 
a set of two haplotypes. A haplotype is a sequence of closely linked SNPs on the 
same chromosome within the genomic region of interest. The use of haplotype 
construction is preferred because combinations of SNPs might have a synergistic 
effect. We found no significant association between the SNPs in the COMT gene and 
CP. Furthermore, we found that diplotype ATCA/ACCG was more prevalent in controls 
compared to patients, but this was not significant after correction for multiple testing. 
We concluded that COMT SNPs and diplotypes are not associated with CP. This 
does not support a significant role for the COMT gene in CP. 
In Chapter 3 we studied the transient receptor potential vanilloid receptor 1 (TRPV1) 
gene. The TRPV1 receptor is a nonselective calcium permeant cation channel that 
belongs to the transient receptor potential family (TRP). The transient receptor 
potential (TRP) channels have been associated with regulation of efferent properties 
of primary afferent neurons that initiate neurogenic inflammation and are required 
for the development of inflammatory hyperalgesia. We genotyped four SNPs 
(rs222749, rs222747, rs224534 and rs8065080) in 228 CP patients and 207 healthy 
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controls and generated diplotypes. We did not demonstrate a significant difference 
in allele frequency between CP patients and controls.
As a consequence, we did not reveal the genetic background of pain in CP by 
investigation of the COMT gene and TRPV1 gene.
In the next section, we focused on various clinical aspects of CP.
First, in Chapter 4 we reviewed radiological images of patients with a specific type 
of CP, hereditary pancreatitis (HP). HP is a rare form of CP and most frequently 
caused by cationic trypsinogen (PRSS1) gene mutations. We described a cohort of 
15 HP patients in whom a total of 152 imaging studies during a disease course have 
been performed and reviewed all studies. The first remarkable finding was the large 
amount of transabdominal ultrasound-studies that have been performed in this 
cohort of HP patients, not only in advanced stages of disease, but also for diagnosis 
of disease. On reviewing all studies, we found a large variation in size of the main 
pancreatic duct during the disease course, both inter- and intraindividual and even 
after a drainage procedure. A very wide main pancreatic duct often coincided with 
presence of intraductal stones, which were present in a third of patients (size 1-12 
mm). These findings accord with literature, although data on imaging in the specific 
group of HP are scarce.
The phenotype of CP is presented in detail in Chapter 5. In India tropical CP was a 
common disease. Tropical CP is a form of idiopathic CP (ICP) with unique epide-
miological and clinical features, and has similarities with ICP in the Western world. 
We compared the phenotype of 1033 Indian CP patients, with the phenotype of 358 
German CP patients and 358 Dutch CP patients. We found that most Indian CP 
patients had ICP, were younger, had a younger age of onset and smoked less 
frequently. Endocrine insufficiency and pancreatic calcifications were more 
frequently seen in Indian ICP patients. Pain was present in the large majority (> 
85%) of all CP patients. The phenotype of CP and ICP in India is replaced by a more 
‘Western’ type of disease (older onset of disease, less endocrine insufficiency, less 
frequent calcifications). We concluded that most of Indian patients now have a form 
of CP that can be labeled as ICP. This could be due to a change of lifestyle and 
environmental factors but also genetic factors such as SPINK1 might be involved. 
This supports the hypothesis that genetic mutations are associated with idiopathic 
CP in patients from different ethnic backgrounds.
In Chapter 6 we focused on patients with familial adenomatous polyposis (FAP) 
and pancreatitis. We described seven patients with FAP who experienced at least 
one episode of pancreatitis. We searched for underlying risk factors but none of the 
patients had obstructing ampullary adenomas or other common risk factors, 
CHAPTER 9
149
including serine protease inhibitor Kazal type I (SPINK1) gene mutations for 
pancreatitis. In a review of literature 20 FAP patients with pancreatitis have been 
identified. This suggests that pancreatitis may be a manifestation of FAP although 
the actual mechanism is unclear. 
In the third section, we focused on diagnosis and treatment of CP. In Chapter 7 
we presented results of a nationwide survey regarding the diagnosis and 
management and screening in CP. We developed a vignette survey to gastroenter-
ologists, internists and gastrointestinal surgeons in the Netherlands and an 
international expert panel. A total of 110 questionnaires were returned (response 
percentage 8.3%); 31% gastroenterologists, 39% internists and 20% gastrointesti-
nal surgeons. There was a wide variation in strategies regarding diagnosis, 
treatment and screening in CP and we identified important differences between 
physicians. Certain wide spread practices, such as serum amylase as a diagnostic 
test and pancreatic enzyme for treatment pain of CP are in contrast with available 
evidence, and should be addressed by improved education and adherence to 
guidelines. 
Chapter 8 reviewed a number of hypotheses that has been suggested to underlie 
pain in CP and discuss the management of pain. We discussed different hypotheses 
that have been proposed to underlie pain in CP. Several theories include 1) elevated 
pressure in het pancreatic duct and pancreatic parenchyma; 2) an increase in 
oxidative stress, caused by a micronutrient deficiency; 3) peripheral nerve 
damage; 4) central sensitization and hyperalgesia. Furthermore, we discussed the 
management of pancreatic pain. The first step is abstinence from alcohol. Next, 
complications of CP such as pseudocysts should be treated. If the pain persists, 
symptomatic treatment of pain is the only option left. Analgesics are often 
unavoidable: acetaminophen, non-steroidal anti-inflammatory drugs and eventually 
opioids. Pancreatic enzymes have not demonstrated any significant benefit in 
terms of pain relief. We discussed other options in the pharmacological management 
of pain such as antioxidant therapy, loxiglumide, κ-opioid receptor agonists. We 
concluded that there are only a few good randomized controlled trials in CP patients 
with pain. Therefore, it is difficult to give a strict advice about pharmacological 
management. However, in recent years new insights in the pathogenesis of 
pancreatic pain have been gained and new drugs have been evaluated in CP, as 
will be mentioned in the paragraph “future perspectives”. 
In the appendix, we described the design and rationale of a double-blind, 4-week 
cross-over randomized clinical trial on nasogastric and nasojenunal feeding in CP 
patients. Due to stringent inclusion criteria we could only included two patients, of 
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CHAPTER 9
Table 1 
Questions relevant to this thesis
Question 1: Why do some CP patients develop pain while others are left unscathed?
What is the effect on COMT gene variants on the presence and severity of pain in CP?   
(Chapter 2) 
We found no significant association between the SNPs in the COMT gene and CP. 
Could modifications in the TRPV1 gene modify the presence and the phenotypical expression  
of CP? 
(Chapter 3)
We found no significant association between the SNPs in the TRPV1 gene and CP. 
Question 2: What is the clinical presentation of subset of patients with CP, such as  
patients with hereditary or idiopathic forms of CP?
Are there specific radiological findings in HP patients and what is the evolution of pancreatic 
abnormalities during the disease course? 
(Chapter 4)
•	 We found a large a large variation in size of the main pancreatic duct during the disease 
course, even after a drainage procedure.
•	 There was a large variation in size of the main pancreatic duct during the disease course of 
HP, both inter- and intraindividual. 
•	 A very wide main pancreatic duct often coincided with presence of intraductal stones.
Is the phenotype of CP and ICP in India different from CP and ICP in the Western world? 
(Chapter 5)
•	 The phenotype of CP and ICP in India is replaced by a more ‘Western’ type of disease  
(older onset of disease, less endocrine insufficiency, less frequent calcifications).
•	 Most Indian patients now have a form of CP that can be labeled as ICP.
Is there a relationship between FAP and CP and may SPINK1 mutations contribute to the risk  
of pancreatitis? 
(Chapter 6)
We identified 7 patients with FAP and CP but could not find the underlying risk factor, including  
a SPINK mutation.
Question 3: How do we need to treat these patients?
How is current practice in the Netherlands regarding the diagnosis, management and screening  
in CP? 
(Chapter 7)
There was a wide variation in strategies regarding diagnosis, treatment and screening in CP and 
there were important differences between physicians. Certain wide spread practices, such as 
serum amylase as a diagnostic test and pancreatic enzyme for treatment pain of are in contrast 
with available evidence.
What are the suggested mechanisms for pain in CP and what are therapeutic options?  
(Chapter 8)
•	 Suggested mechanisms are:  
1) elevated pressure in het pancreatic duct and pancreatic parenchyma;  
2) an increase in oxidative stress, caused by a micronutrient deficiency;  
3) peripheral nerve damage; 4) central sensitization and hyperalgesia. 
•	 Management of pain:  
1) abstinence from alcohol;  
2) treatment of complications;  
3) Analgesics: Acetaminophen, non-steroidal anti-inflammatory drugs and eventually opioids. 
Pancreatic enzymes have not demonstrated any significant benefit in terms of pain relief.
CP: chronic pancreatitis
ICP: idiopathic chronic pancreatitis
HP: hereditary pancreatitis
FAP: familial adenomatous polyposis
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which only one patient completed the entire protocol. This patient experienced a 
minor improvement of pain and abdominal discomfort while on nasojejunal feeding. 
This was accompanied by a decrease in VAS-score. The limited accrual was mainly 
due to stringent inclusion criteria and particularly the exclusion criteria. We searched 
for patients with daily moderate to severe pain, but without opioid use. We detected 
only a few patients, of which some declined participation because of the interventional 
nature of the study. As a conclusion, we cannot give any recommendations about 
nasogastric or nasojejunal feeding for pain in CP patients.  
Implications of this thesis and future perspectives
Pain in CP
Focussing on pain in CP, we could not demonstrate a significant role for the COMT 
gene and TRPV1 gene in pain in CP patients in our studies. Regarding COMT, there 
have not been any studies so far to endorse this result. There have been no other 
studies on COMT and pancreatitis up to now, as far as we know. There is ongoing 
research about the COMT gene and COMT-inhibitors in other chronic pain 
disorders. Recently, a meta-analysis of the COMT genotype and COMT-inhibitors 
showed that fibromyalgia and chronic widespread pain is associated with the 
COMT SNPs rs4680.1 Interestingly, there are reports that found an association 
between COMT polymorphisms and addiction, although data are conflicting.2,3 A 
subject of future investigation would be the COMT polymorphisms in CP patients 
with chronic pain and alcohol abuse to see if there is a relationship between the 
COMT gene and alcoholic CP.
Regarding TRPV1, the last few years there are new publications about the role of 
TRPV1 in pancreatitis.4-7 However, they are all in experimental animal models of 
pancreatitis which mimic pancreatic pain typically short term and invasive in nature. 
TRPV1 is also investigated in the treatment of CP.  In experimental rat CP blockade 
of NGF (nerve growth factor) significantly attenuated pancreatic hyperalgesia and 
referred somatic pain compared to controls.5 Hence, these results highlight a role 
for TRP channel interactions that contribute to the development of experimental 
pancreatitis. The next step would be to verify the role of TRP channel in human 
studies with CP patients.
We can draw a number of conclusions relevant to the design of studies on this 
subject meriting some discussion.
Relevance of genetic variants to pain in CP
There are a number of reasons to explain our (largely) negative results. First of all 
we examined only eight SNPs of two genes. Although (genetic) variations in these 
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genes have been implicated in pain and pain sensation in humans it is possible that 
they are not relevant for CP. Indeed, the concept that genetic variants are modifiers 
of pain in CP is not well conceived. The major reason for this is that the overall 
majority of studies performed so far have examined genetic variants as a cause for 
CP rather than a modifier of an aspect of the disease. This element of our genetic 
association studies has proven to be a very difficult aspect. A common feature of 
human pain conditions is that they are multifactorial and present clinically as a 
patchwork of biologic and psychological phenotypes. In the recent years we have 
witnessed the discovery of genes that cause a number of monogenic pain 
disorders. These discoveries immediately led to the question whether these genetic 
candidates contribute to more common pain disorders. Because of the high 
comorbidity between clinical pain conditions, it is expected that the identified 
genes will be implicated in more than one condition. This is corroborated by a 
number of reports on the association between pain and variants within the COMT 
gene as well as with the TRPV1 gene. With the design of our genetic association 
study it remains difficult to distinguish the modifying effect of a genetic variant on 
the cause of CP as well as on a specific phenotypical presentation of that disease. 
Measurement of pain
We have included patients in our studies with pain varying from intermittent to 
persistent and pain intensity ranging from disabling to no pain or mild pain, but 
ultimately, the majority of the patients with CP will experience pain. This makes this 
population so attractive as a model of chronic pain where we can expect the 
contribution of environmental factors as well as common genetic variants in pain 
genes. It is a challenge to quantify pain in a complex disorder such as CP due to 
different temporal and spatial levels of pain that patients experience, the use of 
analgesic drugs and different pain scales. The difficulty in measuring the pain, as 
experienced in CP patients, is that we currently fail to have an objective means of 
measuring pain. As far as we know there is no validated CP pain scoring system. In 
most part this is due to the fact that CP patients are known to have an unpredictable 
course with attacks and remissions. In our studies we created a composite score in 
order to distinguish those patients with a protracted course with painful attacks 
from those with a more benign course, but even with the composite score it is 
difficult to quantify pain. Unfortunately, such a composite score is subject to 
criticism and even with a composite score it is difficult to quantify pain. 
Use of controls for genetic association studies
Central to the issue of the experimental design of the genetic association studies is 
the use of appropriate controls. A general guide to control selection for any 
case-control study is that controls should be selected from the same population in 
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which cases arose, and should be representative of the population who would have 
become cases according to the case definition and recruitment strategies for the 
study. This is certainly the case in our study. Therefore we limit the risk of population 
stratification (the difference in frequency of the genetic variant between cases and 
controls is due to the underlying sampling scheme, rather than to a real effect of the 
variant on disease risk). The next issue is whether we should exclude the CP 
phenotype in our population. We excluded CP in our controls as none of them gave 
a medical history or had symptoms of CP. The matter here is whether we should 
have excluded CP on the basis of advanced radiological techniques and subject 
our controls to MRCP or CT scanning. There are several reasons why we do think 
that this is not necessary. First of all, it should be noted that matching is only 
essential when the frequency of the confounder shows such a marked difference 
between cases and controls that it cannot be adjusted for in the analysis, or in 
situations where the confounder cannot be accurately measured. ‘Overmatching’ 
on unnecessary variables will actually reduce power, since all matching variables 
will need to be taken account of in the analysis. Second, given the fact that the 
prevalence of CP in the general population is very low (in the Netherlands 1/50.000) 
it is unlikely that we have undiagnosed CP patients in our sample. Even if there were 
to be (asymptomatic) CP patients among our controls the enrichment of CP in the 
case cohort overcomes this hypothetical limitation. The issue of alcohol use and 
smoking consistently pops up when performing a case control study in CP. The 
issue here is that researchers want to perform a highly rigorous trial and therefore 
want to control for alcohol use and other possible confounders as well. The question 
is whether this rigorous set-up is required at all for these types of studies. At this 
point of time we do not know whether the effect size of alcohol use relative to the 
effect of a genetic variant. We do know that the risk conferred by genetic variants is 
usually small with odds ratios between 1.1 and 1.3, but also that only a small 
minority (~5%) of alcoholics will get ACP. Indeed when setting up this type of study 
we should aim to recruit exact data on environmental exposures (alcohol use) and 
other covariates in all controls in a sample size large enough to allow detecting 
interaction between gene polymorphisms and environmental exposure. Within the 
framework of the studies as we have designed it is not reasonable to assume that 
this (or any other cohort study with sample size <2000-3000) will allow dissection 
of all gene-environmental effects.  
Use of genome wide association studies (GWAS)
A common issue in genetic association studies is the power that comes with the 
design of the study. The studies we have performed have a limited power to detect 
variables that only have a moderate effect on the resulting phenotype. Therefore 
larger studies with increasingly more power are needed to assess the effect of these 
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genetic variants. GWAS studies are larger by nature and in theory are the answer. 
However, GWAS test a limited number of variants and need to be very large to detect 
variants with a moderate effect. We have started a cooperative European effort in 
order to discover genetic variants that underlie alcoholic CP. While this is being large 
enough (> 2000 participants) it is uncertain whether the phenotyping of the patients 
will allow addressing the issue whether pain is driven by a genetic variant.       
Other putative causes of pain in CP    
The last years, research on pancreatic pain has mainly been focused on the 
neuropathic origin of pain. A recent retrospective study endorses the concept that 
pain in CP is not predicted by the severity of abnormalities on imaging of the 
pancreas.8 Human and experimental studies have indicated a critical role of 
neuronal mechanisms which result in peripheral and central sensitization. Recently 
investigators have reported that patients with longstanding abdominal pain from 
CP have visceral hypersensitivity and magnetic resonance imaging microstructural 
changes compared with normal persons, including reduced cortical thickness of 
the brain areas involved in processing of pain.9,10 Thus, cortical thickness might be 
a surrogate for overall pain system dysfunction in CP. Furthermore, this study group 
showed in a randomized, double-blind, placebo-controlled trial that gabapentoid 
pregabalin is an effective adjuvant therapy for pain in 64 CP patients.11 Pregabalin 
was also superior to placebo for attenuation of experimental visceral pain by 
electrical gut stimulation in CP patients.12 These results are very promising for the 
future therapy for the pain in CP. The definite role of pregabalin should be explored 
in a head-to-head study comparing pregabalin with standard analgesic treatment 
in CP. 
Clinical aspects of CP
We showed different imaging modalities in HP patients during a long disease 
course. We gathered knowledge about various aspects on radiological imaging in 
patients with HP, such as the large variation of main pancreatic duct and large 
intraductal stones. Data about imaging findings in CP are relatively scarce and to 
the best of our knowledge this is one of the first studies to report a series of imaging 
findings in HP patients. It would especially be of interest to do a longer follow-up of 
patients with HP and prospectively collect the clinical data about these patients. 
Furthermore, in a cohort of HP patients it would be interesting to do serial imaging, 
preferable secretin-enhanced MRCP, at fixed intervals (e.g. every two-five years) to 
learn more about disease course related to pancreatic abnormalities on imaging. 
Not only HP patients should be subject of this study, but also patients with CP. At 
this moment, there is a CP study group preparing a study on pancreatic imaging on 
CP patients in the Netherlands. 
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By comparing the ICP patients from India and the Western world we found that the 
phenotype of CP and ICP in India is replaced by a more ‘Western’ type of disease. 
An implication of our study is that the ICP in India can no longer be seen as a 
specific entity, which is seen only in India in malnourished patients, with cassava as 
the etiology, starting at childhood and with a high prevalence of diabetes. The 
consequence of this statement is that the term “tropical pancreatitis” used for ICP 
in India is currently not accurate anymore and should no longer be used. Of interest 
is the genetic background of these entities. There is growing evidence that ICP in 
India has a strong genetic predisposition, what breaks the myth about cassava as 
etiology. In a recent study, mutations in the SPINK1 and CFTR genes have found to 
be strongly associated with ICP patients in India.13 Since ICP of India might resemble 
ICP in the West, it is of special interest to further unravel the etiology of ICP by 
comparing large cohorts of ICP patients from different countries from all over the 
world, to see if there is still a geographical difference of the phenotype and to learn 
more about the impact of environmental aspects. This is not only interesting in ICP, 
but also in alcoholic CP, as there is growing evidence that also the development of 
CP is due to an interaction of multiple risk factors and that, besides alcohol, 
additional cofactors are required. This is especially interesting in developing 
countries where the use of alcohol is increasing. 
Issues with epidemiological case series studies 
We used the phenotypical expression of CP recorded in a database as a model of 
study. There are several difficulties inherent to database research. As we used 
different databases to contrast CP from different regions, it is very important that all 
databases use the same definition of disease. In CP there are several criteria for 
diagnosis. For example, in the South-African guideline the following definition is 
recorded: ‘The diagnosis can be made by morphologic criteria alone, or by a 
combination of morphologic and functional criteria’.14 Other groups define CP 
according to the M-ANNHEIM classification.15 It is very important to align criteria for 
diagnosis before setting up a database. Furthermore, since imaging is involved in 
the diagnosis of CP, it is essential to have the same imaging modalities in the 
different centers. After all, the diagnosis of early CP on imaging is difficult and 
depends on the accurateness of the modality; for instance, transabdominal 
ultrasound is not very precise in comparison to secretine-enhanced MRCP. Next, 
the accurateness of database research is essential. It is very important to update 
the clinical information of the patients who entered the database. This seems 
logical, but obtaining up-to-date clinical information in an out-patient clinic study 
population can be challenging.
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Diagnosis and treatment of CP
From our nationwide survey on the current practice of Dutch gastroenterologists, 
internists and gastrointestinal surgeons we learned that there is discordance 
between the different specialties that treat CP patients, but also among experts. 
This is not very surprising since guidelines on the management of CP are scarce 
and not always corresponding. In 2010 two guidelines on the diagnosis and 
treatment of CP were published: an Italian guideline and a South-African 
guideline.14,16 However, today there is a need for an international guideline composed 
by international experts on CP, preferable composed in collaboration with for 
instance the EPC (European Pancreatic Club) or the APA (American Pancreatic 
Association). A national guideline would also be helpful to acquire a more uniform 
strategy in diagnosis and management in the Netherlands. 
Use of an expert panel in CP
Recently, the Dutch Pancreatitis Study Group has greatly improved the launch of 
multicenter studies on CP.17 This Study Group has established an expert panel that 
accepts clinical questions on acute pancreatitis and recently also on CP. This has 
led to a more uniform management of pancreatitis in the Netherlands. Clinicians, 
gastro-intestinal surgeons, radiologists, gastroenterologists from different hospitals 
in the Netherlands, all with substantial expertise on CP and selected on the basis of 
demonstration of knowledge and competence, are part of this panel. The advantage 
of an expert-panel is that their advice is based on their great expertise on CP. 
Furthermore, since the expert panel is involved in therapeutic dilemmas in hospitals 
widely spread in the Netherlands, the treatment of CP is up-to-date and more 
uniform between the hospitals. The disadvantage is that the evaluation of the patient is 
based on the information supplied by the treating physician, without assessment of 
the patient itself. Ideally, there would be a consulting expert team, which evaluates 
the patient on location, discusses the advice with the medical team and compose 
a widely supported therapeutic strategy, accompanied by education on location. 
Randomized clinical trials in CP 
Regarding treatment, we tried to perform a double-blind, 4-week cross-over 
randomized clinical trial on nasogastric and nasojenunal feeding in CP patients. We 
could not complete this trial due to (too) stringent inclusion criteria. However, the 
concept of enteral feeding in the treatment of pain in CP is still highly relevant. In 
clinical practice, patients are regularly treated with enteral nutrition, in case of 
malnutrition but frequently also as treatment for pain. Sometimes, enteral nutrition 
is administered with a nasogastric tube, sometimes by a nasojejunal tube. There is 
no evidence for this strategy. A recent study showed that the use of nasojejunal 
nutrition in CP patients is well-tolerated and decreases pain in 79.3% of CP 
9
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patients.18 However, this is a retrospective study and not a placebo-controlled one. 
It would be interesting to perform a trial on nasojejunal and nasogastric feeding in 
CP patients with pain, but the design of our trial needs to be adapted. For instance, 
the inclusion-criteria need to be revised, especially regarding the use of analgesics. 
On the other hand, in more and more CP patients interventional treatment is 
considered in case of chronic pain early in disease course of CP and preferable 
before the use of opioids. This subset of patients would ideally be a subject for a 
study like this. Furthermore, the accrual for CP patients with chronic pain can be 
difficult and no large number of patients can be included in a single hospital. 
Therefore, conducting a multi-centre study would be more appropriate. 
Elements for success of randomized clinical trials in CP
When we compare our study design to other studies on therapeutic management 
of pain in CP patients, we found some differences. Olesen et al. recently conducted 
a double-blind, placebo-controlled, parallel-group study of increasing doses of 
gabapentoid pregabalin as an adjuvant analgesic in CP patients with pain.11 This 
was a multicenter study in The Netherlands and Denmark. Patients were included 
with a diagnosis of CP with chronic abdominal pain typical for pancreatitis. Patients 
taking concomitant analgesic medication including opioids and expected to stay 
on a stable regimen during the trial were allowed to enter the study. The primary 
end point was change in pain intensity after three weeks of study treatment versus 
baseline pain intensity. They screened 236 patients and excluded 172 patients; 136 
patients did not met the inclusion criteria and 27 patients declined to participate. 
Finally, 64 patients were randomized to the pregabalin-group or placebo-group. 
The majority of patients were treated with opioids (71% in pregabalin-group and 
57% in placebo-group) and one-fourth of patients had undergone interventional 
therapy for CP pain. Furthermore, there were patients with ongoing alcohol abuse 
(21% in pregabalin group and 37% in placebo-group). Although a large majority 
(91% in pregabalin-group and 53% in placebo-group) experienced adverse events, 
only two patients were leaving the study because of this. The side effects were 
generally mild to moderate and central nervous system-related (feeling drunk, 
light-headedness, dizziness). Pregabalin, compared with placebo, caused more 
effective pain relief after three weeks of treatment (36% vs. 24%). Since the majority 
of patients was treated with opioids and frequently had undergone interventional 
therapies, this indicates a study population which is very difficult to treat. There are 
some limitations to this study. First, it is a short study-period with a short follow-up. 
Second, there is no head-to-head comparison comparing pregabalin with standard 
analgesic therapy, as it now was used as adjuvant therapy. But all in all, despite 
these limitations, the authors managed to perform a very important trial in this difficult 
patient group, including patients with opioid use and ongoing alcohol abuse. 
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In conclusion, a new design of our study on nasogastric or nasojejunal feeding in 
CP patients should include the following aspects:
•	 Inclusion of patients with opioid use;
•	 A multicenter study;
•	 Close collaboration with the Dutch pancreatitis study group;
•	 A parallel design.
9
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Table 2
Future implications and suggestions for further research
With regard to study objective 1: Why do some CP patients develop pain while others 
are left unscathed?
•	 To study COMT polymorphisms in CP patients with chronic pain and alcohol abuse to see 
if there is a relationship between the COMT gene and alcoholic CP.
•	 To verify the role of TRP channel in human studies with CP patients.
•	 To perform genome wide association studies (GWAS) in a large international CP 
population to discover genes related to pain in CP.
With regard to study objective 2: What is the clinical presentation of subset of patients 
with CP, such as patients with HP and ICP?
•	 To prospectively collect the clinical data about HP patients.
•	 To perform serial imaging, preferable secretin-enhanced MRCP, at fixed intervals in HP 
patients. 
•	 To study pancreatic imaging in CP patients of all causes.
•	 To interest to further unravel the etiology of ICP by comparing large cohorts of ICP 
patients from different countries from all over the world.
With regard to study objective 3: How do we need to treat these patients?
•	 To compose national and international guidelines on diagnosis and treatment of CP.
•	 To use the expert panel in clinical therapeutic dilemmas in CP.
•	 To perform a head-to-head study comparing pregabalin with standard analgesic 
treatment in CP.
•	 To perform a multicenter, parallel, placebo-controlled study on  nasogastric or nasojejunal 
feeding in CP patients, with or without opioid use in collaboration with the Dutch 
pancreatitis study group
CP: chronic pancreatitis
ICP: idiopathic chronic pancreatitis
HP: hereditary pancreatitis
FAP: familial adenomatous polyposis
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Abstract
Introduction
Patients with chronic pancreatitis (CP) often present with chronic pain and 
malnutrition. Enteral feeding is frequently indicated. It has been suggested that 
nasojejunal feeding achieves pancreatic rest and reduces pain, but there are no 
studies demonstrating superiority of nasojejunal over nasogastric feeding in CP 
patients. The aim of our study was to compare the effectiveness of nasogastric and 
nasojenunal feeding on abdominal symptoms and pain in CP patients. 
Methods
We considered CP patients for a double-blind, 4-week cross-over randomised 
clinical trial comparing nasojejunal with nasogastric feeding. Patients with concomitant 
opioid use were excluded. The primary end point was the intra individual difference 
of pain intensity as assessed change in pain intensity by VAS-scores during the two 
study periods.
Results
Due to our stringent exclusion criteria, we recruited only two patients. Only one 
patient completed the entire protocol. The VAS-score for pain decreased and the 
patient noticed a minor improvement of abdominal discomfort during the second 
study period while on nasojejunal feeding. His concomitant analgesic use remained 
stable during the study. The patient reported subjective improvement while on 
nasojejunal feeding. 
Conclusion
In conclusion, we were unable to finish a double-blind randomised cross-over 
study on the effectiveness of nasogastric and nasojejunal feeding in patients with 
CP. Stringent inclusion and exclusion criteria led to difficulties with accrual of 
patients. Therefore, at this moment there are no data to recommend nasojejunal 
over nasogastric feeding in CP patients.  
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Introduction
Many patients with chronic pancreatitis (CP) present with malnutrition and often 
need enteral feeding.1 Several factors contribute to the poor nutritional state in 
these patients. Reduced energy intake due to postprandial pain probably plays an 
important role. A second factor is an increased resting energy expenditure present 
in 30–50% of patients with CP.2 If dietary fat exposure is adequate, low lipase 
production could still result in fat malaborption. Enteral feeding is indicated in case 
of insufficient calorie intake, continuous weight loss continues despite sufficient 
intake, in case of acute complications or prior to surgery.3 The ESPEN guidelines 
state that enteral nutrition should be delivered via a jejunal tube, but robust evidence 
for superiority of jejunal over gastric tube placement is lacking. 
A recent study suggested that long-term nasojejunal tube feeding achieved 
so-called pancreatic rest and significant symptomatic relief.4 However, patients in 
this study had pancreatic masses, so the question remains if the improvement is due 
to induction of “pancreatic rest” or to bypassing the mass. Therefore, we designed 
a clinical study to compare nasojejunal with nasogastric tubefeeding in CP.  
Materials and methods
This study was initiated in 2006 as a double-blind, 4-week cross-over randomised 
clinical trial comparing nasojejunal with nasogastric feeding. The order of nutrient 
infusion was randomised by using computerized random number generation 
blocks of eight at an allocation ratio of 1:1. 
Our CP database was screened for patients that met our inclusion criteria. The clinical 
diagnosis of CP pancreatitis was based on the presence of typical complaints and 
suggestive radiological findings.
Our inclusion criteria were (1) daily pain (type B) for more than three months, with a 
mean pain score  > 3 cm (VAS-scale 0-10 cm), (2) clinical indication for enteral 
feeding; insufficient calorie intake, continuous weight loss or prior to surgery,3 (3) 
age > 18 yrs  and (4) able to understand the questionnaires.
Our exclusion criteria were (1) prior pancreatic, gastric or duodenal surgery, (2) other 
disorders of the upper gastrointestinal tract, (3) alcohol dependence, (4) contra-
indication for enteral tube placement, (5) exocrine insufficiency, (6) pregnancy and 
(7) narcotic analgesics except the use of tramadol. 
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Outcomes
The primary end point was the intraindividual difference of average daily pain 
intensity. Daily pain intensities were recorded during the entire study-period (two 
times four weeks) and the run-in phase (two weeks). This was scored using a pain 
diary (VAS). A secondary outcome was the analgesic requirement and the daily use 
of analgesics. Another secondary outcome was the severity of gastrointestinal 
symptoms, evaluated by a validated questionnaire of 16 prevalent gastrointestinal 
symptoms designed by Bovenschen.5 
Protocol
In the run-in phase of two weeks patients had normal diet. They daily recorded pain 
and the amount of required analgesics. On day one of the first study period, a 
feeding tube (Vygon, Laboratoires Pharmaceutiques, France) was inserted 
endoscopically over a guidewire in the proximal jejunum or in the stomach. After 
four weeks the position of the tube was checked and a new tube was inserted 
according to the cross-over protocol. 
Study personnel and patients were blinded to the location of the feeding tube, 
except the endoscopists who performed the tube placement. The enteral feeding 
consisted of continuous administration of semi-elemental tube feed (Advanced 
Peptisorb, Nutricia, The Netherlands). All patients were reviewed by a dietician, who 
determined the quantity of enteral feeding based on the estimated caloric 
requirement. 
We estimated that we would need a sample size of 10 patients who completed the 
study, based on a clinically relevant difference of 15 mm on a VAS (0-100 mm) and 
a standard deviation of 15 mm with a power 80% and alpha of 0,05. 
The study protocol was approved by the Institutional Review Board from the 
Radboud University Nijmegen Medical Centre (CWOM-nr 2006/101).6 All participating 
subjects gave their written informed consent. 
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Results
After a screening period of four years we included only two patients who met our 
predefined in- and exclusion criteria. Based on this disappointing low number of 
included patients, we decided to stop the trial in 2010.
Analysis of low recruitment
Our database includes 358 patients with CP. A large majority of CP patients in the 
database could not be included due to daily type B pain with opioid use, prior 
surgery and continuous alcohol abuse. Because of our stringent exclusion criteria 
the sample of potential participants was small and we only could include two 
patients, which we will describe in detail.  
Patient 1
Patient 1 was a 64-year-old male known with alcoholic CP for nine years, suffering 
from daily pain for seven years. He underwent a bilateral thoracoscopic splanch-
nicectomy in 2004. The mean VAS score was 4. 6 cm (range 3-7.5) during the run-in 
phase (figure 1). 
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Figure 1 displays the entire study period of patient 1 with VAS-scores and amount of enteral nutrition.
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Study period 1. Nasogastric feeding
The mean VAS-score was 5.7 cm (3.7-7.7), which increased to a VAS score of 6-7 
cm. He qualified the treatment as not effective. His score on the Bovenschen 
questionnaire regarding abdominal pain increased from 3 in the run-in phase to 5 
in the first study period.
Study period 2. Nasojejunal feeding
His daily pain score decreased to a mean VAS-score of 4.8 cm (range 3.8-5.9). He 
reported a slight improvement of abdominal pain during this study period. On the 
Bovenschen questionnaires he reported a slight decrease of pain in the second 
study period (score 4: ‘moderate’).
Patient 2
Patient 2 is a 51-year-old female with a history of alcoholic CP for 10 years and type II 
diabetes mellitus. She was suffering from daily continuous pain for a few years. 
During the run-in phase her average VAS score was 7.1 cm (5.8-8.4) (figure 2).
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Figure 2 displays the run-in phase and first study period of patient 1 with VAS-scores and amount  
of enteral nutrition. On day 10 of the first study period, she removed the tube because of pharyngeal 
irritation.
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Study period 1. Nasogastric feeding
Her pain decreased and on day seven she was no longer in pain without analgesics. 
Unfortunately, she did not tolerate the tube due to pharyngeal irritation so the tube 
was removed on the third day of the first study period. Immediately her pain 
reappeared and she reinitiated her analgesics.
Discussion
This study investigated the effectiveness of nasogastric compared to nasojenunal 
feeding on abdominal symptoms and pain in patients with CP. Our accrual for this 
study was limited so we failed to achieve adequate power to analyze our primary 
efficacy parameter. Ultimately, we recruited only two patients and only one patient 
completed the entire protocol. This patient noticed a minor improvement of pain 
and abdominal discomfort while on nasojejunal feeding accompanied by a 
decrease in VAS-score and he preferred nasojejunal compared over nasogastric 
feeding. 
The limited accrual precludes a robust conclusion on the preferable route of enteral 
feeding in a CP patient with pain. This was mainly due to our stringent inclusion 
criteria and particularly our exclusion criteria. There are a number of explanations 
for the difficulty with accrual. First, we searched for patients who experienced 
moderate to severe pain every day but without opioid use. However, when a CP 
patient has intolerable pain, acetaminophen and NSAIDs are often not enough to 
control the pain. If there is no anatomical substrate of pain such, there is no 
indication for surgery or endoscopic therapy and opioid therapy is often initiated. 
As a result, there are few patients with severe pain and no opioids with no prior 
surgery. The few eligible individuals left often declined participation because of the 
interventional nature of the study. Our experience has implications for future trials 
on pain control in CP patients. In order to obtain relevant results that are generalizable 
to other CP patients we would urge other trialists in the field to limit the number of 
exclusion criteria. 
The concept of enteral feeding in CP patients is still highly relevant. A poor intake, 
malabsorption and gastroparesis may lead to a worsening of the patients’ nutritional 
status and enteral nutrition may be warranted. The choice is to give nasogastric or 
nasojejunal feeding. The concept of nasojejunal feeding is advocated in cases of 
gastroparesis, but also within the framework of the concept of so-called ‘pancreatic 
rest’. Enteral feeding beyond the ligament of Treitz may allow the pancreatic gland 
to rest and minimizes pancreatic secretion.7 It has been established that feeding 
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distal to the ligament of Treitz does not increase lipase, amylase or trypsine, while 
bilirubin output and gallbladder contraction can be reduced.8 Skipworth et al. 
showed that the use of nasojejunal nutrition in CP patients  is associated with 
improvements in weight and blood parameters and is well-tolerated and associated 
with minimal complications.9 This retrospective study only assessed patients with 
nasojejunal feeding and already on opioids. They reported a decrease of pain in 
79.3% of patients with cessation of opioid analgesia intake over the nasojejunal 
feeding period. However, a bonafide comparator was lacking. Others have retro-
spectively analysed 57 CP patients (median duration of jejunal feeding 113 days 
and  found a decrease in the proportion of patients with significant abdominal 
pain.10 However, the decrease of pain as a result of nasojejunal feeding in the 
concept of pancreatic rest is not widely investigated. As a consequence, the jury is 
still out on this issue. This is in contrast with the situation in acute pancreatitis. In 
this condition, several studies did not show any difference between nasogastric 
versus nasojejunal feeding.11,12
In conclusion, we failed to complete a double-blind randomised cross-over study 
on the effectiveness of nasogastric and nasojejunal feeding in patients with CP due 
to stringent inclusion and exclusion criteria and difficulties with accrual of patients. 
The concept of nasojejunal feeding on pain in CP patients is interesting, but at this 
moment there are no data to recommend nasojejunal over nasogastric feeding as 
treatment for pain in a CP patient.  
Second, in our N=1 study we describe a CP patient with daily continuous pain who 
experienced a minor improvement of pain on nasojejunal feeding compared to 
nasogastric feeding. 
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Samenvatting
In dit proefschrift worden drie verschillende aspecten van chronische pancreatitis 
(CP) beschreven. CP is een ziekte van de alvleesklier die wordt gekenmerkt door 
een continue ontsteking die uiteindelijk leidt tot onherstelbare schade aan dit 
orgaan waardoor er exocrien en endocrien functieverlies optreedt. De meeste 
CP-patiënten hebben terugkerende aanvallen van hevige pijn in de bovenbuik die 
het gebruik van (veelal sterke) pijnstillers vereist. Door het ernstige en chronische 
karakter van deze ziekte hebben CP-patiënten veel medische zorg nodig. 
In dit proefschrift richten we ons op eerst op de genetische aspecten van pijn bij 
CP, daarna op de klinische aspecten van CP en tenslotte op de diagnose en 
behandeling van CP.  
 
In hoofdstuk 2 en 3 worden de genetische aspecten van pijn in CP besproken. 
Pijn is de meest voorkomende klacht van CP-patiënten en die pijn heeft een grote 
invloed op hun kwaliteit van leven. De mate van pijn verschilt echter nogal onderling 
bij CP-patiënten. Dit heeft geleid tot de veronderstelling dat genetische factoren 
een rol spelen in hoe CP-patiënten pijn ervaren. Daarnaast lijkt het erop dat pijn ook 
beïnvloed wordt door veranderingen in de zenuwen die de alvleesklier innerveren. 
In dit eerste deel van het proefschrift hebben we gezocht naar genen die 
pijnperceptie bij CP-patiënten veranderen. 
In hoofdstuk 2 onderzoeken we het COMT gen. Dit gen codeert voor ‘catechol-O-
methyltransferase’ (COMT), regelt het niveau van encephalines en beïnvloedt 
pijnperceptie. Uit eerder onderzoek is gebleken dat polymorfismen van het COMT 
gen, de pijnperceptie en de manier waarop een patiënt met pijn omgaat, kunnen 
veranderen. We bestudeerden de vier genetische variaties van het COMT gen 
(rs6269, rs4633, rs4818 en rs4680) bij 240 CP-patiënten en 445 gezonde controles. 
Tevens hebben we op grond van de resultaten haplotypes en diplotypes gemaakt. 
Een haplotype is een combinatie van allelen zoals die voorkomen op een uniek 
chromosoom. Een diplotype is een set van twee haplotypes (een van vader, een 
van moeder). Het gebruik van het haplotypes en diplotypes verdienen de voorkeur 
omdat combinaties van genetische variaties synergistisch zouden kunnen werken. 
We vonden geen significant verband tussen de genetische veranderingen in het 
COMT gen en CP. Hoewel we zagen dat het diplotype ATCA/ACCG vaker voorkwam 
bij gezonde controles dan bij patiënten, was dit verschil niet significant na correctie 
voor multiple testing. Onze conclusie was dat genetische veranderingen in het 
COMT gen niet samenhangen met CP. Dit versterkt de conclusie dat het COMT gen 
geen belangrijke rol speelt bij het ontstaan van CP.
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In hoofdstuk 3 bestudeerden we het ‘transient receptor potential vanilloid receptor 
1’ (TRPV1) gen. De TRPV1 receptor is een niet-selectief ‘calcium permeant cation’ 
kanaal dat tot de ‘transient receptor potential family (TRP)’ behoort. De ‘transient 
receptor potential’ (TRP)-kanalen beïnvloeden zenuwen die betrokken zijn bij 
ontsteking. Bovendien zijn ze in staat om de bij ontsteking bestaande pijn te 
modificeren. We onderzochten vier genetische varianten (rs222749, rs222747, 
rs224534 en rs8065080) bij 228 CP-patiënten en bij 207 gezonde controles. 
Uiteindelijk konden we geen significant verschil aantonen in allelfrequentie tussen 
CP-patiënten en gezonde controles.
 
Op grond van deze gegevens is vast te stellen dat pijn bij CP onafhankelijk is van 
de door ons onderzochte genetische variaties in het COMT gen en het TRPV1 gen.
 
In de volgende deel van dit proefschrift hebben we aandacht besteed aan de 
verschillende klinische aspecten van CP. 
Allereerst hebben we in hoofdstuk 4 radiologische beelden bestudeerd van 
patiënten met een specifiek type CP, namelijk erfelijke (hereditaire) pancreatitis 
(HP). HP is een zeldzame vorm van CP en wordt veroorzaakt door kationische 
trypsinogeen (PRSS1) genmutaties. We hebben een cohort van 15 HP-patiënten 
beschreven bij wie tijdens hun ziekte 152 radiologische onderzoeken zijn verricht. 
Al deze onderzoeken werden opnieuw bestudeerd door een ervaren radioloog. De 
eerste opmerkelijke bevinding was het grote aantal transabdominale echografieën 
dat was uitgevoerd bij deze patiënten. Dit gebeurde bij het stellen van de diagnose 
maar ook in latere stadia van de ziekte. Bij het opnieuw bestuderen van alle 
onderzoeken vonden we een grote variatie in breedte van de ductus pancreaticus. 
Deze variatie leek niet af te hangen van de tijd na ontstaan van de ziekte en nam 
soms zelfs toe na chirurgische drainage. Een sterk verwijde ductus pancreaticus 
werd vaak geconstateerd in combinatie met de aanwezigheid van intraductale 
stenen, die werden aangetroffen bij een derde van de patiënten (grootte 1-12 mm). 
Deze bevindingen zijn in overeenstemming met de spaarzame literatuur in deze 
specifieke groep van HP-patiënten.
 
In hoofdstuk 5 hebben we het fenotype van idiopathische CP (ICP) in verschillende 
landen vergeleken. In India komt een specifieke vorm van CP voor, die van oudsher 
wordt beschreven als tropische pancreatitis. Dit is een vorm van idiopathische CP 
(ICP) met unieke epidemiologische en klinische kenmerken, zoals jonge leeftijd bij 
aanvang van ziekte met frequent voorkomen van diabetes. Er zijn echter ook 
overeenkomsten met ICP zoals die voorkomt in de Westerse wereld. Wij vergeleken 
het fenotype van 1033 Indiase CP-patiënten met het fenotype van 358 Duitse en 
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358 Nederlandse CP-patiënten om te onderzoeken wat de verschillen zijn in het 
klinische beeld van CP in deze landen. We vonden dat Indiase patiënten meestal 
de idiopatische vorm van CP hadden, jonger waren, op jongere leeftijd de ziekte 
kregen en minder vaak rookten. Verder werden endocriene insufficiëntie en 
verkalkingen in de alvleeskliervaker gezien bij Indiase ICP-patiënten. De overgrote 
meerderheid (> 85%) van alle CP-patiënten had pijn. Maar deze verschillen zijn 
veel minder uitgesproken dan werd gezien bij het klassieke beeld van CP zoals dat 
eerder voorkwam in India. Het lijkt dan ook of het fenotype van CP in India 
langzamerhand lijkt te verschuiven naar een meer ‘Westers’ type ziekte (oudere 
leeftijd bij begin van de ziekte, minder voorkomen van endocriene insufficiëntie en 
minder frequente verkalkingen in de alvleesklier). Wij concludeerden dat de meeste 
Indiase patiënten tegenwoordig lijden aan een vorm van CP die in het Westen wordt 
aangeduid als ICP. Dit kan te wijten zijn aan een verandering van levensstijl en aan 
omgevingsfactoren maar ook genetische factoren zoals SPINK1 kunnen hierbij een 
rol spelen. 
 
In hoofdstuk 6 hebben we zeven patiënten met familiaire adenomateuze polyposis 
(FAP) beschreven die ten minste één episode met pancreatitis hebben doorgemaakt. 
We zochten naar een onderliggende verklaring voor de pancreatitis maar bij geen 
van de patiënten werd een van de bekende risicofactoren gevonden, zoals een 
obstructief papiladenoom. Eveneens zochten we naar een genetische verklaring 
voor de pancreatitis. Uit eerdere literatuur is bekend dat een mutatie in het SPINK1 
gen pancreatitis kan veroorzaken. In deze zeven patiënten vonden wij echter geen 
mutatie in dit gen. Bij literatuuronderzoek vonden we in totaal 20 FAP-patiënten met 
pancreatitis. Dit suggereert dat pancreatitis een manifestatie van FAP zou kunnen 
zijn, hoewel het werkelijke mechanisme onduidelijk is. 
 
In het derde deel van dit proefschrift hebben we ons gericht op de diagnose en 
behandeling van CP. 
In hoofdstuk 7 hebben we de resultaten gepresenteerd van een landelijk onderzoek 
over de diagnose, behandeling en screening bij CP. We ontwikkelden een enquête 
waarin klinische vignetten waren opgenomen. Deze enquête verstuurden we naar 
MDL-artsen, internisten en gastro-intestinale chirurgen in Nederland evenals naar 
een panel van internationale deskundigen. In totaal werden 110 vragenlijsten 
teruggestuurd (respons percentage 8.3%); 31% MDL-artsen, 39% internisten en 
20% gastro-intestinale chirurgen. Er bleek een grote variatie te zijn in strategieën 
met betrekking tot diagnose, behandeling en screening van CP tussen specialismen, 
maar ook tussen de individuele artsen. Bepaalde diagnostische testen en behandel-
methoden die in de kliniek vaak worden toegepast, zoals serum amylase als 
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Tabel 1
Relevante vraagstukken in dit proefschrift 
Vraag 1: Waarom hebben sommige patiënten met CP pijn en zijn andere hiervan gevrijwaard? 
Wat is het effect van het COMT gen en het TRPV1 gen op de aanwezigheid en de ernst van pijn  
bij CP?  
(Hoofdstuk 2 & 3)
Pijn bij CP is onafhankelijk van de door ons onderzochte genetische variaties in het COMT gen en 
het TRPV1 gen.
Vraag 2: Wat is de klinische presentatie van een specifieke vorm van CP, zoals hereditaire 
en idiopathische CP? 
Zijn er specifieke radiologische kenmerken bij HP-patiënten?
(Hoofdstuk 4)
•	 We	vonden	een	grote	variatie	in	breedte	van	de	ductus	pancreaticus,	onafhankelijk	van	de	tijd	
na ontstaan van de ziekte en na een drainage-procedure. 
•	 Een	sterk	verwijde	ductus	pancreaticus	werd	vaak	geconstateerd	in	combinatie	met	de	
aanwezigheid van intraductale stenen.
Is het fenotype van CP en ICP anders in India dan in de Westerse wereld? 
(Hoofdstuk 5)
•	 Het	fenotype	van	CP	en	ICP	in	India	lijkt	langzamerhand	plaats	te	maken	voor	een	meer	
'Westers' type ziekte (met oudere leeftijd bij aanvang van de ziekte, minder voorkomen van 
endocriene insufficiëntie en minder frequente verkalkingen in de alvleesklier).
•	 De	meeste	Indiase	patiënten	lijden	tegenwoordig	aan	een	vorm	van	CP	die	in	het	Westen	
wordt aangeduid als ICP. 
Is ere en relatie tussen FAP en CP en zouden SPINK1 mutaties kunnen bijdragen aan het risico  
op pancreatitis?  
(Hoofdstuk 6)
•	 We	identificeerden	zeven	patiënten	met	FAP	en	pancreatitis	maar	konden	geen	onderliggende	
risicofactor aanwijzen.
•	 We	vonden	geen	aanwijzing	voor	een	mutatie	in	het	SPINK1 gen.
Vraag 3: Hoe moeten we deze patiënten behandelen? 
Hoe is de huidige stand van zaken in Nederland met betrekking tot diagnose, behandeling en 
screening van CP?  
(Hoofdstuk 7)
•	 Er	is	een	grote	variatie	in	de	strategieën	van	MDL-artsen,	internisten	en	gastrointestinaal	
chirurgen.
•	 Bepaalde	diagnostische	testen	en	behandelmethoden	die	in	de	kliniek	vaak	worden	
toegepast, worden niet ondersteund door richtlijnen uit de literatuur.
Wat zijn veronderstelde mechanismes voor pijn bij CP en wat zijn de opties voor therapieën? 
(Hoofdstuk 8)
•	 De	theorieën	over	de	oorzaken	van	pijn	bij	CP	zijn	gebaseerd	op	de	volgende	aannames:	 
1) verhoogde druk in de ductus pancreaticus en het parenchym van de alvleesklier;  
2) een toename van oxidatieve stress, veroorzaakt door een tekort aan voedingsbestanddelen; 
3) schade aan perifere zenuwen; 4) centrale sensibilisatie en hyperalgesia. 
•	 De	behandeling	van	pijn	in	CP	houdt	int:	 
1) onthouding van alcohol;  
2) behandeling van complicaties;  
3) analgetica: paracetamol, NSAID's (Non-Steroidal Anti-Inflammatory Drugs)  
en uiteindelijk gebruik van opioïden.
CP: chronische pancreatitis
ICP: idiopathische chronische pancreatitis
HP: hereditaire pancreatitis
FAP: familiaire adenomateuze polyposis
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diagnostische test en pancreasenzymsuppletie als pijnbestrijding bij CP, worden 
niet ondersteund door richtlijnen uit de literatuur. Wij pleiten er dus voor dat de 
behandelend artsen zich beter aan de bestaande richtlijnen houden, maar ook dat 
er nieuwe, verbeterde richtlijnen zullen moeten worden ontwikkeld. 
In hoofdstuk 8 werd een aantal hypothesen besproken die de pijn bij CP kunnen 
veroorzaken. Daarnaast werd de behandeling van pijn bij CP toegelicht. Er zijn 
verschillende theorieën in omloop over de oorzaken van pijn bij CP. Deze theorieën 
zijn gebaseerd op de volgende aannames: 1) verhoogde druk in de ductus 
pancreaticus en parenchym van de alvleesklier; 2) een toename van oxidatieve 
stress, veroorzaakt door een tekort aan voedingsbestanddelen; 3) schade aan 
perifere zenuwen; 4) centrale sensibilisatie en hyperalgesia. 
Vervolgens bespraken wij de behandeling van pijn bij CP. De eerste stap die moet 
worden gezet, is onthouding van alcohol. Vervolgens moeten complicaties van CP, 
zoals pseudocystes, worden behandeld. Als de pijn blijft, is een symptomatische 
pijnbehandeling met medicatie de enige optie die over blijft. Analgetica zijn vaak 
onvermijdelijk: Paracetamol, NSAID›s (Non-Steroidal Anti-Inflammatory Drugs) en 
uiteindelijk opioïden. Van een behandeling met alvleesklierenzymen is niet bewezen 
dat die effectief is als behandeling van pijn bij CP. Andere opties in de farmacolo-
gische behandeling van pijn bij CP zijn: antioxidant therapie, loxiglumide en κ-opioid 
receptor agonisten. Wij concludeerden dat er slechts enkele goede gerandomis-
eerde gecontroleerde studies zijn gedaan bij patiënten met CP en pijn. Het is 
daarom moeilijk om een duidelijk advies te geven over de farmacologische 
behandeling van pijn bij CP. Maar in de afgelopen jaren zijn er nieuwe inzichten 
gekomen in de pathogenese van pijn bij CP en zijn er nieuwe geneesmiddelen 
onderzocht, zoals besproken zal worden in de paragraaf "toekomstperspectieven". 
In de bijlage zijn  opzet en achtergrond beschreven van een dubbel-blinde, 
cross-over, gerandomiseerde studie gedurende vier weken. Deze studie onderzocht 
het effect van nasogastrische versus nasojenunale sondevoeding op pijn in 
CP-patiënten. Als gevolg van strenge inclusiecriteria konden wij slechts twee 
patiënten in het onderzoek insluiten, van wie maar één patiënt het volledige protocol 
afrondde. Deze patiënt bemerkte enige verlichting van pijn met nasojejunale 
sondevoeding. Dit ging gepaard met een afname van de pijnscore. De beperkte 
deelname was voornamelijk te wijten aan de strenge exclusiecriteria, waaronder 
gebruik van opioïden. We zochten namelijk naar patiënten met dagelijks matige tot 
ernstige pijn, maar die geen opioïden gebruiken. We konden slechts enkele 
patiënten op onze polikliniek vinden die aan deze criteria voldeden, waaruit blijkt 
dat de drempel blijkbaar laag is om met opioïden te starten bij CP-patienten met 
pijn. De conclusie die we kunnen trekken, is dat er op dit moment nog geen 
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aanbevelingen zijn te geven over het gebruik van nasogastrische of nasojejunale 
voeding om pijn bij CP te behandelen. 
Implicaties van het onderzoek uit dit proefschrift  
en toekomstperspectieven
 
Pijn bij CP
In onze onderzoeken konden we geen significante rol van het COMT en TRPV1 gen 
bij CP pijn aantonen. Er zijn tot dusver geen studies naar het COMT gen gedaan die 
deze bevinding ondersteunen. Wel zijn er meerdere publicaties verschenen over 
het COMT gen en COMT-remmers in andere chronische pijnsyndromen. Uit een 
recente meta-analyse bleek onlangs dat fibromyalgie en chronische pijn geassocieerd 
zijn met de genetische variatie rs4680.1 Verder zijn er publicaties die een associatie 
tussen COMT polymorfismen en verslaving aantonen, hoewel díe onderzoeken 
tegenstrijdige resultaten laten zien.2,3 Het zou interessant zijn om genetische 
variaties te onderzoeken binnen het COMT gen bij CP-patiënten met chronische 
pijn en alcohol misbruik om te zien of er een relatie is tussen het COMT gen en 
alcoholische CP.
De laatste jaren zijn er meerdere publicaties over de rol van TRPV1 bij pancreatitis 
verschenen.4-7 Dit zijn echter allemaal experimentele dierstudies. Er zijn ook onder- 
zoeken over de rol van TRPV1 bij de behandeling CP verschenen. Bij experimentele 
pancreatitis bij de rat is gebleken dat blokkade van NGF (nerve growth factor) de 
pijn kan mediëren.5 Deze resultaten wijzen daarom op een rol van TRP kanaal 
interacties die bijdragen aan de ontwikkeling van experimentele pancreatitis. Een 
volgende stap zou zijn om de rol van het TRP kanaal in menselijke studies met 
CP-patiënten aan te tonen. 
We kunnen een aantal conclusies trekken die relevant zijn voor het opzetten van 
onderzoeken over dit onderwerp en die we hieronder verder zullen bespreken.  
Relevantie van genetische aspecten in pijn bij CP
Er is een aantal redenen voor onze (grotendeels) negatieve resultaten. Allereerst 
onderzochten wij slechts acht genetische varianten bij twee genen. Hoewel 
(genetische) variaties in deze genen betrokken zijn bij pijn, zijn ze mogelijk niet 
relevant bij CP. Het concept dat genetische varianten pijn bij CP beïnvloeden, is 
immers niet goed aangetoond. De belangrijkste reden hiervoor is dat de 
meerderheid van de studies gericht zijn op het ontrafelen van de genetische 
oorzaak van CP als ziektebeeld en niet op een symptoom van de ziekte. Pijn is 
waarschijnlijk multifactoriëel bepaald. In de afgelopen jaren zijn weliswaar genen 
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van erfelijke pijnsyndromen ontdekt maar dit hoeft nog niet te betekenen dat 
genetische variaties bijdragen aan het ontstaan van pijn bij andere complexe 
aandoeningen. Bij literatuuronderzoek is het wel zo dat genetische varianten van 
het COMT gen alsmede het TRPV1 gen geassocieerd zijn met pijnbeleving. Met de 
opzet van genetische associatie studies blijft het moeilijk te onderscheiden of een 
bepaalde genetische variant samenhangt met CP zelf of met een specifiek feno- 
typisch kenmerk van die ziekte.
 
Het gebruik van gezonde controles voor genetische associatie 
studies 
Een cruciale vraag met betrekking tot de opzet van genetische associatiestudies is 
het gebruik van geschikte gezonde controles. Het is algemeen gebruik om controles 
te selecteren uit dezelfde populatie als die van de patiënten, zoals we ook in onze 
onderzoeken hebben gedaan. Hierdoor hebben we het risico van stratificatie van 
de populatie beperkt.
De volgende vraag is hoe we moeten uitsluiten of CP bij de controles voorkomt. We 
hebben alle controles bevraagd op ziekteverschijnselen die kunnen wijzen op CP. 
De vraag blijft of we CP hadden moeten uitsluiten met behulp van geavanceerde 
radiologische technieken en ze derhalve een MRCP of CT-scan hadden moeten 
laten ondergaan. Er zijn verschillende redenen waarom we denken dat dit niet 
nodig is. Allereerst dient te worden opgemerkt dat ‘matching’ alleen noodzakelijk is 
als de frequentie van de confounder zo’n duidelijk verschil geeft tussen patiënten 
en controles waarvoor bij analyse niet kan worden gecorrigeerd. Verder is dit alleen 
noodzakelijk in situaties waar de confounder niet nauwkeurig kan worden gemeten. 
‘Overmatching’ voor onnodige variabelen vermindert juist de zeggingskracht van 
de studie. Het is dus onwaarschijnlijk dat we patiënten bij wie nog geen diagnose 
van CP is vastgesteld, in onze onderzoekspopulatie hebben opgenomen. De 
prevalentie van CP in de algemene bevolking is namelijk zeer laag is (in Nederland 
1/50.000). 
Gebruik van ‘genome wide association studies’
Een veel voorkomend probleem bij de opzet van genetische associatiestudies is 
het tekort aan power om een associatie te ontdekken. De onderzoeken die wij 
hebben uitgevoerd, hadden te weinig power om associaties tussen variabelen en 
fenotype te ontdekken. Om het effect van deze genetische varianten te beoordelen, 
zijn grotere studies met meer power nodig. ‘Genome wide association studies’ 
(GWAS) zijn in principe groter en zouden dit probleem mogelijk kunnen oplossen. 
Maar GWAS onderzoeken slechts een beperkt aantal varianten en moeten erg 
groot zijn om een genetische variant van enig belang te ontdekken. We zijn 
begonnen met een Europese samenwerking die als doel heeft genetische varianten 
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te ontdekken die ten grondslag liggen aan alcoholische CP. Hoewel deze onder-
zoekspopulatie groot genoeg is (> 2000 deelnemers), is het onzeker is of de 
fenotypering van de patiënten zo goed is dat daarmee de vraag kan worden 
beantwoord of pijn in CP wordt beïnvloed door genetische varianten.
Meting van de pijn
We hebben in onze studies patiënten opgenomen met een breed scala aan pijn 
presentatie. Sommigen hadden zeer invaliderende pijn maar anderen hadden 
milde pijn of zelfs geen pijn. Uiteindelijk heeft de meerderheid van de CP-patiënten 
pijn. Dit maakt de populatie zo aantrekkelijk als een model voor chronische pijn 
waarbij we de invloed van omgevingsfactoren en genetische varianten in pijngenen 
kunnen bestuderen. Wel is het zo dat er een aantal beperkingen zijn. In de eerste 
plaats is er geen objectieve maat voor pijn bij CP. Bovendien hebben we nog geen 
betrouwbare meetinstrumenten om daadwerkelijk vast te stellen dat bijvoorbeeld 
medicijnen een verbeterend effect hebben op de meting. Daarbij kent CP een 
onvoorspelbaar beloop met acute verergeringen en niet te voorspellen remissies. 
Om een en ander te ondervangen, hebben we in onze onderzoeken een ‘composite’ 
score samengesteld om patiënten met een ernstig verloop van de ziekte te kunnen 
onderscheiden van de patiënten met een milder verloop. Maar zelfs met deze 
‘composite’ score is het lastig gebleken om pijn te kwantificeren. 
  
Andere mogelijke oorzaken van pijn bij CP
De laatste jaren is onderzoek naar pijn bij CP vooral gericht op beïnvloeding van de 
neuropathische aspecten van de pijn. In een recente retrospectieve studie wordt 
het concept onderschreven dat pijn bij CP niet wordt voorspeld door de ernst van 
de afwijkingen op de beeldvorming van het pancreas.8 Menselijke en dierexperi-
mentele studies hebben een belangrijke rol van neuronale mechanismen 
aangetoond die  leiden tot perifere en centrale sensitisatie. Onlangs werd een 
onderzoek gepubliceerd waarin wordt vermeld dat patiënten met langdurige pijn 
door CP viscerale hypersensitiviteit hebben ontwikkeld. Daarnaast zijn bij beeld- 
vorming op MRI microstructurele veranderingen in vergelijking met normale personen 
aangetoond, die een afname lieten zien van corticale dikte in hersendelen die 
betrokken zijn bij de verwerking van pijn.9,10 Zo zou corticale dikte een surrogaat-
marker kunnen zijn voor het algeheel disfunctioneren van het pijnsysteem in CP. 
 
Klinische aspecten van CP
In dit proefschrift werden verschillende beeldvormende technieken onderzocht bij 
HP-patiënten gedurende hun ziekteperiode. We kwamen meer te weten over 
verschillende aspecten van radiologische beeldvorming bij patiënten met HP, zoals 
de breedte van de ductus pancreaticus en de aanwezigheid van grote intraductale 
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stenen. Er is weinig literatuur beschikbaar over beeldvorming bij HP. Het zou zeer 
interessant zijn om een langere follow-up van HP-patiënten te realiseren waarbij we 
prospectief klinische gegevens over deze patiënten verzamelen. Daarnaast zou het 
interessant zijn om in een cohort van HP-patiënten seriële beeldvorming te 
verrichten op vaste tijdstippen (bijvoorbeeld om de twee tot vijf jaar), om zo meer 
informatie te vergaren over de progressie van de schade aan het pancreas. 
Vervolgens vergeleken we ICP-patiënten uit India en de Westerse wereld waarbij we 
zagen dat het fenotype van de CP en ICP in India is vervangen door een meer 
‘Westers’ type ziekte. Een gevolg van onze studie is dat ICP in India niet meer zal 
moeten worden beschouwd als een specifieke entiteit die slechts in India wordt 
aangetroffen bij ondervoede patiënten. Tropische pancreatitis wordt als een 
specifieke entiteit gezien met cassavegebruik als risicofactor. Het bestaat vanaf de 
kindertijd en er is een hoge prevalentie van diabetes en pancreas verkalking. Het 
gevolg van onze bevinding is dat de term ‘tropische pancreatitis’voor ICP in India 
thans geen juiste benaming meer is en niet meer zou moeten worden gebruikt. 
Hierbij is de genetische achtergrond van deze ziekte van belang. Er zijn namelijk 
steeds meer aanwijzingen dat ICP in India een duidelijke genetische aanleg heeft, 
wat de mythe over cassave als etiologie ontkracht. In een recente studie werd 
aangetoond dat mutaties in het SPINK1 en CFTR gen sterk geassocieerd zijn met 
ICP in India.11 Aangezien ICP in India zou kunnen lijken op ICP in het Westen, is het 
van bijzonder belang om de etiologie van ICP verder te ontrafelen door grote 
cohorten van ICP-patiënten uit verschillende landen uit de hele wereld met elkaar 
te vergelijken om te zien of er nog steeds een geografisch verschil van het fenotype 
bestaat en om meer over de impact van de omgevingsfactoren te weten te komen. 
Dat is niet alleen belangrijk voor ICP, maar ook voor alcoholische CP, aangezien er 
steeds meer aanwijzingen zijn dat de ontwikkeling van CP ook een gevolg is van 
een interactie tussen meerdere risicofactoren en dat, naast alcohol, andere 
co-factoren nodig zijn  om de ziekte te laten ontstaan. Dit is vooral interessant in 
ontwikkelingslanden, waar het gebruik van alcohol toeneemt.
 
Problemen met epidemiologische ‘case series studies’
Als model van ziekte voor onze studies gebruikten we de fenotypische kenmerken 
van CP, die we in een database opnamen. Bij database-onderzoek kunnen echter 
verschillende problemen ontstaan. Aangezien we verschillende databases uit 
verschillende regio’s gebruiken om CP te onderzoeken, is het essentieel om 
eenzelfde definitie van CP te gebruiken. Er worden echter verschillende criteria voor 
de diagnose van CP gehanteerd. In de Zuid-Afrikaanse richtlijn wordt bijvoorbeeld 
gesteld: ‘De diagnose kan worden gesteld aan de hand van morfologische criteria 
alleen, of aan de hand van een combinatie van morfologische en functionele 
criteria”.12 Anderen delen CP in volgens de M-ANNHEIM classificatie.13 Voor het 
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opstellen van een database is het vooral erg belangrijk om de criteria voor het 
stellen van een diagnose goed op elkaar af te stemmen. Aangezien beeldvorming 
een onderdeel is in de diagnostiek van CP, is het essentieel om over dezelfde 
beeldvormingsmodaliteiten in de verschillende centra te beschikken. Immers, de 
diagnose van CP in een vroege fase aan de hand van beeldvorming is vaak lastig 
en is afhankelijk van de nauwkeurigheid van beeldvorming. Een transabdominale 
echo is bijvoorbeeld niet erg nauwkeurig in vergelijking met een secretine-MRCP. 
Vervolgens is het belangrijk zeer zorgvuldig database-onderzoek te doen. Hierbij is 
het vooral belangrijk om de klinische gegevens van patiënten in de database 
doorlopend te actualiseren. Dat lijkt logisch, maar up-to-date klinische informatie 
van een poliklinische onderzoekspopulatie te krijgen blijft een uitdaging.
 
Diagnose en behandeling van CP
Uit onze landelijke enquête is gebleken dat er geen overeenstemming is in de 
huidige praktijkvoering met betrekking tot diagnose en behandeling van CP tussen 
Nederlandse MDL-artsen, internisten en gastro-intestinaal chirurgen, maar ook niet 
tussen experts. Dit is niet zo verwonderlijk, omdat er weinig richtlijnen zijn voor de 
behandeling van CP die ook nog eens vaak niet overeenstemmen. In 2010 zijn twee 
richtlijnen over de diagnose en behandeling van CP gepubliceerd; een Italiaanse 
en een Zuid-Afrikaanse richtlijn.12,14 Dit zijn goede richtlijnen, maar momenteel is er 
behoefte aan een internationale richtlijn, die is samengesteld door internationale 
experts op het gebied van CP, en bij voorkeur  in samenwerking met bijvoorbeeld 
de EPC (European Pancreatic Club) of de APA (American Pancreatic Association). 
Een landelijke richtlijn zou ook bijdragen aan een meer uniforme strategie in de 
behandeling en diagnose van CP in Nederland.
  
Het gebruik van een panel van deskundigen bij CP
De Pancreatitis Werkgroep Nederland (PWN) heeft sterk bijgedragen aan het in 
gang zetten van diverse multicenter studies op het gebied van CP.15 De PWN heeft 
een panel van deskundigen samengesteld dat zich buigt over klinische vraagstukken 
op het gebied van acute pancreatitis en meer recent ook CP.  Dit heeft geleid tot 
een meer uniforme behandeling van pancreatitis in Nederland. Dit panel is samen- 
gesteld uit gastro-intestinale chirurgen, radiologen en MDL-artsen uit verschillende 
ziekenhuizen in Nederland, allen met aanzienlijke expertise op het gebied van CP 
en geselecteerd op grond van hun kennis en competenties. Het voordeel van een 
expert-panel is dat hun advies is gebaseerd op hun ruime ervaring op het gebied 
van CP. Aangezien het panel van deskundigen betrokken is bij therapeutische 
dilemma’s in ziekenhuizen wijd verspreid in Nederland, wordt hiermee de 
behandeling van CP meer up-to-date en meer uniform tussen de verschillende 
ziekenhuizen. Een nadeel is dat de beoordeling van de patiënt op basis van de 
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informatie van de behandelend arts wordt gedaan, zonder dat de patiënt zelf wordt 
beoordeeld. Idealiter zou er een consulterend expert-team moeten zijn, dat de 
patiënt op locatie beoordeelt en vervolgens het advies met het medisch behandel- 
team bespreekt. Daarna volgt een breed gedragen behandelplan in combinatie 
met onderwijs op locatie.
Gerandomiseerde klinische studies bij CP
We hebben getracht een klinische, gerandomiseerde, dubbel-blinde cross-over 
studie uit te voeren door CP-patiënten vier weken lang nasogastrische of 
nasojenunale voeding  te geven. We konden echter deze studie niet voltooien door 
de strenge inclusiecriteria. Maar het concept van enterale voeding als behandeling 
van pijn in CP is nog steeds zeer relevant. In de klinische praktijk worden patiënten 
regelmatig behandeld met enterale voeding. Dit gebeurt in situaties van onder- 
voeding, maar vaak ook om pijn te behandelen. Soms wordt enterale voeding 
toegediend door een maagsonde, soms door een nasojejunale sonde. Er is geen 
bewijs voor deze behandeling. Een recente studie toonde aan dat het gebruik van 
nasojejunale voeding bij CP-patiënten goed verdragen wordt en de pijn vermindert 
bij 79,3% van de CP-patiënten.18 Dit is echter een retrospectieve, niet placebo- 
gecontroleerde studie. Het zou interessant zijn om onderzoek uit te voeren met 
nasojejunale en nasogastrische sondevoeding bij CP-patiënten met pijn, maar de 
opzet van onze trial zal moeten worden aangepast. De inclusie-criteria moeten 
worden herzien, vooral voor wat betreft het gebruik van analgetica. Daarnaast 
wordt bij steeds meer CP-patiënten met chronische pijn vroeg in het ziekteverloop 
een interventie overwogen, bij voorkeur vóór het starten van opioïden. Deze groep 
patiënten zou een ideale groep zijn om bij hen dit onderzoek uit te voeren. Verder 
kan het problematisch zijn CP-patiënten met chronische pijn op te nemen in het 
onderzoek en kan in één enkel ziekenhuis geen groot aantal patiënten in een 
onderzoek worden opgenomen. Daarom is een multicenter studie qua opzet meer 
geschikt. 
 
Wat bepaalt het succes van gerandomiseerde klinische trials bij CP?
Toen we onze onderzoeksopzet vergeleken met andere studies over pijnbehandeling 
bij CP-patiënten, zagen we een aantal opvallende verschillen. Olesen et al. verrichtten 
onlangs een dubbel-blinde, placebo-gecontroleerde studie met het gabapentoid 
pregabaline, dat in toenemende dosis toegevoegd werd aan de analgetica bij 
CP-patiënten met pijn.11 Dit betrof een multicenter-studie die werd uitgevoerd in 
Nederland en Denemarken. CP-patiënten met chronische buikpijn die typisch is 
voor pancreatitis, werden in het onderzoek opgenomen. Patiënten die gelijktijdig 
analgetica inclusief opioïden in een stabiele dosis gebruikten, werden toegelaten 
tot de studie. Het primaire eindpunt van het onderzoek was de verandering in 
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intensiteit van pijn te meten na drie weken medicatie versus intensiteit van de pijn 
bij start van de studie. Er werden 236 patiënten gescreend waarbij men 172 
patiënten uitsloot uit het onderzoek: 136 patiënten voldeden niet aan de inclusiecri-
teria en 27 patiënten weigerden deel te nemen aan het onderzoek. Uiteindelijk 
werden 64 patiënten gerandomiseerd voor de pregabaline-groep dan wel de placebo- 
groep. De meerderheid van de patiënten werd behandeld met opioïden (71% in 
pregabaline-groep en 57% in de placebo-groep) en een vierde van de patiënten 
had een interventie ondergaan als behandeling voor pijn bij CP. Verder waren er 
patiënten met aanhoudend alcoholmisbruik (21% in pregabaline groep en 37% in 
de placebo-groep). Hoewel een grote meerderheid (91% in pregabaline-groep en 
53% in de placebo-groep) bijwerkingen kreeg, verlieten slechts twee patiënten de 
studie om deze reden. De bijwerkingen waren meestal matig tot mild en gerelateerd 
aan het centrale zenuwstelsel (gevoel van dronkenschap, licht gevoel in het hoofd, 
duizeligheid). Pregabaline gaf na drie weken behandeling een betere pijnbestrijding 
in vergelijking met de placebo (36% vs 24%). Aangezien de meeste patiënten 
werden behandeld met opioïden en vaak interventies hadden ondergaan, wijst dit 
op een onderzoekspopulatie die zeer moeilijk te behandelen is. Er zijn een aantal 
beperkingen aan deze studie. Allereerst is de periode van onderzoek kort met 
eveneens een korte follow-up. Ten tweede is er geen head-to-head vergelijking 
gemaakt, maar werd pregabaline nu als adjuvante behandeling toegevoegd. Maar 
al met al zijn de auteurs er ondanks deze beperkingen in geslaagd om een studie 
uit te voeren die meer inzicht geeft in de behandeling van pijn bij deze moeilijke 
groep patiënten. Pregabaline was ook superieur aan placebo voor vermindering 
van experimentele viscerale pijn door middel van elektrische stimulatie bij CP-
patiënten.13 Deze resultaten zijn veelbelovend voor  toekomstige behandelopties 
voor pijn bij CP. De definitieve rol van pregabaline dient te worden bepaald in een 
head-to-head studie waarin pregabaline met standaard pijnstillende behandeling 
bij CP wordt vergeleken.
Als conclusie kunnen we stellen dat een nieuwe studie naar het effect van naso-
gastrische of nasojejunale sondevoeding bij CP-patiënten aan de volgende criteria 
moet voldoen: 
•	Inclusie	van	patiënten	met	opioïd-gebruik;
•	Een	multicenter-studie;
•	Nauwe	samenwerking	met	de	Pancreatitis	Werkgroep	Nederland;	
•	Een	parallel	design.
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Tabel 2
Toekomstige onderzoeksvragen en –doelstellingen op basis van dit proefschrift
Betreffende vraag 1: Waarom hebben sommige patiënten met CP pijn en zijn andere 
hiervan gevrijwaard? 
•	 Het	bestuderen	van	genetische	variaties	binnen	het	COMT bij CP-patiënten met 
chronische pijn en alcohol misbruik.
•	 Het	bestuderen	van	de	rol	van	het	TRP	kanaal	in	CP-patienten.	
•	 Het	doen	van	‘genome	wide	association	studies’	(GWAS)	in	een	grote	internationale	
populatie met CP-patiënten om te onderzoeken of pijn in CP wordt beïnvloed door 
genetische varianten.
Betreffende vraag 2: Wat is de klinische presentatie van een specifieke vorm van CP, 
zoals hereditaire en idiopathische CP? 
•	 Het	prospectief	verzamelen	van	klinische	data	van	HP-patiënten	om	meer	te	weten	te	
komen over het ziekteverloop.
•	 Het	verrichten	van	goede	beeldvorming,	zoals	secretine-MRCP’s,	bij	HP-patiënten	met	
vaste intervallen om meer te weten te komen over het beloop van de radiologische 
afwijkingen gedurende de ziekte.
•	 Het	vergelijken	van	grote	cohorten	ICP-patiënten	uit	de	hele	wereld	om	de	oorzaak	van	
ICP te achterhalen. 
Betreffende vraag 3: Hoe moeten we deze patiënten behandelen?
•	 Het	samenstellen	van	nationale	en	internationale	richtlijnen	voor	de	diagnostiek	en	
behandeling van CP
•	 Het	consulteren	van	het	expert-team	van	de	Pancreatitis	Werkgroep	Nederland	bij	
dilemma’s in de behandeling van CP. 
•	 Het	verrichten	van	een	‘head-to-head’	studie	waarin	pregabaline	met	standaard	
analgetica wordt vergeleken.
•	 Het	verrichten	van	een	multicenter,	placebo-gecontroleerde	studie	naar	het	effect	van	
nasogastrische of nasojejunale sondevoeding bij CP (met of zonder opioïden)  
in samenwerking met de Pancreatitis Werkgroep Nederland. 
CP: chronische pancreatitis
ICP: idiopathische pancreatitis
FAP: familiaire adenomateuze polyposis
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Dankwoord
Het is eindelijk zover; het boekje is af, ik ben over de finish! Het was een lange reis 
over een bochtige weg, soms met hobbels, soms met kuilen. Uiteindelijk bleek na 
iedere bocht de weg toch weer door te gaan totdat in de verte zelfs de eindstreep 
in zicht kwam. Het laatste jaar werd de versnelling dan ook fors ingezet en werd 
de reis een race, waarbij onderweg ook nog een extra passagier aan boord stapte. 
De race is niet zonder slag of stoot gegaan en zonder het goede team langs de weg 
was het niet mogelijk geweest de finish ongeschonden te halen. Hierbij wil ik dan ook 
iedereen bedanken die direct of indirect aan het tot stand komen van dit proefschrift 
heeft bijgedragen. Een aantal mensen wil ik in het bijzonder noemen. 
Prof. dr. J.P.H. Drenth, beste Joost, tijdens deze reis heb jij mij over de route 
genavigeerd. Soms leken de wegen doodlopend, maar op de één of andere manier 
vond je altijd wel een nieuwe afslag. Ik herinner me goed hoe ik in 2005 op de 
afdeling MDL met Prof. dr. J.B.M.J. Jansen kwam praten over een mogelijke 
overstap vanuit de interne geneeskunde naar MDL. Dit kennismakingsgesprek 
bleek direct een sollicitatie te zijn en was mijn overstap naar MDL een feit. Jij tackelde 
mij toen direct om bij jou onderzoek te doen. De jaren erna was de snelheid in het 
onderzoek soms ver te zoeken, door de aandacht die de opleiding opeiste. Pas toen 
ik als staflid op je afdeling aan de slag ging, werd het tempo opgevoerd. En eind 2011 
werd tijdens het schrijfweekend de eindsprint echt ingezet. Door jouw hulp en snelle 
reacties, zelfs in weekends en vakanties, kon ik deze snelheid handhaven. Dank voor 
je geduld en vertrouwen in mij en voor de immer geruststellende woorden: ‘het 
komt goed’. Eerlijk gezegd heb ik hier meer dan eens aan getwijfeld, maar gelukkig 
heb jij in deze gelijk gekregen.
Leden van de manuscriptcommissie, Prof. dr. J. de Graaf, Prof dr. J.H.J.M. van 
Krieken, Dr. M.G. Besselink, dank voor jullie beoordeling van het manuscript en 
voor jullie goede adviezen. Beste Jacqueline, veel dank voor je begrip en je hulp 
om het tijdig behalen van de eindstreep mogelijk te maken.
Beste collega’s van de staf MDL, secretariaat en andere MDL-collega’s; zeer 
bedankt voor jullie steun. Vooral het laatste jaar moest ik op een aantal gebieden 
regelmatig even mijn schema aanpassen onder het mom van die eeuwige op 
stapel staande promotie. Nu is het af en komt er eindelijk meer tijd voor andere 
dingen, zoals het IBD-team en het endoscopiecentrum.
Verder wil ik alle medeauteurs bedanken voor hun bijdragen aan de artikelen, 
waarbij een aantal personen in het bijzonder.
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Dr. F.M. Nagengast, beste Fokko, één van de eerste artikelen schreef ik samen met 
jou. Jouw enorme ervaring op MDL-gebied waardeer ik zeer, maar zeker ook je 
verhalen over Italië en kleinkinderen zijn altijd erg onderhoudend. Dank voor alle 
adviezen! 
Ing. R.H. te Morsche, beste René, zonder jouw hulp met de genetische analyse 
waren de genetische stukken er nooit geweest. Dank voor het inzicht in de voor mij 
vaak onbegrijpelijke materie van genetica.
Dr. J. Hermans, beste John, het hele archief moest worden doorzocht en de lichtbak 
werd van stal gehaald voor ons onderzoek. Ik vond het erg leerzaam om eens een 
uitstapje te maken naar de wondere wereld van de radiologie. 
Dr. W.P. Hopman, beste Wim, de COPE-trial was een pittige kluif, waar je me goed 
bij hebt geholpen. Dank hiervoor!
Dr. M.G.H. van Oijen, beste Martijn, ik wil je bedanken voor de hulp bij de statistiek 
maar vooral bij het kritisch bekijken van mijn onderzoek.
Jessica Vogel, beste Jessica, dank voor je steun en inspirerende gesprekken.
Ook dank voor de bijdragen van studenten, die mij hebben geholpen bij dit promotie-
onderzoek; Eelke de Vries, Mark Lamberts en Monique Derikx. Inmiddels allen 
geen studenten meer en in een aantal gevallen op weg naar een carrière binnen de 
MDL-ziekten. Ik wens jullie veel succes in jullie verdere loopbaan!
Dr. M.C.A. van Kouwen, beste Mariëtte. Als mijn kamergenoot heb je van dichtbij de 
laatste paar jaar van mijn onderzoek meegemaakt; de leuke momenten maar zeker 
ook de minder leuke momenten. Ik kon altijd goed mijn hart bij je luchten, maar ook 
even ontspannend met je kletsen onder het genot van een lekkere cappuccino. 
Bedankt voor de gezelligheid op onze kamer: je bent een superfijne collega! Fijn 
dat je mijn paranimf wilt zijn!
Dank aan mijn vrienden en familie, die voor de hoognodige ontspanning hebben 
gezorgd maar ook voor steun en praktische adviezen, vooral in de laatste fase.
Mijn broer en zus, Joris en Marieke, dank voor jullie aanmoediging en interesse in 
mijn vaak onbegrijpelijke en ondoorgrondelijke bezigheden. Joris, over een tijd sta 
jij ook voor de corona, ik zie er naar uit! Marieke, daar waar je kon heb je mij als 
zus bijgestaan tijdens mijn onderzoek. Dank daarvoor! Ik ben trots dat jij vandaag 
naast me staat!
Mijn schoonmoeder, Ria, dank voor je steun, interesse, maar ook grote hulp. Het is 
fantastisch te zien hoe je geniet van kleine Tijs. Jammer dat opa Thijs er niet bij is 
om dit mee te maken; die had hier ongetwijfeld van genoten. 
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Mijn ouders, lieve papa en mama, zonder jullie had ik hier echt niet gestaan, letterlijk 
en figuurlijk. Jullie hebben mij altijd gesteund: tijdens mijn school- en studietijd, 
maar ook tijdens mijn specialisatie en onderzoekstijd daarna. Jullie hebben mij 
continu gestimuleerd om mijn doel te bereiken. Jullie steun was vaak praktisch; de 
vele keren dat jullie voor Tijs hebben gezorgd, het uitlenen van ‘studiehuis de 
Sterrenhof”, waar ik op mijn vrije dagen die snelheid kon vasthouden en jullie hulp 
tijdens de laatste loodjes. Jullie onvoorwaardelijke steun en vooral het vertrouwen 
maken dat ik dit boekje af heb kunnen krijgen. En pap, ik heb dan wel geen 
co-promotor, maar gezien jouw hulp met mijn boekje heb jij deze plek verdiend! 
Lieve Tijs, jouw komst heeft alles doen relativeren en heeft meteen duidelijk 
gemaakt wat echt belangrijk is in het leven. Je hebt op je jonge leeftijd al door waar 
het om draait, want ik je van school ophaal vraag je ‘Mama, hoeveel mensen heb 
je vandaag beter gemaakt?’ Na een drukke werkdag, gaat het vervolgens niet meer 
over ingewikkelde dingen, maar gewoon over spelen in de zandbak, ridderzwaarden 
en boekjes lezen. Straks ben jij de grote broer en dan heb ik ècht meer tijd om te 
genieten van jullie!
Lieve Maurice, eindelijk is het zover en is het af. Sinds we elkaar kennen, is er altijd 
wel wat geweest: jouw uitzendingen, opleidingen en functies ver van huis, mijn 
studie, specialisatie en diensten maar vooral dit onderzoekstraject de afgelopen 
jaren. Het is soms een uitdaging om onze drukke levens gepland te krijgen en vrije 
tijd is door onze carrières een schaars goed, maar wel onze way of life. Je hebt me 
de tijd en ruimte gegeven en mij op jouw manier geprikkeld om dit traject succesvol 
af te ronden, ook als ik weer eens niet te genieten was doordat ik een kuil in de weg 
was tegengekomen. Ik zie uit naar het moment dat we met z’n vieren kunnen gaan 
genieten van de mooie en hopelijk, maar waarschijnlijk tegen beter weten in, 
rustigere tijd. 
DANKWOORD
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Aura van Esch is op 9 juni 1975 geboren te Nijmegen. In 1993 behaalde zij haar 
VWO-diploma aan het Stedelijk Gymnasium te Nijmegen. In 1993 startte zij met de 
opleiding geneeskunde aan de Katholieke Universiteit Leuven te België, die zij 
vanaf 1994 vervolgde aan de Katholieke Universiteit Nijmegen (thans: Radboud 
Universiteit Nijmegen). Na het behalen van haar artsexamen in november 2000, 
was zij werkzaam als arts-assistent op de afdeling Interne Geneeskunde van het 
Canisius Wilhelmina ziekenhuis (CWZ) te Nijmegen. In juli 2001 startte Aura in dit 
ziekenhuis met de opleiding Interne Geneeskunde (opleiders: dr. R.W. de Koning, 
later dr. A.S.M. Dofferhoff). Van november 2001 tot juli 2002 vervolgde zij haar 
opleiding in het Universitair Medisch Centrum (UMC) St Radboud te Nijmegen 
(opleider: Prof. dr. J.W.M. van der Meer) om hierna weer tot mei 2005 terug te keren 
naar het CWZ. Hierna keerde zij terug naar het UMC St Radboud. In september 
2005 maakte zij de overstap gemaakt naar de opleiding Maag-, Darm- en 
Leverziekten in het UMC St Radboud (opleider: Prof. dr. J.B.M.J. Jansen). In deze 
periode startte zij, onder leiding van Prof. dr. J.P.H. Drenth, met het onderzoek dat 
tot deze promotie heeft geleid. In juli 2007 vond registratie als internist plaats. De 
opleiding tot MDL-arts ronde zij in maart 2010 af. Sindsdien is zij werkzaam als 
staflid binnen de vakgroep MDL-ziekten van het UMC St Radboud te Nijmegen met 
als aandachtsgebied inflammatoire darmziekten (IBD) en als medisch hoofd van 
het Endoscopie Centrum. 
Aura woont samen met Maurice Houben. Samen hebben zij een zoon, Tijs.
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